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Influenza A virus (IAV) is a minus-sense, segmented, single-stranded RNA virus that 
infects the respiratory tract of humans and can cause severe illness.  Novel IAV variants 
perpetually emerge on every continent, and the emergence of variants with increased 
transmissibility and/or pathogenesis in the human population is a serious concern for 
global public health.  Infection with IAV typically causes an acute, self-limiting upper 
respiratory tract disease.  However, severe IAV disease is characterized by infection of 
the lower respiratory tract which can lead to pneumonia and may result in the 
development of acute respiratory distress syndrome (ARDS).  Viral and host 
contributions to the development of ARDS are poorly understood, however IAV 
pathogenesis has been linked mutations in the receptor binding protein and the viral 
polymerase.  Ferrets and mice are two important laboratory animal models for studying 
IAV pathogenesis. In 2009, a novel H1N1 subtype IAV (H1N1pdm) emerged in the 
human population and displayed variable pathology in humans.  Using a mouse model, 
we show the variability of clinical isolates of H1N1pdm is driven by viral mutations, 
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and that the timing of the inflammatory response is correlated with disease severity.  To 
investigate spatiotemporal aspects of potential host and viral contributions to influenza 
pathogenesis, we developed a live imaging platform for ferrets infected with a human 
clinical isolate of H1N1pdm.  We detected an early recruitment of neutrophils into ferret 
lungs following infection, which accumulated at foci of H1N1pdm infection within 
specific anatomical regions of the lung by 24 hours post-infection.  The neutrophil 
response was biphasic, characterized by the recruitment of two populations with differing 
gene expression profiles, and baseline neutrophil levels were increased throughout the 
entire lung, including areas with no apparent viral infection.  Changes in the viral 
microenvironment resulted in the regeneration of lung epithelium during recovery phase 
of infection, and this was imaged with PET-CT using a radiolabeled glucose analog.  In 
summary, these data illustrate critical features of the immune response to IAV, and 
emphasize important considerations about the timing and accuracy of innate immune 
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1. Establishing a role for neutrophils in influenza A viral pneumonia 
Influenza A virus (IAV) infection is the cause of a respiratory disease that poses a significant 
global public health concern (1-5).  Influenza disease is commonly relatively mild and self-
limiting, although highly pathogenic forms exist (6-13). The major complication from IAV 
infection is the formation of severe influenza pneumonia (SIP) which may develop into an 
acute respiratory distress syndrome (ARDS) (7-9, 11-15). The reason(s) why infection with 
IAV may lead to severe viral pneumonia and ARDS is poorly understood, but is thought to 
involve both host and viral factors.  The respective and combined contributions of the host 
immune response and viral factors to the timing and severity of SIP are poorly understood.  
Neutrophils are immune cells that are well-known to be present during many types of lung 
diseases associated with ARDS, and may contribute to acute lung injury (16-25).  
Neutrophils are present in the respiratory tract during infection with mild seasonal IAV, 
moderate and severe IAV infection, and highly pathogenic avian influenza viruses (HPAI) (7, 
8, 14, 26-30).  During SIP and HPAI infection, an increase in the number of neutrophils in 
the lower respiratory tract (LRT) is correlated with disease severity (7, 8, 14, 28-30).  
However, neutrophils are poorly studied with respect to viral infection, respiratory viral 
disease, and specifically IAV infection.   Herein, the contribution of neutrophils to IAV 
disease pathogenesis is reviewed.   
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IAV poses a concern for global public health due to emergence of strains with increased 
human transmission and/or increased pathology (2, 5, 31-34).  In 2009, an H1N1 subtype 
IAV (H1N1pdm) emerged that was observed to have increased transmission and caused 
moderate to severe pathology relative to seasonal human IAV (1, 6, 28, 35-46).  Clinical 
isolates of H1N1pdm have relatively little genetic variability yet caused variable clinical 
outcomes from moderate to severe pathology, including ARDS (1, 30, 38, 44, 45).  Therefore 
they are well suited to understand host and viral contributions to IAV pathogenesis.  
Laboratory animal models, such as mice and ferrets, provide a way to study and test 
hypotheses about the pathogenesis of IAV, specifically about the contributions of viral and 
host determinants to severe disease (47-50).  There are common occurrences in the formation 
of severe IAV (including SIP and ARDS) in humans, ferrets, and mice; these include 
increased cytokine secretions in the lung, diffuse alveolar damage (bronchointerstitial 
pneumonia in veterinary pathology), and neutrophilic infiltration (9, 14, 47, 50-56). 
 
The lung has a global inflammatory response to infection, and this response includes the 
infiltration of neutrophils and macrophages in response to chemotactic signaling which 
originates in the lung (16, 18, 25, 57-64).  However, the immune system requires additional 
information to control specific causes of infection.  In other words, although similar cellular 
and systemic signaling systems are activated in response to infection of the lungs, in general 
the type I interferons (IFN) and interferon-stimulated genes (ISGs) are necessary to signal a 
benevolent immune response during a viral infection (65-68).  During experimental IAV 
infection in mice, a breakdown of transmission of “viral” information causes malevolent 
immune responses, and a dysregulated immune response is lethal (e.g., via suppression of 
type I IFN, or productive infection of major IFN-producing cells, the alveolar macrophages) 
(69-75).  Ultimately, all forms of respiratory infection require resolution of the infection and 
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inflammation.  Interferons are essential components of initiating sterilizing immunity via the 
adaptive immune system (i.e., resolution of infection), at which point the resolution of 
inflammation can effectively proceed (67, 68, 76).  In regards to resolution of both infection 
and inflammation, neutrophils may be a keystone cell type in determining pathologic 
outcomes in the viral microenvironnment.  Although the mechanisms are poorly understood, 
through their direct antiviral actions and indirect actions on the lung microenvironment (e.g., 
efferocytosis of apoptotic neutrophils by macrophages), neutrophils have the ability to 
influence outcomes towards successful resolution as well as towards the formation of ARDS 
(16, 18, 25, 26, 57, 77-84).  In general, the interactions of neutrophils with IAV, the antiviral 
microenvironement, and resident lung cells deserve further study.   
 
Here, the role of neutrophils in IAV disease is reviewed.  First, the various presentations of 
disease caused by IAV infection are introduced followed by a description of the viral 
replication cycle.  This is essential for understanding viral determinants of disease severity in 
humans, as well as the justification for the use of animal models in studying IAV 
pathogenesis.  Finally, the host acute (exudative) response to IAV is reviewed, focusing on 
the role of neutrophils in disease and data from both human, mouse, and ferret studies.  The 
role of neutrophils in the generation of adaptive immunity and resolution have been 
established in a mouse model of IAV, however, this aspect of the relationship between 
neutrophils and IAV infection is beyond the scope of this review (26, 83, 85-87).  The 
intention here is to present what is known about the interaction between neutrophils and early 
events within the airways following IAV infection.  In doing so, this review will also discuss 
the relationships between neutrophils and other respiratory virus infections to establish a role 




2. Influenza A virus pathology 
Although clinical pathology suggests that a spectrum of disease results from IAV infection, 
there are at least three disease “phenotypes” caused by infection with IAV, listed by 
increasing case fatality rate: a mild URT tract infection, a SIP which can lead to ARDS, and a 
LRT infection which can lead to hypercytokinemia (Figure 1.1).  As discussed below, the 
virological basis for disease phenotype is related to IAVs adaptation to humans, for which 
some mechanisms have been well defined; thanks in part to the use of experimental animal 
models (2, 32, 33, 49, 88-91).  An “ideal” viral infection (i.e., one that is successful for the 
virus and non-lethal for the host) may be considered a balance between virus replication and 
an immune response necessary to promote viral shedding, typical of mild seasonal 
(“epidemic”) IAV.  In general emergent IAV, directly or indirectly from avian enzootic 
cycles, have increased pathology in humans, the most fatal form of which is a syndrome of 
complete immune dysregulation (10, 11, 14, 92-95).  IAV is genetically highly variable, and 
mechanisms for increased disease severity are multifactorial, involving host and viral factors, 
and thus are poorly understood. 
 
2.1 Uncomplicated influenza.  
The majority of yearly, seasonal IAV infections in the world cause a relatively mild, self-
limiting URT disease (96).  Influenza disease is characterized by an abrupt onset fever, 
myalgia and malaise, with symptoms similar to other URT infections, such as sneezing, 
coryza, and rhinorrhea (7, 97).  Symptoms can last anywhere from 1-5 days, and are 
clinically indistinguishable from other “flu”-like illnesses, including bacterial and viral 
infections that cause the common cold (e.g., Streptococcus pneumoniae, Haemophilus 
influenzae, human rhinovirus infection, human respiratory syncytial virus infection, and 
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coronavirus infection) (97-100). Experimental infection of humans with IAV suggests that 
the virus is mainly restricted to the URT, although sampling the LRT is difficult (7, 8, 99, 
101).  While fever typically begins two days post-infection, virus is shed from the URT in 
nasal secretions as quickly as 24 hours post-infection, allowing efficient transmission prior to 
symptom onset, and continues until 4-5 days post-infection (98, 99, 101).  Rhinorrhea is 
coincident with neutrophilic rhinitis and shedding of necrotic nasal epithelium (7, 102, 103).  
Surprisingly, the LRT seems to be involved in uncomplicated IAV infection, although this 
observation is frequently overlooked or unaddressed in studies (8, 104).  In humans, local and 
systemic concentrations of IL6, CXCL8/IL8, and MCP1/CCL2 correlate with increased 
disease severity (i.e., symptoms and increased virus shedding) (99-101, 105). 
 
2.2 Pandemic influenza and SIP. 
Histopathology. The 2009 H1N1pdm virus spread quickly throughout the globe, much like 
previous pandemic viruses such as the 1918 H1N1 “Spanish flu”.  H1N1pdm infections also 
presented with typical flu-like symptoms (e.g., fever, cough), however there was an increased 
number of cases presenting with dyspnea, respiratory distress, and pneumonia (1, 6, 28, 35-
37, 39-45, 106, 107).  Additionally, retrospective assessments show a proportionately greater 
number of adolescents and adults with severe disease compared to typical seasonal influenza, 
and patients with comorbidities such as obesity and asthma were at higher risk of severe 
infection (30, 108-110).  In general, the virus causes infection of URT, as well as bronchitis 
and bronchiolitis, and a high proportion of cases presented with severe disease in the form of 
viral pneumonia (6, 30, 108).  Histopathologic changes in autopsies revealed extensive 
cytonecrosis, desquamation, and inflammatory infiltration of the bronchus and trachea, mild 
to severe necrotizing bronchiolitis (6, 28, 30, 111).  The primary pathologic finding of SIP 
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was sporadic to diffuse alveolar damage with hyaline membrane formation, edema, and 
occasionally hemorrhage (6, 28, 30, 111).  As is typical of influenza infections, some patients 
experienced bacterial co-infection although this was not in a majority of patients, including 
those dying from ARDS (6, 28, 30, 45, 105, 111-115).  This may distinguish the 2009 
H1N1pdm virus from the 1918 H1N1 “Spanish” IAV, for which bacterial super-infection 
was determined to cause a majority of the deaths (116, 117), although this may more 
accurately reflect improved hygiene and standard of care.  As discussed below, studies of the 
reconstructed 1918 H1N1 IAV using animal models suggest that this virus was highly 
pathogenic irrespective of secondary bacterial pneumonia (53, 118-120). 
 
Immune response. Across many cohorts of clinical patients, serum concentration of IL-6, 
CCL2, and CXCL8 were significantly elevated in severe cases of H1N1pdm pneumonia 
when compared to patients with other confirmed illnesses including seasonal IAV, mild 
forms of H1N1pdm, bacterial pneumonia, or other viral respiratory infection (Human 
respiratory syncytial virus [hRSV], human rhinovirus [HRV], human adenovirus [hAdv]) 
(105, 112-114, 121).  These cytokines and chemokines remained elevated over time (up to 6 
days following hospital admission) in cases of severe H1N1pdm pneumonia, where as they 
decreased as patients recovered from seasonal and mild H1N1pdm infection (105, 112).  In 
severe cases of H1N1pdm infection, decreased type I IFN and ISG production was 
occasionally noticed compared to adult patients with seasonal IAV infection (105).  The 
H1N1pdm viruses have received much scrutiny and a large dataset of the genetics and 
pathogenic phenotypes of virus isolates exists in human and animal models. The H1N1 
subtype IAV are highly important viruses due to their pandemic potential, as supported by 
the historical record (8, 53, 122).  Some H1N1pdm viruses can infect the lower respiratory 
tract in humans and in the ferret animal model, which makes them excellent laboratory 
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viruses to investigate the involvement of the LRT in pathogenesis, specifically in the 
development of severe disease (6, 123-127).  Their overall genetic similarity makes for 
excellent comparison studies between natural clinical isolates, and reverse genetics systems 
exist to study molecular pathogenicity (1, 107, 125, 128-138).  This review will focus on the 
H1N1pdm viruses for these reasons. 
 
2.3 HPAI and cytokine storm. 
H5N1 HPAI. Avian IAV has sporadically entered the human population in the last 20 years, 
emerging first in China in 1997 (11, 93, 139, 140).  It is likely that this (H5N1 avian IAV) 
and other emergent strains result from contact with infected domestic poultry who are 
infected with HPAI (93).  The disease caused by H5N1 IAV is characterized by diffuse 
alveolar damage, alveolar necrosis, and alveolar hemorrhage (human disease, including 
pathology, is reviewed in (94)).  There is evidence of viremia and systemic spread; IAV 
antigen has been detected in the trachea, bronchi and alveolar pneumocytes (10, 29), as well 
as infrequently in the brain and gastric epithelium (9, 29, 94).  The innate cellular immune 
response in the lungs was characterized by an increase in inter-alveolar 
macrophages/histiocytes (9, 10, 12, 14, 92, 141) and only moderate infiltration of 
lymphocytes and neutrophils (10, 29).  Systemically, patient serum had high concentrations 
of CXCL10, CCL2, IL6, IL8, and IL10 compared to matched control patients with either 
seasonal H3/H1 IAV, and these concentrations were correlated with viral load in throat (9, 
10, 14). In lethal cases, the result of infection and immune dysregulation led to multiple 
organ failure, (e.g., kidney tubular inflammation, necrotic lesions in brain, impaired liver 
function) and abnormal clotting.  Reactive histiocytes undergoing hemophagocytosis were 
8 
 
frequently found in bone marrow and lungs of patients, which is indicative of diseases 
involving hypercytokinemia.(9, 11, 14, 92, 94, 142). 
 
Continuing emergence of avian IAV. Other events involving avian IAV transmission to 
humans are known, and are often associated with veterinary or other animal workers; for 
example a 2004 case of H7N7 infection in a veterinarian in Europe showed severe fatal 
pneumonia and DAD (143).  It was reported that 1 L of serosanguineous fluid was drained 
from his chest upon autopsy. In 2013, another avian IAV emerged in Southeast Asia; this 
time an H7N9 virus (12, 13, 141, 144).  The histopathology was similar to H5N1; severe 
pneumonia, diffuse alveolar damage, and epithelial necrosis were common features of 
infection with both viruses (12, 13).  Patients infected with either virus had high levels of 
CXCL10, CCL2, IL-6, and CXCL8 in the plasma and displayed peripheral blood leukopenia 
and neutrophilia (10, 14, 92, 141, 142, 144).  There were slightly more bacterial co-infections 
in cases of H7N9 compared to H5N1 avian IAV (12, 13, 92).  In a direct comparison, serum 
from patients with infected with H5N1 avian IAV had higher concentrations of IFNa and 
IFNg in the blood and lower levels of IL8, whereas the opposite was true for patients with 
H7N9 (145). Similarly, CXCL9 and CXCL10 were higher in patients with H5N1 avian IAV, 
whereas CCL4 concentrations were higher in patients with H7N9 avian IAV (145).  Infection 
with either virus resulted in higher blood C-reactive protein (CRP) (141). 
 
3. Influenza A virus components and replicative cycle  
IAV was first isolated in 1933 as a “filterable agent” that was capable of infecting ferrets and 
satisfied Koch’s postulates in ferrets (146-148).  It caused a respiratory tract disease in ferrets 
that was very similar to influenza disease in humans (147-149).  Currently, many aspects of 
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IAV replication cycle are understood through the use of cell culture techniques.  Modern 
molecular genetic techniques have developed a reverse genetics system, which allows direct 
manipulation of the viral genome to study biochemical properties of viral proteins (128, 150).  
Today, efforts by the WHO and agencies in collaborating countries have standardized 
techniques for the isolation and description of clinical IAV to provide constant, world-wide 
IAV monitoring with the goal of preventing or predicting future pandemics . 
 
3.1 Virion structure and components.  
IAV are enveloped, minus sense, RNA viruses in the family Orthomyxoviridae (151).  Each 
virion carries one copy of the genome, which is composed of eight segments of viral RNA 
(151, 152) (Figure 1.2).  In the virion, each genomic segment is bound with a polymeric 
helical viral nucleoprotein and a single molecule of the trimeric viral RNA-dependent RNA 
polymerase (RDRP) (153-156). This ribonucleoprotein (RNP) complex is encased in a shell 
of matrix (M1) protein, which is enveloped by a phospholipid bilayer membrane derived 
from host plasma membrane (157, 158).  The IAV viral envelope contains three 
transmembrane proteins: the HA, the NA, and the M2 ion channel protein (158-162).  The 
pleiomorphic virions are approximately 100 nanometers in diameter, and filamentous virus 
particles are produced which are typically greater than 1 micrometer in length (163-165).  
The complexities of virion assembly are not fully understood, particularly with respect to the 
formation of these filamentous particles and the production of virions lacking a complete 




3.2 Receptor binding, fusion, and entry.  
Influenza viruses bind to glycosylated host proteins via the viral HA, which has a specificity 
for glycans with terminal SA residues (159, 168, 169) (Figure 1.3, step 1).  Currently, it is 
thought that this receptor binding maintains the virus in close proximity of the plasma 
membrane until the virus can be taken up by clathrin-mediated endocytosis, although other 
forms of uptake are possible (170, 171).  Clathrin-mediated endocytosis results in a gradually 
acidified endosome, which allows a two-step conformational change in the HA protein (172, 
173).  The HA is classified as a class II membrane fusion protein, and the conformational 
change results (1) in the insertion of an alpha helical domain near the cleavage site into the 
host’s endosomal membrane followed by (2) a “pinching” movement at approximately pH 
5.5 which fuses the host endosomal membrane with the viral envelope (159, 172, 174-176) 
(Figure 1.3, step 2).  For this high energy fusion reaction, the HA must undergo a maturation 
step prior to endocytosis in which a host protease cleaves a residue on the pre-fusion 
conformation of the HA protein to prepare the protein for membrane fusion (177-181).  
During endocytosis, the M2 ion channel allows for the acidification of the interior of the 
virion simultaneously during the acidification of the endosome by host processes (182, 183).  
This prepares the matrix (M1) protein to release the viral RNPs into the cytoplasm once the 
membrane fusion event has occurred (157, 184, 185). 
 
3.3 Viral replication and gene expression.  
Nuclear localization signals designate transport of the RNP and other viral proteins to the 
host cell’s nucleus where replication and transcription can occur (184, 186-189) (Figure 1.3, 
step 3).  Once in the nucleus, the viral RDRP initiates these processes by creating 
complementary plus-sense copies of the gene segments (cRNA), which can be then replicated 
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back into vRNA (190, 191). The RDRP has a “cap-snatching” function, which removes a 5’-
terminal methylated structures from host mRNA and attaches it to viral cRNA to make viral 
mRNA (192, 193).  IAV lack methyltransferases, so this is an essential step for mRNA 
translation initiation on ribosomes (192, 193).  This is also necessary to evade intracellular 
immune systems which detect 2’-O and 5’-penultimate unmethylated RNA structures in the 
cytoplasm (194, 195). Viral mRNA is exported and translated on ribosomes in the cytoplasm, 
while transmembrane glycoproteins are co-translated on the endoplasmic reticulum (Figure 
1.3, step 4). 
 
3.4 Non-structural gene products.  
There are several non-structural gene products encoded by IAV.  All seem to have the 
primary function of modulating the host’s immune response (151, 196-198) (Figure 1.3, step 
5).  As discussed below, NS1A protein reduces anti-viral type I IFN responses in infected 
cells through a variety of hypothesized mechanisms (reviewed in (199-201)).  The IAV PB1-
F2 is thought to modulate host cell apoptosis by targeting the mitochondrial activator MAVS 
and interfering with mitochondrial membrane potential (196, 197, 202, 203).  Recently, 
several other gene products have been discovered (e.g., PB1-N40, PA-X) by identifying start 
codons in alternate reading frames (204).  The approach to understanding these has been to 
use reverse genetics systems to create viruses with mutations in the polypeptide’s ORF or 
insert a stop codon to disrupt translation of the putative polypeptide in a way that does not 
affect the full-length protein and test the effects compared to the wild type virus in vitro or in 
vivo (205-207).  With this approach, it is difficult to control the effects on other gene 
products; therefore the relative importance of these lesser-known non-structural proteins 




3.5 Virion assembly and budding.  
As IAV proteins are being made, the RNP complex escapes the nucleus via the interaction of 
NS2 (nuclear export protein, NEP) with nuclear pore proteins (208).  Transmembrane 
proteins, such as the HA, NA, and M2, are translated on rough ER and transported through 
the Golgi body to the plasma membrane (151).  Currently, it is thought that the cytoplasmic 
domains of glycoproteins, the M1, and the M2 proteins coordinate the assembly of all eight 
RNPs at cytosolic locations near plasma membrane rafts of viral membrane proteins (166, 
209, 210) (Figure 1.3, step 6).  New virions deform the membrane outwards, eventually 
budding off from the host membrane (158, 166) (Figure 1.3, step 7).  Release from the host 
cell is performed by the NA protein, which is a viral receptor destroying enzyme.  Destroying 
SA receptors on the infected host cell may be beneficial by preventing re-infection of that 
cell.  There is strong evidence in both natural and experimental systems for coevolution of 
the HA and NA proteins to enable an efficient balance between receptor binding and receptor 
destruction (211-215). 
 
4. Influenza A virus ecology and epidemiology 
4.1 Sources of IAV variation and subtypes.  
There are two important rules governing the transmission cycle of IAV in nature: (1) the 
error-prone viral RDRP creates mutations which allow viral progeny to quickly adapt to new 
selective pressures (e.g., “drift” over time within a host taxon), (2) optimized virus 
“solutions” to replication become genetically fixed across host taxa due to host-adapting 
selective pressures such as receptor binding (2, 32, 216).  It is thought that host herd 
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immunity is the driving factor behind drift, and this makes influenza unique amongst RNA 
viruses ((217),reviewed in (218)).  However, variation of the glycoproteins does not exist in a 
spectrum and certain “solutions” have been fixed in the IAV gene pool (219, 220).  “Fixed” 
subtypes of IAV have been classified according to antigenic characteristics of the envelope 
glycoproteins, HA or NA (i.e., antibody cross-reactivity) (2, 32, 221).  This system is well-
supported genetically, and viruses are identified using an “H” number and “N” number to 
specify the antigenic subtype of each.  There are 16 subtypes of HA and 9 subtypes of NA 
which have been described from influenza viruses found in mammals and birds (219, 220, 
222, 223).  Recently two additional influenza-like viruses have been described from bats 
which have H17N10 and H18N11 glycoprotein subtypes (224-227).  Biologically, the two 
membrane glycoproteins, HA and NA, have important roles in the viral life cycle, and are 
important features for the generation of host adaptive immunity via neutralizing antibodies.   
 
4.2 IAV zoonoses.  
Host restriction is intrinsically linked to the initial receptor binding step; thus HA subtypes 
remain antigenically stable within reservoir species with some drift (reviewed in (216)). 
Subtypes of HA can be classified by their ability to bind specific SA terminal linkages ((223), 
reviewed in (159)).  For example, avian IAV have undergone selection to bind preferentially 
to SA forming a terminal linkage to the carbon-3 of a penultimate galactose (i.e., alpha 2,3-
linked SA), which is the most common type of linkage in the avian gastro-intestinal tract (95, 
169, 228, 229).  In mammalian hosts, the isomeric linkage of SA to the carbon-6 of galactose 
is more common, resulting in alpha 2,6-linked SA which are found throughout the 
mammalian respiratory tract (95, 169, 228-230).  The first step in determining whether 
transmission between taxa can occur is if receptor binding can occur in the new taxon. Once 
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in a new host species, gradual mutations in the HA and other viral proteins (i.e., drift) may 
allow for increased efficiency of replication and transmission and establish these viruses 
within a new enzootic cycle (216, 231).  For example, equine H7N7 and H3N8 IAV 
circulates in horses, canine H3N8 IAV circulates in dogs and originated from the horse strain, 
and swine H1N1, H1N2, H3N2, and the “variant H3N2” IAV circulates in domestic pigs (2, 
38, 232-234).  Throughout the last century there is evidence that novel H1N1, H2N2, and 
H3N2 subtypes of IAV have entered an endemic human cycle of transmission from an 
epizootic event and are now responsible for “seasonal” influenza (122).  As the viruses drift 
and adapt with their host, the subtype proteins retain their original antigenicity; thus, for 
example, the canine, equine, human, and swine “H3” are genetically distinct, yet they are 
more similar to one another than any are to an “H1” (reviewed in (2, 216)).   
 
4.3 Avian IAV.   
Birds are natural reservoirs for all HA and NA subtypes of IAV (with the recent exceptions 
noted above), and as such all known influenza A viruses are avian influenza viruses (235-
238).  Avian viruses may infect domestic poultry, i.e., chickens or turkeys (order 
Galliformes), and can be divided into highly pathogenic avian influenza viruses (HPAI) or 
low pathogenicity avian influenza viruses (LPAI) according to their pathogenicity in 
domestic birds (236-238).  HPAI causes significant mortality in humans but transmits poorly 
between humans, and thus the 2003 H5N1 and 2013 H7N9 IAV outbreaks in China were 
contained (10, 11, 145, 239, 240).  The reason(s) for the poor transmissibility of avian IAV 
between mammals is not known, although recently two laboratories have attempted to 




4.4 Epizootic transmission of IAV.  
The hypothesis explaining the emergence novel IAV in the human population is that swine 
act as intermediate hosts between human population and the avian reservoirs (2, 31-34).  Pigs 
have the ability to become infected with an avian virus and may foster adaption of avian 
viruses to mammalian SA linkages (241, 242).  Additionally, coinfection allows for the 
reassortment of gene segments into novel viruses with altered virulence (241-244).  
Combined with the population size of modern pig farming (60 million in the U.S. alone) and 
the conditions in which the pigs are kept (i.e., overcrowding), this creates conditions for the 
emergence of novel IAV variants.  An excellent recent example is the March 2009 
emergence of a triple reassortant H1N1 IAV in a single pig farm in Mexico (H1N1pdm), 
which spread globally within three months and eliciting a WHO worldwide pandemic alert 
by June 2009 (1, 132).  There is evidence that this H1 is the ancestor of the 1918 H1N1 virus 
that has remained in swine reservoirs, and in the years following the 2009 H1N1pdm, a 
reassortment event with H3N2 viruses have been associated with swine at agricultural fairs in 
the U.S. (1, 234, 245) 
 
4.5 Human IAV.  
Influenza viruses are present year-round in the human population, and the seasonality may be 
related to cold weather influencing human behavior (e.g., spending winters indoors and 
increasing transmission rates) and favoring the persistence of the virus on fomites (246).  
Since the beginning of the 20th century, three main subtype combinations are readily 
transmitted within the human population: H1N1, H2N2, and H3N2 (122).  For most of the 
last century, a novel antigenic form has displaced the previously circulating forms, e.g., the 
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“Asian flu” H2N2 IAV from 1957 no longer circulates in the human population (122).  The 
1957 H2N2 IAV was instead replaced by a reassortment event with circulating H3N2 viruses, 
which were subsequently related to the cause of the 1968 H3N2 “Hong Kong” IAV pandemic 
(122).  However the latest 2009 H1N1 failed to displace the seasonal human H3N2, and has 
even led to the formation of variant H3N2 IAV, which is a reassortant of the two as a direct 
result of mixing in the pig “vessel” (1, 132, 234, 247).  Since 2005 other subtypes, 
particularly highly pathogenic subtypes, have been transmitted to humans from avian species, 
although so far they have resulted in dead ends for the virus (13, 141, 144).  In summary, 
viral reassortment (antigenic shift) and random mutations under selection the reservoir host 
(antigenic drift) account for genetic complexity and adaptability of IAV (238).  In the last 
100 years, several emergent IAV have been recorded with varying levels of pathogenicity 
and transmissibility in humans. 
 
5. Studying pathogenesis of IAV. 
5.1 Mouse model of IAV.   
Mouse IAV disease. Mouse IAV disease is characterized by increased infection of the 
respiratory epithelium (55, 248, 249) (Figure 1.4).  This is often dose-dependent, and viral 
replication is typically in both the URT and the LRT (reviewed in (248, 249)).  
Histopathologic findings after mouse intranasal IAV infection include pneumonia, alveolar 
edema, and mixed inflammatory infiltrates (248, 249).  Infection of the LRT is not always 
fatal in mice, although the severity of disease in mice is difficult to assess.  Signs of severe 
disease in mice include: hypothermia (as opposed to fever in humans), lethargy, hunched 
posture, ruffed fur, dehydration, and weight loss, the latter of which is typically used as a 
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humane endpoint (248, 249).  Mouse respiratory epithelial cells display mainly alpha 2,3-
linked SAs, and viruses with increased binding affinity to this receptor are known to replicate 
to a higher titer in mice which may result in a lethal disease (50, 230, 247).  Human isolates 
(e.g., seasonal IAV) do not replicate well in mouse lungs and cause minimal disease, 
however 1918 H1N1 IAV (“Spanish” flu) and avian IAV both infect mouse lungs to high 
titer and systemic spread of viral infection is frequently noted (50, 55, 118, 250-254).  This 
may be due to receptor binding affinity of the HA, as well as the presence of a multi-basic 
HA cleavage site in avian IAV (253-255).  As discussed below, the innate immune system of 
mice has many similarities to humans.  
 
Benefits and limitations of mice in IAV research. Mice are the most frequently used 
experimental animal model in modern biological laboratories, and in IAV research. (49, 50, 
248, 249, 256, 257)(Figure 1.4)  Genetically, laboratory mice are well-defined, 
homogeneous, and capable of experimental manipulation (i.e., transgenic mice).  Housing 
and husbandry costs are relatively low which allows for a comfortable level of statistical 
replication in experiments.  Reagents and tools are commercially readily available for mice, 
which are important for studying the immune system.  However mice are not natural hosts of 
IAV infection, and their lung anatomy, including the frequency and distribution of IAV 
receptors within the respiratory tract, is different compared to humans (49, 50, 248, 249, 256, 
257). Mice are capable of becoming infected with certain IAV and may develop lower 
respiratory disease that has similarities to human influenza disease in a general sense (i.e., a 
viral inflammatory immune response and the development of specific adaptive immunity) 
(49, 50, 248, 249, 256, 257).  The pathogenicity of a given IAV isolate (e.g., human or avian) 
is variable between mouse strains, and does not always match human disease susceptibility 
(250, 258).  The most well-studied host factor that contributes to increased pathology in mice 
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is the lack of a functional Mx1 gene (an ISG) in certain laboratory mouse strains (259-262).  
To overcome these limitations to studying IAV pathogenesis, strains of IAV may evolved to 
increased pathogenicity upon experimental passage through mice (49, 50, 248, 249, 256, 
257).   
 
5.2 Ferret model of IAV.   
Ferret IAV disease. Ferrets are considered the best laboratory animal model for human IAV 
pathogenesis and transmission (47, 49, 50, 249, 256, 257, 263-266).  They have a similar 
anatomy and physiology of the respiratory tract as compared to humans, including SA 
receptor frequency and distribution (267, 268) (Figure 1.4).  They can be infected with 
human isolates of IAV without adaptation, and they are, themselves, natural hosts of IAV 
with human-like SA linkages (267, 268).  Ferrets display signs of disease following infection 
that are very similar to humans, including fever, malaise, rhinorrhea, sneezing, dyspnea, and 
inappetence (47, 49, 50, 249, 256, 257, 263-266).  Pathology from experimental IAV 
infection of ferrets may match human IAV pathology depending on IAV strain, specifically 
URT disease (71, 102, 103, 269) and bronchointerstitial pneumonia (related to human diffuse 
alveolar damage), although the latter is not as common as expected, possibly due to the 
practice of inoculating with an intranasal bolus (48, 270-272).  Similar to human cases, 
infection with avian IAV causes infection of the LRT, and pathology shows severe 
pneumonia, inflammatory infiltrates of the lung, blood neutrophilia and leukopenia (56, 266).  
However ferrets display distinct neurological symptoms after infection with avian H5N1 
IAV, a feature that was not common during human outbreaks (56, 273, 274).  Importantly, 
viral traits that are associated with increased pathogenicity in humans are thought to be 
similar in ferrets: for example, viral receptor affinity that affects infection of the LRT verses 
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URT, increased polymerase activity, and to viral mechanisms of immune modulation (e.g., 
type I IFN suppression by viral NS1A) (56, 69, 89, 91, 275, 276).  The ferret model is an 
enormous benefit for evaluating novel IAV for pandemic potential, measuring aspects of both 
transmission and pathogenicity, as well as testing vaccines and therapeutics for human use.  
 
Benefits and limitations of ferrets in IAV research. Although ferrets are an excellent model 
for studying transmission and pathogenicity of IAV, and despite their use in IAV research for 
80 years, the ferret model is poorly characterized compared to the mouse (47, 48, 148, 249, 
264).  The complete genome and transcriptome of the domestic ferret have been completed 
and published only very recently (277, 278).  Laboratory ferrets are outbred and are therefore 
genetically diverse.  In addition, there are very few ferret-specific tools and reagents 
commercially available, and these are poorly validated (279, 280).  As a result, aspects of the 
ferret immune system remain unknown with respect to specific similarities/differences to the 
human immune (compared to the mouse, about which much more is known).  Ferrets require 
special handling, housing and care, they are expensive and they are considerably larger than 
mice (47, 48, 264). This has the effect of reducing experimental sample size and, ultimately, 
reducing the statistical power achieved with many ferret studies.  Perhaps for these reasons 
there is still variation in the experimental methods employed in IAV studies using ferrets 
(e.g., inoculation volume, sex, and age are not standardized), and clinical endpoints continue 
to become better defined (263, 265, 266, 272).  Finally, many commercial vendors do not 
house ferrets in barrier facilities and it is possible, and very likely, that many research ferrets 




6. Viral determinants of increased pathogenicity. 
6.1 HA tropism and cleavage.  
Sialic acid receptor binding. As discussed above, variation in viral HA leads to changes in 
amino acid constellations that affect receptor binding preference.  This leads to increased 
efficiency of infection within a given host taxon. Just as different species have different 
frequencies of SA linkages, epithelial cell types within a given host various have different 
frequencies of certain SA linkages.  The central dogma of the increased pathogenicity of 
avian IAV in humans has been that a preference of avian IAV for alpha 2,3-linked SAs 
enables the virus to replicate in the lower respiratory tract (52, 88, 231, 281, 282).   IAV that 
cause severe pneumonia, such as H1N1pdm and 1918 H1N1 have an increased ability to bind 
to alpha 2,3-linked SAs, whereas mild seasonal IAV and H1N1pdm viruses with low 
pathogenicity have binding affinities to alpha 2,6-linked SA (88, 116, 282-284) (Figure 1.1).  
Further support of the link between receptor specificity and disease in a natural system came 
in 2013, where emergent avian H7N9 IAV had dual receptor specificity and caused viral 
pneumonia and ARDS, and not hypercytokinemia (145).  The fact that H5 does not bind 
alpha 2,6-linked SA may be tied to the unique pathogenicity of avian H5N1 IAV, a disease 
marked by hypercytokinemia (88, 94, 145, 282) (Figure 1.1). 
 
HA determines site of infection. The human URT and most of the LRT contain alpha 2,6-
linked SAs, whereas the alveolar epithelium, submucosal epithelium, and alveolar 
macrophages contain mostly alpha 2,3-linked SAs (228, 229, 282).  It is not known how 
avian H5N1 IAV is able to bypass the anatomical and chemical defenses of the URT to begin 
infection of the LRT, however ferret aerosol inoculation suggests IAV can be deposited in 
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the LRT (285).  On the contrary, it has been shown that if H1N1pdm viruses are manipulated 
to have altered tropism to alpha 2,6- or alpha 2,3-linked SAs, this has no major effect in 
pathogenicity in ferrets (116). Therefore, properties of these viruses other than HA binding 
affinity (e.g., binding avidity of HA or contributions of other gene segments) cannot be 
ignored.  In summary, replication in the URT may progress to pneumonia and ARDS if viral 
HA allows LRT replication; but replication in the LRT, alone and without URT involvement, 
is linked to a disease characterized by hypercytokinemia.  Likewise, it is clear that HA 
receptor affinity is important for transmission of avian IAV to mammals and between 
mammals, and is therefore an important not only as a virulence but also for pandemic 
potential. 
 
HA maturation and cleavage. Other features of the HA that are related to increased 
pathogenicity are related to viral entry and membrane fusion.  The immature HA requires 
cleavage by host proteases so that fusion can occur during the reduced pH of the endosome 
(177, 179, 181).    A feature of the HA of HPAI, compared to LPAI, is the presence of a 
polybasic cleavage site (177-180, 286).  The polybasic cleavage site allows for cleavage by 
the ubiquitous protease furin, which makes it possible for the virus to replication in many 
mammalian tissues (178, 181).  Additionally, it was recently observed that some H1N1pdm 
isolates carried a mutation that altered their specific pH of fusion (287).  HA typically fuses 
within the late endosome at pH 5.5, and specific amino acid mutations that stabilize the pre-
fusion complex may reduce the pH of fusion (172, 174, 287-290).  This may change the 





6.2 Replication in mammalian cells.   
The rate of viral replication in the host cell is dependent upon the RDRP.  Host adaptation 
has shaped a key residue in the polymerase subunit, PB2, which allows increased RDRP 
activity in either mammalian or avian cells (275, 291-296).  Avian IAV adapted to human 
cells (E627K) have a distinct increase in RDRP activity at 33°C, the temperature of the 
human respiratory tract, whereas a glutamate at the site has a maximum RDRP activity at 
42°C (296, 297).  Similar to the viral properties bestowed by HA, this alteration is important 
for pathogenicity as well as the transmission and pandemic potential of avian IAV in 
mammals. 
 
6.3 NS1A and IFN.   
Many viruses have evolved strategies to counteract an efficient host response to infection, 
which almost unanimously includes the ability to interrupt the type I IFN system (66-68).  
IAV accomplishes this through NS1A, a non-structural protein that is involved in direct and 
indirect disruption of the type I IFN response system (198, 298).  Using reverse genetics 
techniques, IAV lacking NS1A functionality or lacking NS1A altogether can be made and 
can infect cells (299).  However, these viruses are very sensitive to cellular type I IFN 
stimulation, and cells infected with these viruses produce much more type I IFN than cells 
infected with wild-type IAV (299-301).  Through studies with these viruses, it has been 
shown that NS1A masks cytoplasmic viral nucleic acids by interacting with dsRNA 
molecules (299-301).  This effectively hides (sequesters) dsRNA from cytoplasmic PRRs 
such as 2’5’oligoadenylate synthase (OAS)-RNaseL, protein kinase R (PKR), and the RLR 
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family of helicases (such as RIG-I and MDA5). The binding of cytoplasmic viral dsRNA by 
RIG-I or MDA5 begins downstream transcriptional activation of type I IFN (299-301).  In 
addition, NS1A may also bind these host cell factors, either directly or via co-binding to 
dsRNA, to inhibit the translation of host cell mRNA to counteract establishment of an anti-
viral state (198, 302).  The interactions of NS1A are an illustration of IAV as a master at 
effecting an acceptable and necessary level of inflammation and cellular activation (291, 303-
305), and the pathogenicity of some isolates may result from an inability of IAV to manage 
the balance between cell activation and immune suppression (199, 306).  For example, delay 
of type I IFN signaling via NS1 mediated increased virulence in ferrets (69).  In this scenario, 
inflammation (e.g., NFkB-mediated effectors) would result in leukocytic infiltration without 
the appropriate information (i.e., type I IFN) to generate a “correct” anti-viral response (65, 
69, 70, 300, 301, 307).  Powerful effector cells like neutrophils may respond inappropriately, 
and begin a cascade of immune dysregulation (70, 71, 301). 
 
7. Immune response to IAV infection  
7.1 Site of infection.   
IAV infects and replicates in epithelial cells of the respiratory mucosa (151).  The human 
respiratory system is divided functionally and anatomically into URT and LRT at the larynx, 
by convention.  The function of the respiratory system is to facilitate gas exchange between 
the host blood and the atmosphere.  The LRT is the primary site of gas exchange, and it is 
highly sensitive to (and highly protected from) inflammation.  The URT serves as a 




The upper respiratory tract. The URT is made up of the nasal cavity, the sinuses, and the 
pharynx (often the laryngopharynx and larynx are included in the URT).  The nasal cavity 
and nasopharynx are lined with a pseudostratified columnar epithelium which contains both 
ciliated and non-ciliated cells.  Anatomical barriers in the URT include the vibrissae and 
nasal turbinates (conchae) which block large particles and vortex air to remove smaller 
particulate matter. During this process the air is warmed and humidified, and receptors 
transmit chemical information to the brain via the olfactory nerves. Particulates which 
become trapped in the mucous of the URT are moved up and out of the URT via beating of 
the ciliated epithelial cells, rhinorrhea and sneezing.  The nasal turbinates are heavily 
vascularized, and during inflammation may be the site of extreme leukocytic infiltration. 
Neutrophils, mast cells, and eosinophils contribute to both allergic and infectious 
inflammation which leads to rhinitis and associated symptoms (especially rhinorrhea). 
 
The lower respiratory tract. The LRT begins below the larynx, and includes the trachea and 
main bronchus.  These structures are supported by cartilage, and the mucosal barrier consists 
of a thick layer of a psuedostratified, ciliated, columnar epithelium with non-ciliated 
columnar and basal cells (Figure 1.5).  Fibroblasts and antigen presenting cells are found in 
the lamina propria, which is supported by a submucosa that is thick with connective tissue.  
Specialized non-ciliated cells, goblet and/or clara cells, are vacuolated secretory cells within 
the epithelial layer which contribute primary chemical defenses to the respiratory mucosae in 
the form of mucous containing defensins and other innate immune effector proteins (Figure 
1.5).  Similarly, invaginations of the bronchial epithelium which extend into the submucosae 
contain patches of additional specialized secretory epithelial cells, the seromucinous (or 
submucosal) glands (Figure 1.5). They also contribute to the mucosal lining which protects 
the epithelium and is the vehicle of the mucociliary elevator.  These features of the URT and 
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the upper portion of the LRT appear to exist solely to protect the sensitive alveolar spaces 
below.   
Beginning with the branching of the trachea into the main bronchi, the LRT (the lung, 
proper) is divided into lobes fed by branches of the bronchi which split into smaller 
bronchioles and even smaller alveoli.  This arrangement creates an enormous surface area in 
a minimal volume.  The alveoli are arranged in acini and are composed of two types 
“alveolar” epithelial cells: the thin type I pneumocytes at the air/water interface and the 
cuboidal type II pneumocytes that secrete surfactant lipids and proteins (“I” and “II” in 
Figure 1.5).  Associated with the bronchioles are pulmonary blood vessels which branch into 
smaller capillaries that cover the alveolar clusters as the lung microvasculature.  The 
individual capillaries are typically composed of a single cell of endothelium creating a tube 
that is thinner than a single red blood cell.  The thin capillaries and thin type I pneumocytes 
facilitate the efficient transport of gases between the blood and air.  The barriers to infection 
and debris in the alveoli consist of surfactant proteins and patrolling alveolar macrophages.  
Surfactant proteins help buffer the surface tension of the mucosal lipid layer to prevent the 
collapse of the alveoli.  Surfactant protein-A and surfactant protein-D are lectins (specifically 
they are C-type lectins, collectins, that resemble C1q complement protein) that opsonize 
certain viruses for phagocytosis by alveolar macrophages, including IAV (reviewed in (308)).   
 
Alveolar macrophages. Alveolar macrophages are resident phagocytic myeloid cells within 
the lungs, and are the most abundant immune cells in the lung, comprising over 90% of cells 
in lung lavage fluid (reviewed in (309, 310)).  Alveolar macrophages perform anti-
inflammatory functions during homeostasis, and their capacity as phagocytic cells constantly 
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clears debris from the sensitive alveoli . Despite extensive anatomical and chemical barriers, 
the alveoli inevitably receive both harmful and harmless antigens (311).  Alveolar 
macrophages rely on immune “ignorance” to maintain homeostasis, and suppress dendritic 
cell and T cell activation via secretion of IL-10, TGFb, and/or NO in vitro (311, 312).  
Phenotypically alveolar macrophages are similar to dendritic cells, and they perform similar 
functions by constantly sampling the alveolar microenvironment for antigens and PAMPs 
(313).  For the most part they are self-renewing cells, but they can be replaced by bone 
marrow-derived monocytes upon depletion (314, 315).  They are in constant contact with the 
pneumocytes, and this provides essential feedback for both cells in the form of 
CD200/CD200R which maintains an anti-inflammatory state (316-318).  As discussed below, 
they are the “keystone” cells in the lung, and they have important functions in modulating 
inflammation, cell death, and regeneration in the sensitive LRT (313, 319-323).   
 
7.2 Cellular response to IAV infection.  
The initial universal response to the detection of viral PAMPs is the secretion of type I IFN 
(reviewed in (66, 68)).  The release of type I IFN triggers interferon receptor pathways which 
activate transcriptional regulators to initiate production of ISGs via JAK-STAT signaling 
(reviewed in (324)).  This operates in an autocrine and paracrine manner in an effort to stop 
the infection process and prevent neighboring cells from becoming infected.  The ISGs 
include pro-inflammatory cytokines and chemokines such as type I IFN, CXCL1 and 
CXCL10, as well as cytoplasmic anti-viral proteins such as Mx1, OAS, RNaseL, and PKR 
(reviewed in (325)). Similarly, these initiate well-studied inflammatory systems, such as 
activation of the transcriptional regulator NF-kappaB, to release other cytokines and 
chemokines, such as IL-6, CCL2, and CXCL8. The net effect on cells is an increased ability 
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to detect to viral PAMPs, a blockade on cytoplasmic translation, the initiation of apoptosis, 
the display of viral epitopes on major histocompatibility complexes, and pro-inflammatory 
signaling to alert neighboring cells and recruit inflammatory cells.  IAV has mechanisms to 
buffer the activation of these cascades via NS1A-mediated suppression of type I IFN 
translation or anti-apoptosis via PB1-F2 (196-198, 300, 301). 
 
7.3 Epithelial cell response to infection.  
In the URT, IAV infects epithelial cells. Non-immune cells (non-myeloid) have cellular 
sensors of viruses that rely on detection of viral nucleic acids, and mammalian immune 
systems rely chiefly on the presence of dsRNA in the cytoplasm to recognize these viruses 
(326, 327).  Double-stranded RNA is a common intermediate to the replicative cycles of both 
RNA and DNA viruses.  RLRs are cytosolic helicases, such as RIG-I or MDA-5, which 
recognize dsRNA (327, 328).  These activate pathways leading to transcription factors that 
initiate type I IFN secretion from the cell (Figure 1.6).  Similarly, PKR is capable of 
recognizing and responding to viral dsRNA after activation via type I IFN signaling. TLRs 
(for detecting PAMPs in the extracellular and endosomal spaces) are typically not as 
abundant in epithelial cells as they are in myeloid cells (326, 327, 329).   
 
In vitro infection of well-differentiated human primary respiratory epithelial cell culture 
systems and primary lung explants allows the study of the interaction between IAV and 
epithelial cells without confounding comorbidities in human patients (75, 330-334).  In 
addition, this allows side-by-side comparison of various IAV isolates in the same human 
genetic background.  Infection of these cultures with many IAV isolates causes the 
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production of type I IFN, IL-6, CCL2, and CXCL8, indicating that the epithelial cells 
contribute to the immune response, specifically by recruiting leukocytes to the site of 
infection (331, 334-338).  There are differences between the response to infection with 
seasonal, H1N1pdm, and HPAI viruses; for example, seasonal IAV infection causes increase 
in the cytokines mentioned above, indicating that H1N1pdm viruses may be suppressing the 
immune response of these cells (viral titers were similar) (331, 334) and there is indication 
that this is strain-specific (331, 333, 335, 336).  Interestingly, this was only true for apical 
secretion of cytokines and chemokines from these cells – we have shown that H1N1pdm 
viruses have increased basal secretion of cytokines and chemokines, such as IL6, CXCL8, 
CCL2, CCL4, and CCL5, from IAV-infected well-differentiated normal human bronchial 
epithelial cells grown in collagen-coated inserts (331).  Moreover, infection of human 
epithelial cells with H5N1 viruses causes a comparatively higher level of IL6, CXCL8, 
CXCL10, TNFa, and CCL5 secretion in side-by-side studies (332, 334).  Heat-inactivated 
virions (i.e., fusion-competent but non-replicating) were sufficient to activate human 
neutrophil chemoattractant gene signatures, such as CXCL1 and CXCL8 (333).  Finally, 
necrotic epithelial cells are typical of severe influenza infection, and these cells provide a 
source of immune signals, as they release CXCL8 upon death (338).  
 
7.4 Alveolar macrophages shape the viral microenvironment.  
Alveolar macrophages play an important role in contributing to and limiting inflammation 
from epithelial cells and infiltrating macrophages during infection with IAV.  In mice, 
depletion of alveolar macrophages prior to IAV infection results increased viral replication in 
the lungs, increased cytokine and chemokine production in the lungs, increased neutrophil 
infiltration, and increased lung pathology (322, 323, 339).  Unlike epithelial cells, in vitro 
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experiments using human alveolar macrophages show that they release a wide variety of 
cytokine, chemokines, lipid mediators, and ROS into the environment upon sensing virus or 
via cytokine/chemokine receptors (75, 340-342).  While pneumocytes are capable of immune 
signaling and release of cytokines following IAV infection, alveolar macrophages are the 
cells that shape the early lung microenvironment following IAV infection, and determine the 
pattern infiltration of leukocytes to the lung (61, 320-322, 337, 343-345).   
 
Disrupting homeostasis. Upon introduction of IAV into the alveolar space, the alveolar space 
contains virus, pulmonary surfactant, and alveolar macrophages (Figure 1.5).  Upon infection 
of either the epithelium or the alveolar macrophage, homeostatic cross-talk between alveolar 
macrophages and epithelial cells (e.g., CD200/CD200R) may become temporarily disrupted 
as type I IFN is released into the alveolus (316, 346).  An important consequence of type I 
IFN in the alveoli is the triggered apoptosis of infected epithelial cells by activated 
macrophages via death receptors (65, 343, 344, 347, 348).  Additionally, infection with IAV 
causes increased apoptosis and necrosis in epithelial cells and in monocytes without addition 
aid of death receptor ligation (202, 251, 334, 349-352).  Desquamation of alveolar epithelium 
is characteristic of ARDS; on histological preparations from severe human cases the alveolar 
epithelium is replaced by an eosinophilic hyaline membrane (6-8). 
 
Infection of alveolar macrophages and sensing IAV.  In vitro studies using mouse (73, 353) 
and human alveolar macrophages (75, 341, 342) show that infection is abortive, suggesting 
that alveolar macrophages are not contributing to increased virus in the lung during infection.  
In mice, infection with a pathogenic IAV causes a necrotic depletion of alveolar 
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macrophages, which can be rescued by administering GM-CSF (313, 354).  However, 
abortive infection is critical for sensing infection by activating virus-specific PRR and 
initiating adaptive immunity via MHC-I presentation on antigen presenting cells (355, 356).  
Detection of pathogens via TLR signaling relies heavily on myeloid cells, such as 
plasmacytoid DCs and alveolar macrophages (326, 357, 358), and detection of IAV relies 
heavily on RIG-I signaling (327).  Both of which lead to induction of the type I IFN system 
and provides a crucial link with the innate and adaptive immune systems (67, 329, 348). 
Although there is an established trend that IAV with increased pathogenicity stimulate a 
decreased inflammatory response from alveolar macrophages in vitro (74, 340, 341, 359), to 
my knowledge no studies have investigated the effects on the normal anti-inflammatory 
functions of alveolar macrophages during IAV infection (e.g., TGFb secretion).   
 
7.5 Systemic inflammation.   
As the local inflammatory environment grows, macrophages and endothelial cells amplify 
and transmit the inflammation systemically in the form of chemokines, pyrogenic cytokines, 
and growth-stimulating factors (360) (Figure 1.6).  Chemokines recruit innate immune cells 
to the site of infection (reviewed in (361)).  Following infection, cells such as natural killer 
cells (NK), inflammatory monocytes and macrophages, as well as neutrophils infiltrate the 
airways from peripheral blood circulation (70, 253, 360, 362, 363).  As discussed below, 
these cells become activated while in the peripheral blood circulation, continue to activate 
during migration to the site of inflammation, and then perform effector functions to at the site 
of inflammation in response to the microenvironment.  The activation of the innate immune 
response is immediate and acute, whereas the adaptive immune system requires time but is 




NK cells. In the context of viral infection, NK cells recognize “missing self” and the 
presentation of death receptors to destroy infected epithelial cells.  Interestingly, mammalian 
NK cells are known to contain cell surface proteins, NKp46 and NKp44 in humans (NCR1 in 
mice and ferrets), which activates the cell upon recognition of IAV HA (364-367).  IAV 
seems to have NK evasion strategies that include direct infection of NK cells as well as 
increasing the display of NK cell-inhibiting ligands on infected cells (368).  Even so, NK 
cells seem to be dispensable for the response to influenza, and patients lacking NK cells 
recover fully from IAV infection (369, 370).  In animal models, NK cells are essential for 
clearing viral infection, and they accomplish this by contributing to the generation of a robust 
adaptive immune response (i.e., Th1), potentially through the release of massive amounts of 
IFNg (367, 371, 372). 
 
Inflammatory Monocytes and Macrophages. Macrophages are terminally differentiated cells 
present in tissues (315).  During inflammation their precursors (monocytes) are recruited 
from the peripheral blood circulation and the bone marrow to the site of infection to 
differentiate in response to in situ signals (reviewed in (309)).  These signals may polarize 
these cells to differentiate towards various phenotypes, some of which have pro-
inflammatory features and some have anti-inflammatory functions to various degrees (373). 
Infiltrating inflammatory monocytes and macrophages have a different phenotype than 
alveolar macrophages, and have different susceptibilities to infection by IAV (359, 374, 375).  
Depending on the in vitro preparation of macrophages and the viral strains used, their 
importance in IAV disease is still uncertain.  However, in general it seems that infiltrating 
monocytes and macrophages have a clear pro-inflammatory response to IAV infection (72, 
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351, 376-378).  In a CCR2-/- mouse model of IAV, even a minor delay in infiltrating 
macrophages drastically increases the influx of neutrophils into the lung by exacerbating the 
CXCL1/CXCL2 response (379). Macrophages are the main producers of CXCL9 and IFNb 
(380) following mouse IAV infection.  An interesting experiment used intraperitoneal 
injection of IAV to show that infection of inflammatory macrophages by IAV stimulates an 
immune response in vivo without contribution of epithelial cells (375).   
 
Neutrophils.  Neutrophils are another subset of phagocytic myeloid cells, and exist in steady-
state as mature, terminally differentiated cells.  They are well known to be associated with 
acute lung injury and inflammation in the lungs, and are typically among the first immune 
cells to arrive during many types of infection and inflammation (16, 18, 381).  They are well-
studied with respect to bacterial infection, although their role in viral infection is not clear.  
Neutrophils are present during acute phases of IAV infection of both the URT and LRT, as 
well as during infection with other respiratory viruses (343). A common feature of the 
immune response to pathogenic influenza viruses in human and animal models is an 
excessive infiltration of neutrophils into the LRT (70, 85, 86, 253, 323).  However, 
experimental depletion of neutrophils prior to infection with IAV leads to increased lung 
pathology, increased inflammatory cytokines and chemokines in the lung, and increased virus 
replication (84, 86). Neutrophil activation and their migration to the lungs are steps that are 
critical to recovery from IAV infection (26, 78-80, 83, 84, 86, 323).  Neutrophils are short-
lived during inflammation, and contribute significantly to the cellular debris that accumulates 
in the lung during infection, although they are capable of phagocytosis of IAV-infected 
epithelial cells (79).  There is very little known about neutrophils in the context of viral 
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infection.  In the next section, the possible roles for neutrophils in IAV disease will be 
discussed in detail. 
 
8. Neutrophils in IAV infection 
Neutrophils are increased in the lungs and blood after infection with pathogenic IAV in mice, 
humans, and ferrets (294, 363, 382).  Neutrophils are necessary for recovery from severe, but 
not mild, IAV infection (86, 381). Studies in mice show that neutrophils have effects during 
both early and late stages of disease (85).  Signals from both alveolar macrophages and 
macrophages initiate neutrophil chemotaxis and activation to the lungs. For example, TLR7 
recognition of IAV dsRNA and Myd88-mediated release of TNFa and CCL3 by mononuclear 
cells is important for neutrophil recruitment to the site of infection (383, 384).  Interestingly, 
TLR3-/- mice have increased neutrophilia and fewer macrophages in the lungs, yet have 
increased survival after infection with IAV (385, 386).  In cell co-culture, human neutrophils 
were seen to interact specifically with IAV-infected cells (387), although the nature of this 
interaction in the infected lung is unknown.  Transgenic mice have been used to study the 
contribution of specific cytokines and chemokines to inflammation following IAV infection, 
particularly as this relates to “hypercytokinemia”, and are summarized in Tables 1.1-1.4.  The 
signals from the infected lung are propagated systemically by endothelial cells, which recruit 
and tether neutrophils.  The complex interactions governing neutrophil extravasation, 
migration through the interstitium, and crossing the alveolar epithelium are well known in 
relation to many forms of ALI and the development of ARDS with the exception of 
conditions surrounding viral infection (16-18, 20, 388, 389).  Due to the mechanical 
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stimulation of passing through the small diameter of the microvasculature of the lung, 
neutrophils in the lung are more activated than peripheral neutrophils (17).  
 
8.1 Neutrophil migration.  
Neutrophil chemotaxis in humans is thought to be mediated by many factors, such as the 
chemokine CXCL8, cytokines IL-1 and TNFa, and complement C5a (388, 390, 391).  During 
both mild and severe IAV disease, patients show increased blood CRP and activation of C5a 
(392), as well as increased secretion of CXCL8, TNFa, and IL-1 in nasal washes which 
correlate with disease severity (99, 101, 105, 393-395).  Studies using mice have offered 
insight into the relationships between inflammation and neutrophil chemoattraction during 
influenza infection.  For example, chemical reduction of C5a during IAV infection reduced 
lung neutrophilia (396).  Similarly, cytokines such as IL-1b and IL-6 are important for 
neutrophil activation and migration to the lungs during mouse IAV infection (Table 1.1) 
(397-399).  Mice do not possess CXCL8, but CXCL1 and CXCL2 have equivalent functions.  
Neutrophils contribute CXCL2 to the IAV-infected mouse lung to further stimulate 
neutrophil recruitment (380).  More recently it was shown that removing a CXCL1 repressor 
(Setdb2) does not increase recruitment of neutrophils to the lungs of mice infected with IAV 
PR8, rather it reduces the ability to respond to bacterial superinfection (400).  In addition, it 
was shown that another ISG, CXCL10, operates on a unique subset of CXCR3+ neutrophils 
present during mouse IAV infection in an autocrine manner, increasing chemotaxis, oxidative 
burst and enhancing inflammation (380) (Tables 1.3 and 1.4).  Finally, aryl hydrocarbon 
receptor is somehow linked to increases in NO and neutrophilia in the lungs of IAV-infected 
mice independently of known neutrophil chemoattractants or mechanisms of neutrophil 




8.2 Neutrophil extracellular PRRs and phagocytosis.   
Neutrophils are phagocytic cells, and their methods for sensing extracellular pathogens relies 
on TLRs (390).  Stimulation of neutrophils through TLRs has been recorded to promote 
cytokine secretion (CXCL8 and TNFa via NFkB and AP-1), ROS formation, phagocytosis, 
granule secretion, NET formation, and migration (388, 390, 391).  Human neutrophils highly 
express nucleic acid-detecting TLRs, specifically endosomal TLR8 (405, 406), but do not 
express nor respond to activators of TLR3 or TLR7 (82, 405, 406).  TLR4 is required for 
LPS-induced neutrophil migration to the lung (407); however, TLR4-stimulation does not 
lead to the production of type I IFN in neutrophils (82, 408).  Surfactant protein D, a lung 
collectin, is an innate immune defense against a variety of viruses, which marks them for 
phagocytosis by neutrophils which cause the production of ROS (409-415).  Human 
neutrophil defensins are short basic peptides released from neutrophil granules during 
inflammation (388, 415, 416).  They have been shown to interact with IAV, reducing 
infectivity, and promote neutrophil phagocytosis and clearance of IAV (415-419).  Defensins 
may also buffer the oxidative burst from neutrophils that follows from phagocytosis of 
viruses that have been opsonized by surfactant protein D (415-417).  One study indicated that 
neutrophils do not interact with immunoglobulin-bound IAV (420), however another showed 
that protective anti-IAV antibody therapy only protected mice in the presence of neutrophils 
(78). 
 
8.3 Neutrophil intracellular PRRs.  
Neutrophils express sialic acid receptors and may become infected with IAV (26, 421, 422).  
Neutrophils infected with IAV have increased apoptosis, but infection does not result in the 
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production of virus (422). Infection of human neutrophils with IAV treated at 56°C to 
denature the viral replicase but not HA suggested that infection alone, but not replication, is 
sufficient to stimulate the release of CXCL8 and CCL4 in human neutrophils (423).  
Neutrophils infected with IAV have rapid up-regulation (<9 hpi) of type I IFN pathways, 
including cytoplasmic PRRs, IFNb, and ISGs (422), which is counter to the long-held dogma 
that neutrophils were incapable of gene expression.  This is may be due to RLR sensing of 
viral dsRNA, as neutrophils transfected with poly(I:C) (a viral RNA mimic) have a similar 
response (82).  Additionally, neutrophils express nod-like receptors (NLRs) but it is unclear 
how these interact with IAV infection (424, 425).  In general, inflammasome and pro-IL1 
activation following IAV infection is poorly understood (307, 397, 398, 426).  However, 
studies of IAV infection using caspase-1, IL-1b, or IL-1R transgenic mice show modulation 
of neutrophil infiltration and pathology, and suggest that it is an IAV subtype-dependent 
effect (397, 426-430) (Tables 1.1 and 1.2).  Furthermore, it has been demonstrated that the 
HA of some IAV isolates suppresses neutrophil activation, providing further evidence for 
IAV subtype-dependent effects on neutrophils (421, 422, 431). 
   
8.4 Neutrophil activation and degranulation.  
Activation of TLRs and RLRs trigger degranulation and the upregulation of CD11b (82), 
which pairs with CD18 to form the “Mac-1” integrin dimer that binds collagen (432). This 
facilitates migration through tissues, and release of gelatinase or collagenase (MMP-2 and 
MMP-9) from neutrophils assist in clearing connective tissue from the path.  At the site of 
infection, neutrophils release microbial effectors (reviewed in (81, 388)).  Neutrophils 
develop granules sequentially (azurophilic, specific, gelatinase, secretory) and secrete 
granules in the reverse order (388).  Secretory and gelatinase granules are released shortly 
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after endothelial transmigration and contain membrane proteins essential for movement 
(extracellular matrix [ECM]-binding integrins) and pathogen recognition (immunoglobulin 
[FcR] and complement receptors) (388).  Specific and azurophilic granules contain tissue-
destroying enzymes and anti-microbial proteins.  For example, neutrophil MPO may 
contribute to lung injury during IAV infection (77), however it may have direct antiviral 
effects on IAV (433).  An investigation found no difference between IAV infection of a wild-
type and neutrophil elastase knockout mouse, measuring lung function, chemokine secretion, 
and neutrophil recruitment (434) (Table 1.5).  The contents of the granules can be secreted to 
destroy ECM (such as MMP-9) or directed towards phagosomes to destroy engulfed 
microbes.  The production of hypochlorous acid (HOCl) is the main oxidant used in 
phagosomal killing, and its production is dependent on the generation of reactive oxygen by 
the neutrophils.  Interestingly, infection by IAV was related to the inhibition of phagosomal 
killing of bacteria (431). 
 
8.6 Oxidative burst.  
Neutrophil degranulation primes neutrophils for ROS generation by mobilizing NADPH 
oxidase components to the plasma membrane (388) and exocytosis of MPO.  IAV infection 
causes the generation of reactive oxygen species in neutrophils (435).  Oxidative burst is 
thought to have direct microbial effects, however the direct effect on IAV has not been 
published (436).  IAV infection benefits from the presence of ROS in the environment (437, 
438), yet IAV also suppresses NADPH oxidase activity within infected phagocytes (439, 
440).  Many have investigated the effects of ROS and NO on lung inflammation during IAV 
infection and found that reduction of oxidative stress in the form of both ROS and NO alieves 
IAV-dependent lung injury (439, 441-446) (Table 1.5).  For example, oxidized lipids in the 
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lung environment may trigger TLR4, activating immune cells and contributing to increased 
lung injury (447-449). 
 
8.7 Neutrophil netosis.  
Neutrophils undergo a form of programmed cell death called netosis, in which NETs are 
formed (450).  NETs have the effect of killing many pathogens, including bacteria (389), 
fungi (451), and protozoans (452).  NETs are becoming the focus of study in autoimmune 
disease atherosclerosis, since they damage endothelium (453-455).  Recently, it was shown 
that hantavirus stimulates NET production during infection which leads to the generation of 
autoantibodies and may provide a mechanism for the hemorrhagic fever caused by Old 
World hantaviruses (456).  NETs are typically found with histones, MPO, and neutrophil 
elastase, and the effect is to isolate the effects of these molecules directly onto the pathogen 
surface with a “sticky” NET of nucleic acid. NETs contribute to acute lung injury and 
alveolar capillary damage during IAV infection (381).  Yet very little is known about the 
relationship between NETs and viral infection  in viral disease pathogenesis (457). 
 
8.8 Contribution to the viral microenvironment. 
Resolving inflammation. At some point, neutrophil infiltration into the lung must stop, and 
increased neutrophils are present in lethal cases of ARDS.  This may be regulated by 
secretion of IL-1RA and chemokine-destroying factors by recruited macrophages (373, 458). 
Additionally, it has been proposed that efferocytosis of apoptotic neutrophils is a key step in 
resolution of inflammation (459-461), and occurs in the lung during bacterial pneumonia 
(462).  It is unclear if this happens during IAV infection. Finally neutrophils act as antigen 
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presenting cells during IAV infection of mice and enhance cytotoxic T cell responses (26, 
83), contributing to resolution via the production of an adaptive immune response.   
 
Prolonging inflammation.  Factors that prolong the life span of neutrophils in the lungs 
increase the probability that they may contribute to immunopathology.  IL-6 and G-CSF are 
immune mediators present in the lung during infection and are known to prolong survival of 
neutrophils in mouse lungs following IAV infection (463).  Both neutrophils and 
macrophages are known to phagocytose apoptotic epithelial cells in mouse lungs during IAV 
infection (79).  The cells may be recruited via chemokines or damage receptors.  For 
example, necrotic IAV-infected epithelial cells are a source of CXCL8 (338), which attract 
neutrophils to dying cells.  In addition, neutrophils can detect DAMPs such as S100A9 (464). 
It has been shown that extracellular S100A9 is abundant during IAV infection in mice (465).  
Antibody-mediated neutralization of S100A9 decreased lung inflammation in mice and 
improved disease outcome (465).  Apart from potential tissue-destroying effects of neutrophil 
proteases, the presence of NETs may induce even more inflammation in the lungs (80, 381).  
Thus, there are limited data supporting directly malevolent actions of neutrophils (Table 1.5), 
yet factors that increase their presence and prolong their survival in the lung are correlated 
with increased disease severity. 
 
9. Neutrophils in viral respiratory disease 
There appears to be a correlation between IAV infection and neutrophils, but this may not be 
a causal relationship.  In bacterial pneumonia, there is direct evidence of the importance of 
neutrophils in disease: bacterial PAMPs upregulate neutrophil activating and chemoattractant 
chemokines, bacteria have defined anti-neutrophil functions, and some bacteria, e.g., 
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Mycobacterium tuberculosis, rely on neutrophils to establish their granulomatous niche (19, 
466, 467).  Similarly, in ARDS there are data that directly support the role of neutrophils as 
both beneficial and detrimental (16, 57, 58).  To substantiate a link between neutrophils and 
IAV, evidence for the role of neutrophils in viral respiratory disease is briefly reviewed 
below.  Although scarce, evidence presented here relies heavily on prospective clinical data 
as well as pathological reports from human cases of respiratory infection of confirmed viral 
and bacterial etiologies.  Specific animal models are not considered here due to differences in 
the types of cells called neutrophils between species, as well as limitations in animal models 
to directly recapitulate human disease from these specific pathogens. 
 
For both viral and bacterial etiologies, the most severe clinical complications result from 
infection of the LRT.  Infection of the LRT by viruses such as human parainfluenza viruses, 
H1N1pdm, HPAI, New World hantavirus infections (causing hantavirus pulmonary 
syndrome), Severe acute respiratory syndrome-related coronavirus (SARS-Cov), and Middle 
East respiratory syndrome coronavirus (MERS-CoV) may develop into ARDS (22, 23, 51, 
63, 143, 468-470).  Clinically defined, ARDS has three phases; and most patents die within 
the first phase, the acute or “exudative” phase (reviewed in (25, 57, 58)).  This phase is 
characterized by an increased immune response with high production of pro-inflammatory 
cytokines and chemokines, increased neutrophil infiltration and accumulation in the alveoli, 
and disruption of the alveolar epithelial-capillary barrier, which leads to increased vascular 
permeability and edema (57).  The distinctive role for lung neutrophil infiltration in viral 
infection is summarized as follows: some, but not all, viruses that infect the LRT result in 
clinically-defined ARDS, and lung neutrophil infiltration is associated with viruses that do 
and do not lead to ARDS (16, 18, 22, 23, 51, 77, 143, 468-472).  Therefore, perhaps there are 
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specific viral factors or virus-induced host factors that indicate a common mechanism for 
neutrophil infiltration into the respiratory tract (Table 1.6). 
 
9.1 Viruses that cause neutrophilic infiltration.   
Human rhinovirus. Infection with HRV is a well-studied virus for which there are several 
studies on the link between neutrophils and disease (87, 473-475) (Table 1.7).  HRV are plus-
sense single-stranded RNA viruses with an icosahedral nucleocapsid in the Picornaviridae 
family, genus Enterovirus (476).  HRV virions enter nasal epithelial cells via endocytosis, 
yet, unlike influenza, infection does not cause major damage to the nasal epithelium (476-
478).  Neutrophilic rhinitis, increased vascular permeability, and mucus hypersecretion are 
the key pathological features of HRV infection (87, 473, 474, 477), and infected epithelium 
seems to be the source of large amounts of neutrophil chemotactic molecules, particularly 
CXCL8 and kinins (473, 475, 479, 480).  Interestingly, in vitro studies have shown that 
TLR3 and MDA5, but not RIG-I, are important for detecting dsRNA, and HRV capsid is 
recognized by TLR2 on the epithelial surface (473, 481).  Thus, viral recognition shares 
features with hRSV, but is somewhat different than with IAV (300, 327, 482).  Even so, in 
vitro infection of nasal epithelial cells with HRV indicates similar secretion of inflammatory 
mediators is the result of these respiratory diseases: HRV causes upregulation of IL-1, IL-6, 
CXCL8, GM-CSF, CCL5, CCL11, and type I IFN (483).  It has been established that there 
are virus-specific and cell-specific differences in sensing RNA viruses via primarily TLR- 
and/or RLR- pathways (and even in a preference for RIG-I versus MDA5), yet these 
pathways may have similar general endpoints, such as chemokine and cytokine signaling 




Paramyxoviruses. Numerous viruses in the family Paramyxoviridae infect the human 
respiratory tract and may cause significant pathology (Table 1.6).   Paramyxoviruses are 
minus-sense single-stranded RNA viruses that include hRSV, which is the leading cause of 
childhood bronchiolitis and pneumonia during interpandemic years of IAV transmission 
(484).   Infection with hRSV causes neutrophilic infiltration in the LRT, where thick luminal 
mucous plugs filled with neutrophils may cause bronchiolar obstruction (485, 486).  Nasal 
washes and BAL from patients with hRSV contain neutrophil chemoattractant chemokines 
(21, 487-489) and there is evidence that neutrophils and other respiratory cells may recognize 
hRSV virions directly through TLR2/6 (482, 490).  Other viruses within this family include 
Measles virus, Human metapneumovirus (MPV), and the highly pathogenic emerging 
viruses, Hendra virus and Nipah virus; all of which have reports of neutrophilic infiltration at 
sites of infection to various degrees (491-494).  Interestingly, there are no reports of 
neutrophils associated with infection from any of the human parainfluenza viruses (PIV) 
(495).  Human PIV infects ciliated epithelium of the respiratory tract and may cause 
bronchiolitis and alveolitis (470).  However, infection does not cause a cytopathic effect, 
which is thought to be due to viral proteins which block PRR signaling and apoptosis (470, 
496).  Even so, cases of severe PIV infection have elevated chemokines in nasal washes 
(CCL3, CCL4, CCL5, CXCL8, CXCL9, and CXCL10), some of which are neutrophil 
chemoattractants indicating that neutrophils may be present at some point in the disease 
progression (470, 480, 495-497). 
 
Coronaviruses.  Members of the family Coronaviridae are plus-sense single-stranded RNA 
viruses and infect a wide variety of mammalian and avian species (498) (Table 1.7). Two 
genera of coronaviruses are important human pathogens:  members of the genus 
Alphacoronavirus include Human coronavirus NL63 (HCoV-NL63); and the genus 
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Betacoronavirus includes HCoV-HKU1 and the highly pathogenic SARS-CoV and MERS-
CoV (498).  Human coronaviruses, such as HCoV-HKU1, HCoV-NL63, HCoV-OC43, and 
HCoV-229E, have recently been identified and are thought to cause both URT and LRT 
infections (499, 500).  Very little is known about specific pathology associated with HCoV 
infection.  However, much more is known about infection with SARS-CoV and MERS-CoV. 
These emergent viruses infect pneumocytes in the LRT and may cause a severe disease that 
can lead to ARDS and even have pathophysiological symptoms of hypercytokinemia (22-24).  
Infection with either of these viruses is correlated with increased IL-6, CCL2, CXCL8, and 
CXCL10 in the blood and respiratory tract, and neutrophils are noted in respiratory tissues 
from lethal cases of infection with either of these viruses (23, 24, 501). 
 
Other respiratory viral infections.  Human adenovirus (hAdV, members of the family 
Adenoviridae, genus Mastadenovirus) infections have been documented to cause an initial 
neutrophilic alveolitis that may progress to a viral pneumonia (specifically serotype hAdv-7), 
which may be related to the release of CXCL8 and CXCL10 from infected epithelial cells 
(502) (Table 1.7).  Human cytomegalovirus (family Herpesviridae) may cause a viral 
pneumonia that includes hyaline membrane formation and neutrophilic alveolar exudates 
(503).  Autopsies from patients who died from hantavirus pulmonary syndrome, caused by 
infection with New World hantaviruses, were seen to have neutrophilic infiltration 
surrounding antigen positive lung lesions (504) (Table 1.7).  These cases are particularly 
remarkable, since hantaviruses infect and cause inflammation of the endothelium, often with 
no apparent damage to the epithelium (504).  However, hantavirus pulmonary syndrome 
(HPS) is a severe pulmonary infection characterized by interstitial pneumonitis, focal hyaline 




9.2 Comparisons of respiratory viral infections. 
Cytopathic effect. A key question is whether virus-induced cytopathy drives neutrophilia or 
whether it is the result of host response to viral infection.  Infections with H1N1pdm, HPAI, 
SARS-CoV, and MERS-CoV are thought to cause acute lung injury which results in ARDS; 
characterized by excessive damage to the alveolar epithelium and involving the infiltration of 
neutrophils (7, 8) (Tables 1.6 and 1.7).  However, less pathogenic strains such as HRV 
infections do not cause significant damage to the respiratory mucosa, yet neutrophils are 
present (477, 478).  Conversely, viruses that cause moderate, focal cytopathy in the lungs, for 
example seasonal IAV and hRSV, are known to cause neutrophilic infiltration (478-480).  
Therefore, neutrophils are not necessarily associated with direct cytopathic effect, nor are 
they exclusively associated with severe disease.  
 
Host response to viral versus bacterial infection.  Specific host responses to infection may 
act as a driving force behind neutrophil infiltration.  As evidenced above, many viral 
infections associated with neutrophil infiltration have RNA genomes.  Host cells detect RNA 
viruses primarily through RLR as well as TLR, whereas bacteria rely on a different group of 
PRRs to detect extracellular PAMPs (327, 328, 357, 505).  Because of the importance in 
diagnostics, many studies have focused on biomarkers that identify bacterial versus viral 
infection (e.g., (506, 507)).  Although it is debated, these studies routinely point to CRP as a 
correlate of bacterial infection (506-511).  However, cases of IAV and hRSV infection are 
known to activate complement and often show increased CRP (392, 396, 512, 513).  In short 
a single reliable biomarker of bacterial versus viral infection has yet to be found.  In a recent 
study, it was among a group of early conserved differentially expressed genes across species 
(mouse and macaque) and pathogens (IAV and bacterial), all of which were the direct result 
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of an upregulation of ISGs (505).  For example, IFNb, IL-1a, IL-6, IL-23a, TIMP1, M-CSF, 
ISG15, CCL2, CCL5, CXCL10, and CD40 were all common to the early host immune 
response to lung infection (505).  The control of signaling through TLR versus cytoplasmic is 
controlled by complex intracellular adaptor proteins (e.g., allowing the characteristically 
bacteria-specific TLR4 to signal the upregulation of viral-specific type I interferons (514)), 
the implications of this require much more research (reviewed in (515)). 
 
Specific immune response signatures to different viruses.  The relative number of neutrophils 
during viral infection may reflect the different strategies used by viruses to manipulate the 
host defenses, and viral infections such as HRV, hRSV, and IAV may create unique or 
“signature” immune responses that are involved in neutrophil attraction relative to MPV, 
PIV, or HCoV (the latter group have fewer neutrophils during infection).  In other words, 
where there are often redundancies in a typical “viral” immune response, investigating 
differences between these patterned immune responses en masse between viruses may be 
informative (e.g., (516)).  Unfortunately, there are very few studies that approach this topic.  
In general, clinical studies have shown that viruses causing increased concentrations of 
CXCL8, TNFa and IL-1 are associated with increased neutrophilia, confirmed in patients 
with HRV, IAV, and hRSV infection (480, 517), yet CXCL8 is only correlated with 
symptom scores for HRV and IAV (480).  Interestingly, the lung microenvironment to hRSV 
has been shown to be different from IAV, specifically in the presence of IL-4 (508, 518).  It 
is thought that this is driven by the presence of alternatively activated macrophages during 
RSV infection (519).  It is not known if this directs differences in neutrophil chemoattraction, 




CXCL10. Patients with ARDS resulting from infection with SARS-CoV (501), H1N1pdm 
(105), or H5N1 HPAI (10, 54, 330, 521) had a common marker of inflammation: high levels 
of CXCL10.  A prospective study of patients with severe respiratory disease found BAL 
concentrations of CXCL10 (but not CXCL8) and eotaxin/CCL11 were significantly 
upregulated in confirmed cases of viral infection (HRV, IAV, hRSV, MPV, HCoV-NL63, 
PIV, hAdv, or polyomavirus) compared to non-viral respiratory disease (522).  CXCL10 is an 
ISG that binds the CXCR3 receptor on NK cells and plasmacytoid DCs and induces 
chemotaxis, apoptosis, cell growth, and angiostasis (523-527).  CXCL10 is released during 
many viral infections, not just respiratory viral infections. Although it is not a classical 
neutrophil chemottractant, it is also known to operate in an autocrine manner with a unique 
subset of CXCR3+ neutrophils during influenza infection (380).  
 
9.3 Neutrophils in the viral microenvironment. 
In general, immune activation pathways that involve the activation of NFkappaB lead to the 
secretion of neutrophil chemotactic chemokines (reviewed in (528)).  This is heavily driven 
by PAMPs, and during a viral infection type I IFNs and ISGs are the unique elements in the 
virus-inflamed lung environment (reviewed in (66-68, 324, 325)).  This single difference 
between viral and bacterial infections could have drastic effects on the actions of neutrophils 
once in the lung. Moreover, without this information (e.g., pathogenic viruses that suppress 
type I IFN) neutrophils may respond to inflammation in an inefficient way, potentially with 
pathologic effects (65, 69-71, 298, 300, 301, 422, 529, 530).  Neutrophils are known to 
respond to IAV and type I IFN by upregulation of ISGs (422).  In systemic lupus 
erythematosus, neutrophils may be a large contributor of type I IFN (531, 532).  During 
increased inflammation, left-shifted or immature neutrophils emerge from the bone marrow – 
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a classic sign for sepsis, but also known to be present during some severe viral respiratory 
diseases (e.g., HPS) (504). It is known that immature neutrophils do not express IFN 
receptor, nor many other cytokine receptors (530).  It is unknown what affect this would have 
during increased inflammation during pathogenic influenza infection, although their role in 
other inflammatory conditions suggests it may affect their functions (529, 530, 533, 534). 
 
Concluding remarks. 
Are neutrophils associated with viral infection? Are they associated with respiratory viral 
infection?  When, where, and how are they associated?  In the context of viral infection, what 
is a productive response of neutrophils? Is a productive response determined by type I IFN?  
There is substantial data that suggest neutrophils are a part of a viral response to infection.  
Neutrophils are among the first responders to IAV infection in the lung, and they remain in 
great numbers throughout the development of ARDS.   However, many questions remain 





Figure 1.1 Three disease states caused by human infection with influenza A virus.  
Human infection with influenza A virus (IAV) produces three main types of disease.  
Seasonal human IAV (left) causes upper respiratory tract disease that is characterized as 
an acute, self-limiting flu-like illness.  Seasonal IAV and some emergent IAV can cause a 
severe influenza pneumonia (center), which involves infection and inflammation of the 
lower respiratory tract.   Some highly pathogenic avian IAV (right) cause a lethal 
infection characterized by a dysregulated immune response; this can also lead to severe 
pneumonia.  Beneath each heading are the viral strains that typically cause each disease, 
following by a cartoon diagram showing primary site of viral replication.  Arrows below 
point to pathological outcomes, followed by typical immune responses measured in 





Figure 1.2 Influenza A virus genome. 
Influenza A viruses have an 8-segmented, single-stranded, negative sense RNA genome 
that codes for 10-13 gene products.  The cartoon shows the arrangement of those gene 
products along each gene segment.  Gene segments are sized relative to each other, and 
the total genome is over 13 kb in length.  The basic formulas for making protein and 
replicating the genome are shown in the box; most steps are performed by the viral RNA-





Figure 1.3 Influenza A virus life cycle diagram. 
Seven major steps in the influenza A virus life cycle include: (1) binding to host cells via 
sialic acid residues (SA) and entry into cells via clathrin mediated endocytosis; (2) fusion 
to host cell membrane allows release of viral genome into cytoplasm and import into 
nucleus; (3) viral genome transcription (3a) and replication (3b) occur in the nucleus by 
the viral RNA-dependent RNA polymerase (RDRP); (4) mRNA is exported for 
translation by host ribosomes; (5) some proteins modify the host immune response, 
glycoproteins are exported to the cell membrane through the Golgi body and proteins that 
form the ribonucleoprotein (RNP) are imported back to the nucleus to bind to new 
vRNA, which is exported from the nucleus (6) to the plasma membrane where virions are 




Figure 1.4 Animal models of influenza A virus infection 
Mice and ferrets are commonly used animal models to study influenza A virus 




Figure 1.5 Cartoon diagram of normal human airways 
The upper airways are on the left, consisting of ciliated pseudostratified epithelium with 
occasional secretory cells and submucosal (SM) secretory glands embedded within the 
extracellular matrix (ECM).  In the lung, the airways branch into bronchioles and end in 
alveoli, which are made of type I (I) and type II (II) pneumocytes which are in near-
constant contact with alveolar macrophages (AM).  The alveoli are the site of gas 
exchange, working in close proximity to the lung microvascular endothelium to expel 
carbon dioxide (CO2) from the pulmonary arteries and carry oxygen (O2) through the 
pulmonary veins back through the heart and into circulation. The airway epithelium is 
lined with mucus containing mucins, defensins; and the alveoli contain surfactant 
proteins that aid in surface tension and innate immune defenses.  Because the entire blood 
volume passes through the lungs, innate immune cells (such as natural killer cells, NK; 
monocytes, Mo; and neutrophils, N) are transient through the lungs and must navigate 




Figure 1.6 A cartoon diagram of IAV infection in the human respiratory tract. 
Infection of epithelial cells in the bronchus results in the release of type I interferons 
(IFN/) which signal to nearby cells.  The result of IAV/ signaling is the release of 
proinflammatory cytokines (e.g., IL-1, IL-6, TNF) that signal to endothelial cells, 
which help spread inflammatory signals (chemokines such as CCL2, CCL5, CXCL8, 
CXCL10) throughout the blood to recruit innate immune cells to the site of infection.  
Recruited of innate immune cells (such as natural killer cells, NK; monocytes, Mo; and 
neutrophils, N) must interact with activated endothelium to leave the blood stream and 
crawl towards the site of infection.  There they can perform effector functions to control 
infection, such as releasing reactive oxygen species (ROS) and directly killing infected 
cells (cytolysis).  
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Table 1.1 Effect of cytokine knockout mice infected with IAV on neutrophils 
Mouse 
Model 










No 5x105 PFU Same as wt Same as wt (428) 
IL-1-/- H3N2 A/TW/3446/02  
with  
PA gene from 
A/VN/1194/04 







No 5x105 PFU Same as wt Same as wt (428) 
IL-1 
(Casp 1-/-) 
H3N2 A/TW/3446/02  
with  
PA gene from 
A/VN/1194/04 
















H1N1 A/PR/8/1934 70-80% 
Survival 
8000 EID50 Reduced Increased 
Lethality 
(535) 
IL-6-/- H5N1 A/Hong 
Kong/483/1997 
Yes 103 MID50 n/c Same as wt (430) 
IL-6-/- H5N1 A/Hong 
Kong/486/1997  
No 103 MID50 n/c Same as wt (430) 
IL-6-/- H5N1 
A/Vietnam/1203/04 
Yes 103 EID50 n/c Same as wt (536) 








Yes 103 EID50 n/c Same as wt (536) 
IL-18-/- H3N2 X31 
(A/PR/8/1934) 
No 104 PFU Increased Increased virus 
in lungs early, 
cleared virus 
same as wt 
(362) 
Leth? = “yes” means it is a lethal model of disease; wt refers to wild-type mice; Casp 1 = 
caspase 1; PFU = plaque forming units; EID50 = 50% egg infectious dose; MID50 = 50% 















compared to wt 
Ref 




Same as wt Same as wt (380) 




Reduced Protection (65) 




Reduced Protection (65) 











Increased Delayed Death (429) 




Increased Delayed Death (429) 




Same as wt Same as wt (430) 






































Yes 1 LD90 Reduced Protection (399) 





Reduced Delayed Death (429) 

































Reduced Delayed Death (429) 
Leth? = “yes” means it is a lethal model of disease; wt refers to wild-type mice; Casp 1 = 
caspase 1; PFU = plaque forming units; EID50 = 50% egg infectious dose; MID50 = 50% 
mouse infectious dose; EIU = egg infectious units, n/c = no change. *PR = Puerto Rico, 




Table 1.3 Effect of chemokine receptor knockout mice infected with IAV on neutrophils 
Mouse 
Model 
Virus Leth? Dose Effect on 
Lung 
Neutrophils 
Effect on Disease 
Phenotype 













5 HAU Increased, 
delayed 
Reduced lethality, 









5 HAU Increased Increased 
lethality, 
increased virus in 
lung, , increased 
CCL2, CCL5, 








5 HAU n/c Reduced lethality, 







Reduced Increased lung 
macrophages 





No 3.3 PFU Reduced Same as wt (539) 
CXCR3-/- H1N1 
A/PR/8/1934 
Yes 6.7 LD50 Reduced Increased 
Survival 
(380) 
Leth? = “yes” means it is a lethal model of disease; wt refers to wild-type mice; Casp 1 = 
caspase 1; PFU = plaque forming units; EID50 = 50% egg infectious dose; MID50 = 50% 





Table 1.4 Effect of chemokine knockout mice infected with IAV on neutrophils 
Mouse 
Model 











Yes 103 EID50 n/c Same as wt (536) 
CCL3-/- H5N1 A/Hong 
Kong/483/1997 
Yes 103 MID50 n/c Same as wt (430) 
CCL3-/- H5N1 A/Hong 
Kong/486/1997 
No 103 MID50 n/c Same as wt (430) 
CCL5-/- H1N1 A/PR/8/1934 No 3.3 PFU Same as wt Same as wt (539) 
CXCL10-/- H1N1 A/PR/8/1934 Yes 6.7 LD50 Reduced Increased 
Survival 
(380) 
Leth? = “yes” means it is a lethal model of disease; wt refers to wild-type mice; Casp 1 = 
caspase 1; PFU = plaque forming units; EID50 = 50% egg infectious dose; MID50 = 50% 






Table 1.5 Effect of neutrophil effector knockout mice on IAV infection 
Mouse 
Model 































Same as wt Same as wt (434) 
NETs  
(PAD4-/-) 
H1N1 A/WSN/33 50% 
Survive 
1 LD50 Same as wt Same as wt (457) 
Leth? = “yes” means it is a lethal model of disease; wt refers to wild-type mice; Casp 1 = 
caspase 1; HAU = hemagglutinating units; PFU = plaque forming units; LD50= mouse 























































































































































































































































































































































































































































































Families and species of (-)-sense RNA respiratory viruses for which the presence or 
absence of neutrophils in the respiratory tract has been documented. Also listed are: the 
host species (Human, Non-Human Primate, Mouse, Ferret, Swine) in which neutrophils 
have been known to be increased following infection; the primary site of infection (URT 
= upper and LRT = lower respiratory tract); the typical pathology associated with 




Table 1.7 (+) sense RNA and DNA respiratory viruses that cause increased neutrophil 























































































































































































































































































































































































Families and species of (-)-sense RNA respiratory viruses for which the presence or 
absence of neutrophils in the respiratory tract has been documented. Also listed are: the 
host species (Human, Non-Human Primate, Ferret) in which neutrophils have been 
known to be increased following infection; the primary site of infection (URT = upper 
and LRT = lower respiratory tract); the typical pathology associated with increased 
neutrophils, including Acute Respiratory Distress Syndrome and notes on the 
circumstances in which neutrophils were increased; the relative amount of neutrophil 





PHENOTYPIC DIFFERENCES IN VIRULENCE AND IMMUNE RESPONSE IN 
CLOSELY RELATED CLINICAL ISOLATES OF INFLUENZA A 2009 H1N1 
PANDEMIC VIRUSES IN MICE 
Overview 
To capture the possible genotypic and phenotypic differences of the 2009 influenza A 
virus H1N1 pandemic (H1N1pdm) strains circulating in adult hospitalized patients, we 
isolated and sequenced nine H1N1pdm viruses from patients hospitalized during 2009-
2010 with severe influenza pneumonia in Kentucky. Each viral isolate was characterized 
in mice along with two additional H1N1 pandemic strains and one seasonal strain to 
assess replication and virulence. All isolates showed similar levels of replication in nasal 
turbinates and lung, but varied in their ability to cause morbidity. Further differences 
were identified in cytokine and chemokine responses. IL-6 and KC were expressed early 
in mice infected with strains associated with higher virulence. Strains that showed lower 
pathogenicity in mice had greater IFN, MIG, and IL-10 responses. A principal 
component analysis (PCA) of the cytokine and chemokine profiles revealed 4 immune 
response phenotypes that correlated with the severity of disease. A/KY/180/10, which 
showed the greatest virulence with a rapid onset of disease progression, was compared in 
additional studies with A/KY/136/09, which showed low virulence in mice. Analyses 
comparing a low (KY/136) versus a high (KY/180) virulent strain showed a significant 
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difference in the kinetics of infection within the lower respiratory tract and immune 
responses. Notably by 4 DPI, virus titers within the lung, bronchoalveolar lavage fluid 
(BALf), and cells within the BAL (BALc) revealed that the KY/136 replicated in BALc, 
while KY/180 replication persisted in lungs and BALc. In summary, our studies suggest 
four phenotypic groups based on immune response that result in different virulence 
outcomes in H1N1pdm strains with a high degree of genetic similarity. In vitro studies 
with two of these isolates suggested that the more virulent isolate, KY/180, replicates 
productively in macrophages and this may be a key determinant in tipping the response 
toward a more severe disease progression. 
 
Introduction  
The 2009 pandemic H1N1 influenza virus (H1N1pdm) arose through reassortment of two 
preexisting swine influenza viruses, a Eurasian avian-like virus and a North American 
triple reassortant virus (44, 127, 542).  The risk factors associated with human cases of 
H1N1pdm mirrored those of seasonal influenza (543).  As observed with seasonal 
influenza, the most common underlying chronic conditions among hospitalized patients 
were respiratory disease, asthma, cardiac disease, and diabetes (6, 30, 543-546). 
However, in contrast to seasonal influenza, a greater proportion of severe and fatal cases 
had a pre-existing chronic illness.  A second notable difference was the age distribution 
of hospitalized and severe cases.  Children less than 17 years old had the greatest rates of 
hospitalization per capita and adults over 64 had the greatest rates of mortality per capita.  
Retrospective clinical studies focused on surveillance H1N1pdm sequences present in 
ICU admissions suggest that pre-existing medical conditions may be a more important 
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factor in severity rather than particular viral variants (547). However, this does not 
explain why a greater proportion of persons with pre-existing medical conditions had 
more severe disease than typically observed for seasonal influenza.  Further, previously 
unreported comorbidities such as morbid obesity have been widely suggested for 
H1N1pdm for increased risk for admission to the ICU and death (548).  At this time, it is 
difficult to rule out the contribution of viral variants to the resulting illness observed with 
the various comorbidities. Nonetheless, the course of illness and the progression to more 
severe disease are most likely due to the combined interplay of the individual’s health, 
the intrinsic phenotype of the infecting viral variant and the treatment regime. 
 
In contrast to seasonal influenza viruses, the H1N1pdm viruses replicate well and show 
greater pathogenicity with viral antigen in the bronchiolar epithelia and the alveolus by 
day 3 post-infection (DPI) (127, 247, 542). In the BALB/c mouse, A/California/04/09 
and other H1N1pdm viruses show lethality, but only at the highest dose of 106.5 plaque 
forming units (PFU) (247, 542). Studies of infection of BALB/c with several different 
2009 H1N1pdm virus isolates show high virus titers in nasal turbinates (NT) and lung 
tissues by 3 DPI. Virus titers show a slight decrease by 6 DPI in lung and NT although 
the decrease varies among strains, too.  Proinflammatory cytokines and chemokines were 
elevated for most mice in whole lung specimens at 3DPI for KC, IL-6, IL-12(p40), G-
CSF, M-CSF, MCP-1 MIG, MIP-1, and LIF. By 6 DPI, IL-10 was present, albeit low, 
whereas some of the cytokines were reduced (e.g., MIP-2, IL-6), but most remained 
elevated (247, 542). The levels of cytokines and chemokines in humans or mice do not 




The overall genetic distance among H1N1pdm isolates remained low with 7 distinct 
clades in the first wave of the pandemic, while in the second wave a single viral lineage 
dominated (107).  Molecular surveillance, while important, will not confirm potential 
phenotypic differences in vivo resulting from amino acid changes associated with viral 
variants in newly emerging strains or the potential for mixed infections and the genetic 
diversity of the intrahost viral populations (549). Animal studies can complement 
molecular surveillance in monitoring the potential pathogenicity and immunogenicity of 
circulating strains. Further, such studies have potential to reveal the efficacy of treatment 
regimes. Herein we report the isolation, sequence, and characterization of nine H1N1pdm 
influenza A viruses from adult patients hospitalized in Kentucky during the second 
pandemic wave, September 2009 and April 2010.  Four of the nine patients died and all 
of the patients for whom data was available had an underlying chronic condition.  This 
group of clinical isolates, with high genetic similarity, was characterized for virus load, 
virulence, and host immune response in mice. Immune responses in the lungs suggest 
four distinct immunological phenotypes that correlate with the observed mortality in 
mice.  This study underscores the potential variability in the virulence of 2009 H1N1 
influenza A strains circulating in Kentucky during the pandemic.  These data suggest the 
hypothesis that the high severity of disease seen in certain hospitalized patients may be 
related to infection with H1N1pdm viral variants that, due to cell tropism and replication 




Isolation and sequence analyses of H1N1pdm isolates from hospitalized patients  
H1N1pdm strains were isolated from nasopharyngeal swab samples obtained from nine 
de-identified patients enrolled in the Severe Influenza Pneumonia Surveillance (SIPS) 
project, a clinical study of hospitalized patients with severe community-acquired 
pneumonia in Kentucky from December 2008 – December 2011 (Table 2.1).  Hospitals 
included in the SIPS project included two rural areas of Kentucky, one in the east and one 
in the midwest, and one in an urban area (Louisville).  The midwest is active in 
agriculture and one of the highest livestock producers of hogs and pigs.  The age of the 
patients ranged from 31 to 58 and included five females and 4 males.  Many of those 
patients had underlying comorbidities commonly associated with severe influenza disease 
such as obesity, diabetes and chronic obstructive pulmonary disorder (COPD) (Table 
2.S1) Four of the nine patients died. 
 
Viruses were isolated by passage through both Madin-Darby canine kidney (MDCK) 
cells and eggs and virus isolates were designated according to a tracking number that 
contains no patient identifier information. Herein, isolates will be referred to by the 
tracking number and virus isolation method (e.g., A/Kentucky/180/2010 egg-passaged 
isolate will be referred to as “KY/180E”).  Viruses were amplified and the virus titers 
were determined by 50% tissue culture infectious dose (TCID50), plaque forming units 
(PFU) and hemagglutination assays in Madin-Darby canine kidney (MDCK) cells (data 
not shown).  Viral titers measured in TCID50 and PFU assays were similar for MDCK-
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adapted viruses and egg-adapted isolates (e.g., median titer ~107). Some viruses 
(A/KY/96/09, A/KY/99/09, A/KY/108/09, A/KY/180/10) showed a 10-100 fold higher 
titers in MDCK cell culture than in egg, but some (A/KY/80/09, KY/110/09, KY/136/09) 
did not.  Egg-adapted viruses that were not recovered included A/KY/104/09 and 
A/KY/190/10.  Hemagglutination titers were generally lower from egg-adapted viruses 
and showed variability among isolates (data not shown).  
 
Universal and gene-specific primers were designed and used to amplify and sequence 
full-length cDNAs of all viral segments from each isolate.  The amino acid sequences 
encoded by each gene were deduced and compared. All of the isolates have stop codons 
in PB1-F2 at positions 12, 58, and 88 (data not shown) (550).  Amino acids that showed 
polymorphisms are listed for each viral protein for the majority of genes (Table 2.S2).  
The most amino acid changes were observed in HA1 and acidic polymerase (PA) with 18 
and 9 mutations collectively across the 7-8 the KY isolates (not all isolates were 
completely sequenced).  Neuraminidase and the two basic polymerase subunits (NA, PB1 
and PB2) each had 4-5 mutations while the nonstructural protein 1 (NS1) and HA2 
showed 3 mutations collectively.  In contrast, matrix (M1), nucleoprotein (NP) had only 1 
mutation and there were none in M2, NS2 or PA-X.  Of the mutations only a few have 
been previously studied functionally to our knowledge.  For example, in the HA1/HA2 of 
KY/180E we noted changes in D222G, S83P, S183P, and E374K.  E374K was identified 
as a vaccine escape mutation (551). The S183P and the Q293H mutations in HA1 (found 
in KY/180E and KY/96E, respectively) have been reported by others (552-555), and have 
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been associated with alterations in receptor binding and increases in disease severity in 
humans (106, 134).  
 
Differential progression of virus replication and disease in mice infected with 
H1N1pdm strains 
To make an initial assessment of the levels of replication and virulence potential of each 
of the clinical H1N1pdm isolates, groups of six DBA2 mice were intranasally-infected 
and monitored daily for clinical signs and body weight.  In addition to the nine clinical 
isolates, we included two pandemic strains (A/CA/07/09 and A/NY/18/09) and a seasonal 
H1N1 strain (A/BN/59/07).  On days three and six, three mice each were euthanized and 
analyzed for viral load and antibody titers (Table 2.2).  All mice infected with influenza 
strains showed weight loss (Table 2.2).  Mice infected with KY/96M, KY/80M, 
KY/180E, KY/80E, and NY/18E showed the greatest weight loss in this short study 
(Table 2.2).   Mice infected with the seasonal influenza strain BN/59E showed the least 
weight loss (about 9%).  All other mice infected with H1N1pdm influenza isolates 
(KY/136M, KY/99M, KY/136E, KY/110E, CA/07E, KY/108M, KY/110M, KY/104M, 
and KY/108E) showed weight loss averages ranging from 13% to 26%, respectively.  
 
The mortality rates for mock- and virus-infected groups were expressed as a percentage 
of lethal infections (Table 2.2).  BN/59, CA/07, KY/110 and KY/136 showed no lethality 
and low morbidity; whereas KY/190 and KY/180 showed the greatest lethality and 
substantial weight loss.  Both KY/80 and NY/18 showed lethality and weight loss.  On 3 
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and 6 days post-infection (DPI), three animals were sacrificed and the lung tissues were 
collected for virus titration analysis (TCID50 assay of lung tissue homogenate using 
MDCK cells). Virus titers of lungs from each mouse-infected group showed relatively 
little difference between the various isolates on 3 and 6 DPI (p > 0.05 using pairwise 
Wilcoxon Rank-Sum test without correction for multiple comparisons, Table 2.2). Mice 
infected with egg-adapted viruses showed a higher mortality than several of the 
corresponding MDCK isolates (e.g., see KY/96, KY/99, KY/108). However, both egg 
and MDCK-adapted KY/80 and KY/180 showed lethality in mice.  
 
The influenza-specific serum IgG antibody responses in mice were measured at 6 DPI by 
ELISA using antigen prepared from inactivated NY/18 virus (Table 2.2) and reciprocal 
endpoints were determined.  Strains KY/80E, KY/180, and KY/190 had no detectable 
IgG antibody by 6 DPI.  The seasonal strain and all other pandemic strains produced 
detectable IgG antibody; the highest endpoint titers were collected from BN/59, 
KY/108E, NY/18E, KY99M, KY/136, and KY/110M. In some cases, these numbers 
reflect a small numbers of animal remaining at 6 DPI. 
 
Cytokine and chemokines responses in H1N1pdm isolates show four distinct 
phenotypic profiles  
Mouse cytokine and chemokine panels were employed to gain a broad overview of the 
immune response at 3 and 6 DPI in the lungs and sera of mice infected with each of the 
viral isolates (Figures 2.1 and 2.2).  No significant difference was seen between egg- and 
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MDCK-passaged isolates; therefore, the combined data are presented in these two 
figures. There was an overall increase in proinflammatory cytokines (TNFα, IL-1β, IL-6 
and KC) albeit different levels were noted. The levels of TNFα and IL-1β were greater in 
the lungs on day 3 in viral isolates with greater lethality (e.g., KY/180, KY/190) as 
compared to those with no lethality (e.g., KY/136, p < 0.05). These same cytokines were 
higher in the mice with no lethality on day 6 as compared to those showing lethality. A 
similar temporal pattern was noted with some chemokines (e.g., RANTES, Figure 2.2). 
Interferon-gamma (IFNγ) and IL-10, an anti-inflammatory cytokine, were present on day 
6 in mice infected with all but the most lethal strains, KY/180, KY/190 (Figure 2.1, p < 
0.05). 
 
With the exception of isolate KY/110 and KY/104, the chemokines CCL2 (MCP-1), 
CCL3 (MIP1), CXCL9 (MIG), and CXCL10 (IP-10) displayed similar levels in all 
isolates on 3 DPI followed by a relative increase in animals infected with nonlethal 
versus a decrease in animals infected with lethal isolates at 6 DPI (Figure 2.2 and Table 
2.2). IFNγ stimulates both IP-10 and MIG, and as expected the IFNγ levels were low in 
lethal isolates as compared to nonlethal isolates at 6 DPI.  Cytokines and chemokines that 
showed limited response in mice with any viral infection included Eotaxin, GM-CSF, IL-
1a, M-CSF, IL-2, IL-3, IL-4, IL-5, IL-7, IL-9, IL-12p40, IL-13, IL-15, IL-17, MIP2, LIX, 
MIP1, RANTES, IL-12p70, and VEGF (data not shown). 
 
A principal components analysis (PCA) was performed using 11 cytokine/chemokine 
measurements from the lungs of mice infected with each virus (Figure 2.S1). The 
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cytokines and chemokines included in the analysis were selected because they were 
determined to be the most significantly different between isolates on 3 and 6 DPI by 
generalized linear model fitness testing (data not shown).  The first two components 
explained 72% of the variance (Figure 2.S1) and the third component explained an 
additional 10% (data not shown).  CCL3, TNF, IL-10, IL1, and IFN were all highly 
correlated with the first component dimension (>80%), meaning these cytokines were 
principally important in differentiating the isolates.  CXCL10, KC and G-CSF were 
similarly highly correlated with the second component (>70%), and CXCL9 was highly 
correlated with the third component dimension (83%, data not shown).  The remaining 
variables, IL-6 and CCL2, were not highly correlated with the components used in this 
model, although they were significantly different between isolates on 3 and 6 DPI.  The 
mean for each isolate on 3 and 6 DPI are plotted according to the coordinates of the first 
two components in Figure 2.3 (and Figure 2.S1). 
 
The method used for computing this PCA is similar to k-means cluster analysis, and 
therefore we expected to observe the isolates to group according to their 
cytokine/chemokine signatures.  To better visualize these clusters, we connected each 
isolates’ 3 DPI coordinate to its 6 DPI coordinate with an arrow (Figure 2.3). According 
to this method of using a “time-resolved” PCA, the isolates were observed to cluster 
clearly into four groups representing various trajectories of disease.  
  
The first three groups of isolates could be differentiated by their immunogenicity and low 
to moderate lethality.  The first group includes isolates with a low lethality in mice, and 
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was exemplified by infection with the seasonal strain BN/59, and 2009 pandemic strains 
CA/07, KY/80 and KY/136. The second group (KY/96, KY/99, and KY/104) included 
those strains with moderate lethality in the mouse model, and was similar to the first 
group in course of disease, but was characterized by increased inflammatory cytokines 
(e.g., IL-6, KC-like, and G-CSF) and chemokines (e.g., CXCL9). In  contrast to the first 
group, these had a higher level of the anti-inflammatory cytokine IL-10 later in disease, 
as well as increased IFN at 6 DPI.  The third group of influenza strains (KY/108 and 
KY/110) was the most immunogenic compared to the other isolates, and differed from 
the two groups above in that they show the highest levels of inflammatory cytokines late 
in infection (e.g., IL-6, TNF-α, IL-1β) but were similar to Group 2 in terms of lethality.  
They showed the highest level of chemoattractant chemokines, particularly CCL2, CCL3, 
and CXCL10, and produced the highest levels of IL-10 and IFNγ detected in this study.   
 
Finally, the fourth group of isolates, consisting only of KY/180, KY/190, and NY/18, 
were the most lethal of the viruses screened in mice.  Their proinflammatory cytokines 
were elevated throughout the course, but not different from 3 DPI in Group 1 isolates.  
Most notably, these isolates failed to produce any IFNγ or IL-10 by 6 DPI.  In Figure 3, 
the trajectory of these isolates point in an opposite direction from all other isolates, 
perhaps indicating a different course of disease.  In summary (see Table 2.S5), the 
immune responses of the virus isolates clustered similar to other phenotypic markers of 




In-depth comparison of the temporal progression of survival, viral load and 
immune responses of two clinical isolates, KY/136E and KY/180E, with low and 
high virulence, respectively. 
 
KY/136E and KY/180E were selected from the nine H1N1pdm clinical isolates for 
further characterization as representatives of lower and higher virulence based on the 
apparent disease in mice.  These isolates had similar concentrations of lung cytokines and 
chemokines on 3 and 6 DPI compared to other isolates and clustered together in the PCA.  
However, the time-resolved PCA revealed that the isolates differed in the progression of 
immune responses in the course of infection.  To gain additional insight, we first assessed 
dose response to infection in DBA/2 mice. Mice were infected with 100, 102 or 105 
TCID50 of KY/180E or KY/136E and examined daily for clinical signs. Each day, mice 
were weighed and data from each dose group are presented in Figure 4A (KY/136E) and 
Figure 4B (KY/180E). The Kaplan-Meier survival curves of mice infected with KY/180E 
or KY/136E (Figure 2.4C and 2.4D, respectively) confirmed the observations reported 
above in terms of the general lethality of each virus, although KY/136E did show 
lethality in 1-2 mice on 10 DPI (Figure 2.4C).  Mice infected with KY/180E succumbed 
to infection starting at 3 DPI at the high dose and on 6 DPI for the middle dose (Figure 
2.4D).  Animals were humanely euthanized upon showing a moribund state or upon a 
25% loss in body weight as described in the materials and methods. 
 
The levels of infectious virus present in the upper and lower respiratory tracts, nasal 
turbinates (NT) and lung, respectively, were measured at 1, 3 and 5 DPI at the three 
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different doses (100, 102 or 105 pfu per mouse) of KY/180E or KY/136E  (Table 2.S3). 
As expected, levels of virus were greatest in mice with higher doses of infection. Mice 
infected with KY/180E persisted at higher levels of virus over the 5 day period as 
compared to KY/136E which had approximately 2-3 logs lower virus in the lungs and 
had virus levels that decreased from 3 to 5 DPI. The infectious dose (ID50) and lethal 
dose (LD50) were <10
0 TCID50/mouse and 10
1.2 TCID50 per mouse, respectively, for 
KY/180E (data not shown). 
 
To further dissect the immune responses of these two viruses, multiplex 
cytokine/chemokine bead arrays were employed to insight into the temporal patterns for 
the key cytokine and chemokine profiles responses noted in the broad survey of all the 
isolate. Mice (5 per group/per day) were infected with each of the isolates and humanely 
euthanized on 1, 3, and 5 DPI (Figure 2.5 and 2.6). There was an overall increase in 
proinflammatory cytokines (TNFα, IL-1β, IL-6 and KC) in the lungs of all mice, 
however, there were much higher levels of all cytokines in lungs of mice infected with 
KY/180E.  Further the responses were much earlier and correlated with the high levels of 
infection noted in the lung.  In contrast with KY/180E, KY/136E-infected mice showed a 
gradual progression in immune response, however, the overall responses on 6 DPI of 
KY/136E remained low.  Interferon-alpha (IFNα) and IL-12p70 levels were higher in the 
lungs of KY/180E-infected mice as compared to KY/136E-infected mice (Figure 2.S2).  
Virus-infected mice that recovered from KY/136E infection showed a high IL-10 
response by 6 DPI whereas KY/180E-infected mice showed no response (Figures 1 and 
5, p < 0.05).  As expected, and also shown in Figure 1, the IFN levels were low in the 
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lethal KY/180E isolate as compared to the robust response observed in the nonlethal 
KY/136E isolates at 6 DPI (no statistically significant difference).  
  
Mice infected with the middle dose of KY/180E that survived after 6 DPI, and produced 
high concentrations of IFN, eventually became moribund with all but one euthanized by 
Day 10.  These data suggest that the immune response differences between the two 
isolates are due to the high levels of infection in the lung by KY/180E.  The levels of 
cytokines and chemokines in the lung support this observation (Figures 2.S3-2.S6), 
showing a dose response for both isolates on 1, 3, and 5 DPI in mouse lung homogenate.  
Notably, a dose of 102 pfu/mouse of KY/180E showed a progressive increase in 
chemotactic chemokines to 5DPI whereas a higher dose (105 pfu/mouse) began declining 
in concentration of these analytes after 3DPI (Figure 2.S3).  Similar patterns were seen 
for proinflammatory cytokines in the lung (Figure 2.S5) and cytokines involved in 
adaptive immunity initiation, IFNγ and IL12p70 (Figure 2.S6). The endpoint titer IgG 
responses of the mice for the low and middle doses were similar for both viruses (Figure 
2.7; all significantly different from control using Student’s t-test, p < 0.05). Further, the 
HI titers were also very similar except for the lower dose, which was about 2-fold higher 
in mice infected with KY/180E (Figure 2.7). 
 
The leukocyte chemoattractant chemokines CCL2, CXCL10, KC (CXCL8-like), and G-
CSF were greater and earlier in the lungs of mice infected with high doses of KY/180E 
than with a similar dose of KY/136E (Figure 2.6, p < 0.05).  As expected, cytospins of 
BAL revealed that KY/180E contained more neutrophils and monocytes on Day 4 
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compared to KY/136E (Figure 2.8A,B, p < 0.05).  Additionally, we observed a higher 
proportion of macrophages in the lungs in the low dose group of KY/136E compared to 
the higher dose group (p < 0.05, Figure 2.8C).  Despite there being a greater number of 
infiltrating leukocytes in the lungs of KY/180E-infected mice, these mice had a delayed 
clearance of virus in the lung.   
 
Given the apparent clearance of virus from the lungs of KY/136E (Table 2.S4), we were 
interested in whether the apparent differences in lethality of the two viruses could be due 
to the site of virus replication. We tested virus titers from bronchoalveolar lavage fluid 
(BALf), from the cellular pellet of the BALc (BALc) of the mice, and from the 
homogenized lung after lavage using TCID50 assay.  Samples were collected on 3 and 4 
DPI because we began to see decreases in viral titer in the lungs of KY/136E-infected 
mice after 3DPI. In our earlier studies (Table 2.S4), the virus titer in lung reflects lung, 
BALf, and BAL cells combined and we observed a nearly 3 log difference between 
KY/136E and KY/180E. When BAL is collected before isolation of lung tissue, we found 
the majority of infectious KY/136E virus present in lungs of mice was localized in the 
cellular fraction of the BAL (Figure 2.9). In contrast to KY/180E, no infectious KY/136E 
virus was present in the BALf by 4 DPI.  Flow cytometric analysis revealed that the 
influenza NP-positive cells in the BAL from both isolates were also Gr1-positive (clone 




Infection and replication of H1N1pdm viruses in macrophage cell lines 
Given the differences noted within the levels of virus in BALf and BALc, we used a 
BALB/c mouse macrophage cell line (RAW264.7) and a C57BL/6 mouse macrophage 
cell line (NR-9465) to test for the ability of KY/136E and KY/180E to infect and 
replicate in macrophage cells.  Confocal microscopy at 24 hours post-infection showed 
that both viruses were able to infect macrophage cell lines (Figure 2.10). However, 
KY/180E was more efficient at replication, reaching 10-fold higher virus titers that 
persisted longer in both cell culture systems (Figure 2.11 and Figure 2.S7). Although the 
cell culture supernatant was positive at 24 hours post-infection for both viruses in vitro, 
KY/180E was the only isolate detected from the cellular component in BAL (Figure 2.8; 
p < 0.05 at 24 and 48 hours post-infection).  These observations agree with our findings 
in the DBA/2 mouse model and suggest that KY/180 is more successful in vivo in 
replication and production of infectious virus in macrophages (Figure 2.8). 
 
Discussion 
Herein we present data characterizing several isolates of H1N1pdm influenza virus taken 
from human patients with severe pneumonia in Kentucky, USA.  Clinical surveillance 
from foci around the world showed that the majority of human cases of H1N1pdm were 
mild (36, 556).  Severe disease from H1N1pdm infection was more likely to be seen in 
patients with pre-existing chronic illness (557).  It was initially observed that antigenic 
and genetic variation in circulating pdmH1N1 2009 influenza viruses was less than what 
is seen during seasonal human influenza A (H1N1) (38).  Similarly, the isolates listed 
here show relatively low variation, differing at only 43 amino acid positions.  Each 
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isolate contained from 2 to 12 unique non-synonymous mutations from the consensus 
sequence. 
 
Three of the 4 lethal cases occurred in western Kentucky, and 1 of these lethal cases 
(KY/180) contained a virus isolate with the avian-like HA RBS (G222).  The D222 is 
most commonly associated with human H1 strains while the G222 is common in avian 
strains.  The HA 222 position, D222G/N/S/E/Y, was a common polymorphism in severe 
cases of influenza in human patients, which is within the HA receptor binding site, RBS 
(547, 558-561).  Additionally, the D222G has been associated with increased 
pathogenesis in some animal models possibly due to increased replication of the virus 
(125, 129, 131, 558, 559, 562, 563). The aspartic acid functions in binding of the receptor 
and as a calcium antigenic site. Each of these amino acids will give rise to a specific 
binding affinity to the α2-6-sialic acid receptor with the D222G increasing α2-3-sialic 
acid receptor binding specificity (125, 224, 563). However, it is clear that other amino 
acids constellations at positions 183, 186, 187, 216 and 224 will also influence these 
interactions (127), and may result in different overall outcomes. Additional amino acid 
signatures in closely related H1N1pdm isolates have also been implicated in differences 
in virulence in animal models. For example, in a study in a cynomolgus macaque model 
of two highly similar strains of H1N1pdm, A/Mexico/4487 and A/Mexico/4108, showed 
notable heterogeneity in virulence (137).  The amino acid variations responsible for the 
differences noted in these studies have not yet been reported. The HA1 of KY/180E also 
has a P183 (noted as 186 in (552)) rather than a S183 at the Sb antigenic site, which also 
has been noted to affect receptor specificity ((553-555)). This site, independently or 
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together with the D222G mutation, is thought to allow binding to α-2,3 linked sialic acid 
residues.  This substitution may allow the virus to more efficiently enter and replicate in 
the lower airway epithelium (276, 555, 564, 565).  
 
Other mutations observed in the HA gene of the Kentucky isolates have also been 
reported by others.  Belser, et al. (2010) published data that showed A/CA/04/09 also has 
the S83P mutation in HA (as in KY/180E), although this mutation is not a known 
pathogenicity determinant (247).  Ilyushina, et al. (2010) found the S183P (as seen in 
KY/180E) mutation arose from serial passage of A/CA/04/09 in mice and resulted in 
increased pathogenicity (553).  Xu, et al. (2011) report isolates from China show similar 
variability and share some of our mutations in HA (S83P, T203S, and V321I; seen in 
KY/180E, KY/96E, and KY/80E, respectively), as well as mutations in NS1 (V123I, seen 
in KY/99E) and PA (V14I, seen in KY/180E) (566).  Melidou et al. have data that 
suggest V321I mutation in HA may be associated with increased disease severity (134).  
Finally, HA1 amino acid mutation Q293H, identified in KY/96E, has been associated 
with increased severity of disease observed in human cases during the pandemic (106, 
134). We include a summary of those mutations that correlate with virulence in humans 
and mice (Table 2.S6). An understanding of these and other signatures associated with 
more virulent phenotypes will benefit insight into the biology of the virus, patient 




In total, KY/180E contains mutations that differ from KY/136E in seven amino acid sites 
in the HA protein, four sites in PA, two sites in NA, PB1 and PB2, and one site in each of 
M1, NS1, and NP.  Comparison of the CA/07/09, NY/18, NL/602 isolates with the KY 
isolates showed additional variation among all isolates (Table 2.S2). Specifically, 
CA/07/09, NY/18, NL/602 were similar to the KY consensus in M, HA2, PA, PB1 and 
PB2, In HA1, a Q223R occurred in NY/18 only. In NA, a D248N changed occurred in 
CA/07 and NL/602. In NS1, a D247N was noted for KY/110, CA/07, NY/18, and 
NL/602.  Most additional changes were conserved hydrophobic changes such as Val to 
Iso or Met to Leu. No differences were observed among the KY, CA/07/09, NY/18, 
NL/602 isolates in M2 or NS2 (Table 2.S2). Despite the small apparent genomic 
variation between H1N1pdm isolates, we and others have shown that there exists 
substantial variation in the course of disease, pathogenicity, and immune response in 
human patients, in animal models, and in primary cell culture (106, 135, 137, 566, 567).  
As virulence determinants of influenza viruses typically involve the genes encoding the 
HA, NA, and polymerase proteins, we would expect changes in these genes to be of 
future interest for biological function (568).  Addition genome diversity that might give 
rise to unique phenotypes during infection may be revealed be deep sequencing or 
isolation of clones that sample the population of the virus (549).  
 
To gain insight into the potential phenotypic variability inferred from the genotypic 
variability each virus was screened in DBA2 mice.  All IAV tested so far, H1N1pdm, 
1918 H1N1, and seasonal influenza A H1N1 virus, infect DB2 with varying levels of 
lethality without adaptation (569), and express comparatively high levels of 
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proinflammatory cytokines and chemokines (570, 571).  Herein all DBA2 mice showed 
high levels of infection with all isolates similar to infection of BALB/c mouse with 
H1N1pdm viruses (247, 542) with relatively little difference between the various isolates 
on 3 and 6 DPI (p > 0.05 using pairwise Wilcoxon Rank-Sum test without correction for 
multiple comparisons, Table 2.2). However, the isolates did show three groupings in 
lethality (lethal, moderately lethal and not lethal) in DBA2 mice with KY/180, KY190 
and KY/96 showing the highest lethality. Using a statistical method, PCA, we asked if 
based on these differences in lethality we might be able to cluster cytokine and 
chemokine responses across the H1N1pdm isolates.  To our knowledge, this is the first 
time this method (a “time-resolved” PCA) has been used to discriminate phenotypic 
characteristics of viruses.  Classically PCA is used as a method to reduce multivariate 
data so that they are better suited for a predictive statistical model.  The most common 
contemporary usage of PCA in microbiology is during the analysis of gene expression 
arrays to check reproducibility of replicates.  We chose to use the PCA method because 
of its similarity to common clustering algorithms (specifically, k-means clustering), and 
therefore its potential to elucidate clusters of the immune response of mice after infection 
with genetically similar influenza isolates.  Our approach relied on two defined time 
points to detect differences between virus isolates using expression of multiple immune 
markers.  Although some of the markers used in this analysis may be redundant in a virus 
model (e.g., pro-inflammatory IL-6 and CXCL10), subtle differences that may go 
unnoticed are seen using this multivariate approach, particularly in the timing of these 
responses (and not necessarily the magnitude). Therefore, using indicators of adaptive 
immune priming (IFN) and reduction of inflammation (IL-10) were critical to the 
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successful implementation of this strategy.  More data of this kind from other influenza 
isolates and other respiratory virus infections may assist in the development of this 
method, and may reduce the number of soluble immune markers needed for analysis in a 
clinical setting. 
 
Analyses of our data suggest that there are at least two main trajectories of H1N1 
influenza infection in these mice: one that successfully resolves infection, and one that 
does not.  The majority of the isolates followed a trajectory that led to resolution and 
clearance of the virus from the lungs.  These isolates could be further clustered into three 
subgroups, and these subgroups differ according to the overall immunogenicity of the 
isolates (i.e., the levels of cytokines/chemokines in the lung). In general, the isolates 
showing the least mortality in DBA2 mice share in common a trajectory of disease that is 
characterized by a gradual increase, then decrease, in inflammatory cytokines and 
leukocyte chemoattractant chemokines, and concomitant increase in anti-inflammatory 
cytokines and IFN.  The isolates causing the highest lethality in the DBA2 mouse 
(KY/180E, KY/180M, and KY/190M) showed an early rise in the proinflammatory 
cytokines and chemokines, and a delayed or absent rise in IL-10 and IFN.  The lethal 
isolates were clearly differentiated using the time-resolved PCA in that they showed a 
trajectory that was opposite of all other isolates. The small sample size of human patient 
data and their confounding comorbidities limit the inferences that can be made 
connecting locale, age, sex, and length of hospital stay with genotype and pathogenicity 
of the isolates in the human patients. Recent data suggest that human polymorphisms in 
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genes that restrict virus infection (e.g., Ifitm3 gene) may also play an important role in 
outcome (572). A final challenge is there are no relevant scoring systems for influenza 
pneumonia. A pneumonia severity index (PSI) is commonly used in hospitals by 
clinicians for community acquired pneumonia, but the comorbidities (e.g. high BMI, 
diabetes) complicate interpretation. 
 
Selecting two isolates, KY/180E and KY/136E we sought to better define two of these 
trajectories in DBA2 mice.  We initially observed KY/136E had a low level of 
immunogenicity in mice, which included an increase in IL-10 and IFN by day 6.  
Although mice infected with KY/136E are similar to KY/180E in concentration of IFNα, 
G-CSF, CCL2, KC, IL-6, CXCL10, and other inflammatory cytokines and chemokines in 
the lung, the isolates differ in the timing of these responses.  Increases in these cytokines 
and chemokines are typically seen during infections with H1N1pdm influenza isolates 
(112, 395, 542).  For example, some studies show that IL-6 is released in response to 
influenza infection and that levels of IL-6 in the upper respiratory tract and in blood 
correlate with symptoms (101, 393, 573). 
 
Type-I interferons are known to initiate the anti-viral response to influenza virus 
infection.  One hypothesis to explain a more severe course of illness is that the virus is 
capable inhibiting the effect of type-I interferon signals via NS1 protein (298, 306).  The 
NS1 protein from KY/136E differs from KY/180E in a single amino acid at site 112 
(112M versus 1121I, respectively).  By day 1 post-infection, mice infected with KY/180E 
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had a higher level of IFNα in the lung.  Despite an increased IFNα and IL12-p70 
response, mice infected with KY/180 failed to produce IFN, IL-10, and serum antibodies 
by 6 DPI.  This most closely resembles the type of aberrant immune response seen during 
infections with the pandemic 1918 Influenza A (H1N1) (574, 575) and with severe 
seasonal influenza isolates (71).  Others have shown similar patterns of inflammation 
with isolates of pandemic 2009 H1N1 influenza (135, 560, 576).  
 
Cytokines and chemokines such as CCL2 (MCP-1), CCL3 (MIP1), CCL5 (RANTES), 
and CXCL10 (IP10) are responsible for activating leukocytes and attracting them to the 
lung compartment to clear infection (337).  Indeed, there were a higher number of 
leukocytes, including elevated numbers of neutrophils and monocytes, seen in the lungs 
of KY/180E-infected mice on days 3 and 4 post-infection.  It is known that certain 
pathogenic H1N1 strains, such as the 1918 H1N1 strain, causes the increased neutrophil 
recruitment to the lung due to increased chemokine responses (577, 578), which was seen 
with KY/180E.  Neutrophils are important for assisting in clearing influenza-infected 
cells from the lungs directly and indirectly (579, 580), but the precise mechanisms remain 
to be discovered (78, 86, 577).  Although important to the resolution of influenza virus 
infection, neutrophils contain cytotoxic granules that may cause severe pathology, and 
may contribute to morbidity and mortality (84).  An increase in neutrophils late in disease 




Natural Killer (NK) cells are known to be potent innate immune cells that recognize 
influenza hemagglutinin (581).  Classically, NK cell effector functions include release of 
IFN and direct cytotoxicity to influenza-infected cells by granule exocytosis (e.g., 
granzyme B and perforin).  Mice infected with KY/180E have higher numbers of 
peripheral NK cells at 3 DPI compared to KY/136E using flow cytometry (data not 
shown).  Consistent with this finding, CCL5 (RANTES) was increased in the lungs and 
serum of mice infected with KY/180E compared to KY/136E (Figure 2.2).  NK cell 
deficiency in mouse models of influenza infection leads to increased pathogenicity (582, 
583).  Despite the increase in NK cells in KY/180E-infected mice, it has been shown that 
some influenza isolates may counteract this effector response, causing lysosomal 
degradation of the ζ chain, which is a critical component of the NK-activating receptor 
(584).  Additionally, DBA2 mice lack the NKG2A activating receptor that is responsible 
for recognizing the down-regulation of MHC-I that typically occurs with a viral infection 
(585).  Therefore, KY/180E may be able to exacerbate this deficiency by decreasing NK 
cell effector function.  It has been shown that NK cells also contribute to immune 
pathology in response to influenza and other respiratory virus infections (586). 
 
Finally, this study and others have shown that some strains of influenza virus are capable 
of infecting macrophages (587-590), and may alter their functionality in response to 
infection (591, 592). During influenza infection, alveolar macrophages are critical in 
clearing virus from the lungs and are key producers of IFN to stimulate the adaptive 
immunity (321, 353, 378, 577, 578, 586, 593-595).  Upon infection, influenza viruses 
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may interfere with their normal function (341, 595, 596).  Of the two isolates tested here, 
mice infected with KY/136E showed clearance of virus from the lung by day 4.  (341, 
595, 596).  Our in vitro data using mouse macrophage cell lines indicates that KY/180E 
was able to produce infectious virus better than KY/136E.  Additionally, mice infected 
with KY/180E had a higher number of Gr-1 positive infiltrating cells into the lungs by 
day 4, a delayed IL-10 production, and very low levels of IFNresulting in a deficient 
virus clearance.  Both our in vivo and in vitro data show that KY/180E can infect 
macrophages, which may affect the cell’s ability to release IFN and explain the increase 
pathogenicity observed with this virus compared to KY/136E.  Future studies will focus 
on understanding the mechanism(s) involved in the virus-induced deregulation of 
macrophage function in vitro and in vivo.  Understanding the genetic basis for the 
differences in the interaction between the virus and macrophages as well as other 
pulmonary and immune cells will contribute to understanding the course of influenza 
infection in patients, and assist in predicting potential virulence during future outbreaks. 
 
Materials and Methods  
Detection of influenza in clinical nasopharyngeal swab specimens 
Nasal swab samples were provided by the SIPS project.  A nasopharyngeal swab was 
taken from all patients meeting the case definition, which was defined as a patient 
admitted to an intensive care unit with the physician diagnosis of community-acquired 
pneumonia.  The University of Louisville Institutional Review Board Human Subject 
Protection Program Office (HSPPO) approved this study prior to any data collection 
(#08.0399). Informed consent was waived because it was a retrospective chart review and 
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the data were analyzed anonymously. The nasopharyngeal swabs were taken as part of 
'standard of care' diagnosis. Detection of influenza virus was accomplished using the 
Luminex Respiratory Viral Panel (RVP) detection kit, recently approved for in vitro 
diagnostics by the FDA.  The RVP is a reverse-transcriptase, real-time PCR assay which 
is multiplexed to detect 12 viral targets in a single reaction well.  Those targets include 
Influenza A, Influenza A-subtype H1, Influenza A-subtype H3, Influenza B, RSV-A, 
RSV-B, Parainflunza 1, Parainfluenza 2, Parainfluenza 3, human metapneumovirus, 
Rhinovirus and Adenovirus. Nasal swabs were collected from each patient and placed in 
Universal Transport Media (Copan Diagnostics, Inc, Murietta, CA).  A 5.0 µl aliquot was 
combined with 20 µl of RVP mastermix and processed through several rounds of 
amplification, including a single-tube multiplex reverse-transcriptase PCR, followed by a 
multiplex target-specific primer extension protocol, a bead-hybridization step, and finally 
a data acquisition step in the Luminex reader.  Results are qualitative and read-outs are 
Positive, Negative or a No Call (equivalent).  
 
Viruses and virus isolation  
The viruses CA/07, NY/18, and BN/59 were kindly provided by the Centers for Disease 
Control and Prevention, Virus Surveillance and Diagnosis Branch, Influenza Division.  
Viruses from clinical cases from KY present in nasopharyngeal swab specimens were 
isolated and propagated in the chorioallantoic cavity of 10-day-old embryonated chicken 
eggs and MDCK cell line purchased from ATCC (CCL-34). The allantoic fluid 
containing infectious particles or MDCK supernate was harvested 72 h after inoculation. 
MDCK cells were infected in DMEM virus culture medium (DMEM containing 2% 
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BSA, 1% PEN/STREP, and 2 g/mL of Trypsin-TPCK). The infectious virus titer of the 
resulting seed stock was determined by TCID50 and the titer calculated by Reed and 
Muench (597), and confirmed by plaque assay on MDCK cells.  Egg passage E2 was 
used for the studies involving KY/180E and KY/136E reported herein. 
 
RNA isolation and sequencing   
To sequence each of the gene segments of each H1N1pdm isolate, we followed the 
method described by Inoue et al (598) with minor modifications. In brief, total RNA was 
isolated with MagMAX AI/ND Viral RNA isolation kit (Ambion) from each virus seed 
stock solutions.  Five µL of RNA was used to synthesize cDNA with SuperScriptase III 
(Invitrogen) using the FWuni12 and RVuni13 primers based on those reported by Inoue 
et al (598) and the cDNAs were PCR-amplified based with Accuprime (Invitrogen) The 
amplified products were separated by agarose gel electrophoresis and the DNA bands 
corresponding to the size of each segment were purified using the Wizard SV gel Clean-
Up System (Promega). The purified DNAs were used as templates for automated dideoxy 
sequencing with BigDye 3.1 cycle sequencing kit (Applied Biosystems). To sequence the 
entire gene we used approximately 500 bp overlapping gene-specific primers in both 
directions. For the sequencing of HA gene, we used FWuni12, RVuni13, HA462_f (5′-
GACTCGAACAAAGGTGTAACGG-3′) and HA1202_r (5′-
GTCAATGGCATTCTGTGTGCTC-3′) as sequencing primers. For the sequencing of 
NA gene, we used FWuni12, RVuni13, NA_521r (5′-TGACCAAGCGACTGACTCAA-
3′), NA376_f (5′-CCCTTGGAATGCAGAACCTT-3′) and NA905_f (5′-
CGTGGGTGTCTTTCAACCAGAA-3′). The sequences were assembled with the 
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SeqScape™ program (Applied Biosystems). Alignments of nucleic and amino acid 
sequences were completed to identify polymorphisms with other H1N1pdm isolates and 
sequences for all isolates were submitted through the Influenza Research Database and 
uploaded into the GenBank (accession numbers provided in Table S4). 
 
Ethics statement for animal studies 
Mice studies were approved by the University of Louisville Institutional Animal Care and 
Use Committee with Veterinary Medicine tasked to monitor and support all animal 
experiments.  Research was conducted in compliance with the Animal Welfare Act and 
other federal statutes and regulations relating to animals and experiments involving 
animals and adheres to principles stated in the Guide for the Care and Use of Laboratory 
Animals, National Research Council, 1996.  The facilities where this research was 
conducted in a fully accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care International. 
 
Mice studies 
Six to nine-week-old female DBA/2 mice were purchased from Jackson Laboratories 
(Bar Harbor, ME) and housed in the vivarium managed by UofL at the Research 
Resource Center or at the Regional Biocontainment Laboratory. The mice received food 
and water ad libitum, and all experiments were conducted in accordance with rules of the 
Institutional Animal Control and Use Committee of UofL. Mice were anaesthetized by 
isofluorane inhalation and infected intranasally with in a total volume of 30 μl at the dose 
as outlined in the figure legends and text. Viruses were adjusted to the dose required in 
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PBS (pH 7.2). Animals were observed daily for morbidity and measured for weight loss. 
All mice showing more than 25% body weight loss were considered to have reached the 
experimental end point and were euthanized humanely.  
Mice were euthanized on the days noted in the results and on figure legends and blood, 
nasal turbinates and lung tissues were collected and stored appropriately until analyses. 
For collection of BAL after euthanasia, the neck and thoracic area were disinfected by 
soaking with 70% ethanol, and the trachea exposed by dissection. An 18G catheter needle 
was inserted into upper trachea, the needle removed, and the outer catheter sheath moved 
into the lower trachea. A 3 mL syringe filled with 1 mL of DPBS was used to carefully 
inject DPBS into the lungs, and aspirate BAL fluid. Collected fluids were transferred to 
an ice-cold, sterile 15 mL conical tube on ice and repeated once more as above.  BAL 
fluids were immediately centrifuged at 500g for 10 minutes to separate fluids and cells. 
After centrifugation, supernatants are separated and kept separately at -80oC freezer until 
used for TCID50 assay. Cells pellets were washed once by adding 2 mL ice-cold DPBS 
and centrifuged again at 500g for 10 min. Cells were resuspended in 1 mL DPBS and 
kept at -80oC until used.   
 
TCID50 assay for viral load in tissues and bronchial lavage fluid 
Tissues were homogenized in ice-cold virus culture medium (DMEM containing 2% 
BSA, 1% PEN/STREP) within a biosafety cabinet. Tissue homogenates were clarified by 
centrifugation (4000g for 20 min at 4oC) prior to storage at -80oC, and later analyzed by 
TCID50 or Luminex cytometric bead array (next section). For measurement of the level of 
infectious virus present in tissue samples, the titers of the virus were determined by 
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TCID50 assay by titration of the clarified tissue homogenates or BALf on MDCK cells. 
The limit of virus detection was typically 101.5 TCID50/ml or as indicated in each figure. 
Virus titers were calculated by the method of Reed and Muench (597), and are expressed 
as the mean log10 TCID50 per milliliter. Tissues in which no virus was detected were 
given a value of 101.0 TCID50/ml for calculation of the mean titer. 
 
Quantification of cytokine and chemokine levels in lungs  
Sera and lungs from mice euthanized on days as noted in figure legends and text were 
analyzed by using Luminex® xMAP® technology-based assay kit (Millipore) according 
to the manufacturer's protocol. The final reaction plate was read with a Luminex 100 or 
FlexMAP 3D machine and specific concentrations were calculated from a standard using 
Luminex xPONENT software. 
 
Statistics and PCA 
R (version 2.13.0) base statistical package and GraphPad software package were used in 
the analysis of data and generation of figures.  Generalized linear models were 
constructed using each analyte included in the initial screen of Kentucky isolates in 
DBA/2 mice as a response variable (cytokine/chemokine concentrations) and isolate, 
DPI, and egg vs. MDCK stock, were used as predictors.  The stock designation of the 
virus was removed from the model after it was seen that it did not contribute to explain 
significant proportion of the variance.  Log likelihood ratios were used to compare the 
relative fit of each model, and the top 12 models showing the highest parameter estimates 
for the isolates were chosen for inclusion into the PCA (i.e., the cytokines/chemokines 
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that were the most different between isolates, controlling for DPI, selected from the best-
fit models).  The R package “FactoMineR” (version 1.14) was used to perform the PCA. 
Statistically significant differences between multiple groups was assessed using Kruskal-
Wallis tests followed by post hoc tests using pairwise Wilcoxon Rank Sum tests unless 
otherwise noted.  Multiple comparisons were adjusted according to Holm’s method and a 
p-value < 0.05 is considered significant. 
 
Cytospin and flow cytometry 
BAL cells were centrifuged at 300g for 5 min and washed twice in PBS.  Cells were 
resuspended in 0.4 mL PBS and loaded into Shandon Cytospin™ centrifuge funnels.  The 
cytocentrifuge chambers were spun at 1000 rpm for 5 min.  Slides were air dried in a 
BSC and then were fixed and stained with Eosin and Methylene Blue (Kwik-Diff, 
Thermo Scientific).  Slides were inspected under a light microscope.   
For flow cytometry analysis, BAL cells were washed in PBS as above and stained with 
antibodies specific to mouse CD3 (500A2 Pacific Blue, BD Biosciences), Gr-1 (RB6-
8C5 phycoerythrin, eBioscience), and CD49b (DX5 phycoerythrin-Cy7, eBioscience).  
Cells were then washed and fixed in 4% paraformaldehyde for 15 minutes at room 
temperature, followed by permeabilization with 0.2% saponin in 2% BSA for 20 minutes.  
Cells were then stained intracellularly for influenza nucleoprotein using a fluorescein 
isothiocyanate conjugated antibody (NP-FITC, AbCam #ab20921) for 30 minutes.  Cells 
were washed and analyzed on a FACSAria II flow cytometer (BD). 
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Mouse macrophages experiments 
RAW264.7 cells (ATCC #TIB-71) were seeded onto glass chamber slides (LabTek) and 
allowed to rest overnight.  The cells were gently washed in PBS and virus was added at 
1.0 MOI.  The cells were washed and fixed at 24 hours post-infection and permeabilized 
with 0.2% saponin in 10% FBS.  Cells were stained for intracellular influenza 
nucleoprotein as above, and a nuclear counter stain was included for the final 10 minutes 
(TO-PRO3, Molecular Probes).  Cells were washed, mounted under a coverslip with 
ProLong Antifade media (Invitrogen), and visualized using a Zeiss LSM/710 confocal 
microscope.  Kinetics of infection were determined by infecting mouse macrophage cell 
lines, RAW264.7 or BEI Resources #NR9456 (NIAID, NIH), in triplicate wells of a 24-
well plate in DMEM supplemented with 0.2% BSA, 1% Pen/Strep, 2.5% L-glutamine, 
and 25 mM HEPES.  Supernatants were taken and centrifuged prior to performing a 





Figure 2.1 Cytokine levels in mice infected with pandemic and seasonal H1N1 influenza 
viruses.  
Six to eight week old DBA/2 mice were infected intranasally with 105 TCID50 with a 
seasonal virus isolate (BN/59), Kentucky (KY/80, KY/136, KY/96, KY/99, KY/104, 
KY/108, KY/108, KY/110, KY/180, KY/190) or other H1N1 pandemic isolates (CA/07, 
NY/18) from 2009. Cytokine levels were measured at 3 and 6 DPI as described in the 
materials and methods and presented as mean +/- SEM (n=6 per group, although fewer 




Figure 2.2 Chemokine levels in mice infected with pandemic and seasonal H1N1 
influenza viruses.  
Six to eight week old DBA/2 mice were infected intranasally with 105 TCID50 with a 
seasonal virus isolate (BN/59), Kentucky (KY/80, KY/136, KY/96, KY/99, KY/104, 
KY/108, KY/108, KY/110, KY/180, KY/190) or other H1N1 pandemic isolates (CA/07, 
NY/18) from 2009. Chemokine levels were measured at 3 and 6 DPI as described in the 




Figure 2.3 Principal components analysis of immune responses in lungs of mice to 
infection with pandemic and seasonal influenza viruses.   
A principal components analysis was performed using the 14 cytokines/chemokines 
analytes shown to be the most significantly different across all isolates from days 3 and 6 
(determined by generalized linear model fitness testing, data not shown). The data were 
normalized and scaled (zero mean-centered) cytokine responses after influenza infection 
at 3 and 6 DPI for all viruses. The ordinate and abscissa represent the first and second 
components from the PCA, which explain approximately 72% of the variance.  Each 
arrow represents the mean of a virus isolate tested in mice. Arrow tails represent day 3 
components and arrow heads represent day 6 components.  Using this tool to visualize 
the immune response, the arrows depict the trajectory of disease of the various influenza 
isolates as tested in DBA/2 mice.  Additionally, the 12 virus isolates clustered into four 
distinct patterns: Group 1, BN/59, CA/07, KY/80, KY/136; Group 2, KY/96, KY/99, 
KY/104, KY/108; Group 3, KY/108, KY/110; Group 4, KY/180, KY/190, NY/18 (See 




Figure 2.4 Weight loss and Kaplan-Meier curve of mice infected with KY/136 and 
KY/180.  
Mean weight change (+/- SEM) after six to eight week old DBA/2 mice were infected 
intranasally with 100, 102 and 105 TCID50 with KY/136E (A) or KY/180E (B). Mice were 
examined daily for clinical signs and weighed (n=10 mice per virus group).  Kaplan-
Meier Survival curves for these mice show KY/136E to have low lethality (C) compared 




Figure 2.5 Cytokine levels in mice infected with KY/136 or KY/180.  
The levels of notable cytokine responses are shown for 1, 3 and 5 DPI in six to eight 
week old DBA/2 mice that were infected intranasally with 105 TCID50 of KY/180E or 
KY/136E (n=10 mice per virus group per time point).   Statistical significance was 
determined by day using Kruskal-Wallis test followed by pairwise Wilcoxon Rank Sum 
post hoc test with Holm’s adjustment for multiple comparisons.  P-values < 0.05 are 
indicated by the following method: “a” = KY/180 is significantly different from mock; 
“b” = KY/136 is significantly different from mock; “c” = KY/180 is significantly 




Figure 2.6 Chemokine levels in mice infected with KY/136 or KY/180.  
The levels of notable chemokine responses are shown for 1, 3 and 5 DPI in six to eight 
week old DBA/2 mice that were infected intranasally with 105 TCID50 of KY/180E or 
KY/136E (n=10 mice per virus group per time point).  Statistical significance was 
determined by day using Kruskal-Wallis test followed by pairwise Wilcoxon Rank Sum 
post hoc test with Holm’s adjustment for multiple comparisons.  P-values < 0.05 are 
indicated by the following method: “a” = KY/180 is significantly different from mock; 
“b” = KY/136 is significantly different from mock; “c” = KY/180 is significantly 




Figure 2.7  IgG responses of mice infected with different doses of KY/136 or KY/180. 
Serum from day 20 post-infection was taken from six to eight week old DBA/2 mice that 
were infected intranasally with 100, 102 and 105 TCID50 of KY/180E or KY/136E (n=10 
mice per virus group per time point).  Influenza-specific (A/NY/18/09 BPL-inactivated 
whole viral antigen) IgG titers were measured by ELISA and presented as average log2 
endpoint titers (+/-SEM).  No mice survived to day 20 at the high dose of KY/180.  All 
endpoint titers for animals infected with influenza virus isolates were significantly 
different from mock (p < 0.05).  Endpoint titers for both IgG and HI from animals 
infected with KY/180 were significantly different from the same dosage amount of 




Figure 2.8 Cells within bronchial lavage fluid of mice infected with KY/136 or KY/180. 
The cells within the bronchoalveolar lavage fluid (BALf) at 4 DPI from DBA/2 mice 
infected with 105 TCID50 of KY/136E (A) or KY/180E (B) (n=5 mice per virus group per 
time point) were affixed to slides by cytospin centrifuge and stained (Kwik-Diff).  
Microscopic images from three fields per slide were counted by three blinded, 
independent observers. (C) The average number of macrophages, non-specific 
monocytes, and neutrophils are presented as a percent of the total cell count (+/- SEM). 
There were significantly more neutrophils in the BALf of mice infected with KY/180E 
virus (p < 0.05, indicated by asterisks). (D) Cells in the BALf were fixed, permeabilized, 
and stained with anti-influenza nucleoprotein (NP)-FITC antibody conjugate and 
analyzed by flow cytometry.  There were significantly more NP-positive cells in mice 
infected with KY/180 at a dose of 102 TCID50, and in mice infected with KY/136 
compared to mock-infected controls (p < 0.05, indicated by asterisks).  80% of NP-




Figure 2.9  Virus titer the in lung compartments of mice infected with KY/136 or 
KY/180. 
Bronchoalveolar lavage was taken from six to nine week old DBA/2 mice that were 
infected with 105 TCID50 KY/136E or KY/180E on days 3 and 4 post-infection.  Cells 
were separated from the lavage fluid by centrifugation and the fluid (BALf), cellular 
(BAL cell), and whole lung homogenate were tested separately for virus by TCID50 assay 
on MDCK cells.  Lung compartments taken from mice infected with KY/180 had 
statistically higher virus titers at 3 DPI than from mice infected with KY/136 (p < 0.05, 
indicated by asterisks on the figure).  It is not possible to compute statistical differences 
from 4 DPI, as there were only two mice infected with KY/180 in that experiment that 




Figure 2.10 Detection of influenza in mouse macrophage cell lines.   
Mouse macrophage cell line, RAW264.7, was infected in vitro with MOI=1 of each 
influenza isolate (high pathogenic isolate, KY/180, and low pathogenic isolate, KY/136) 
on chambered microscopy slides.  At 24 hours post-infection cells were fixed, 
permeabilized, and stained using a FITC antibody conjugate specific for influenza A 
(H1N1) nucleoprotein (green).  Cells were counterstained with a nuclear dye (TO-PRO3, 
Molecular Probes, red), and visualized on a Zeiss LSM710 confocal microscope.  Both 




Figure 2.11  Replication of KY/180E and KY/136E in mouse macrophage cell lines. 
Mouse macrophage cell line, RAW264.7, was infected in vitro with the influenza isolates 
on a 24-well plate at an MOI = 1.0. After one hour of incubation, the cells were washed 
and returned to the incubator. Cell culture supernatants were collected over time and 
virus titer was determined by TCID50 assay.  Both KY/180E and KY/136E replicate in 
mouse macrophage cell lines.  KY/180E had significantly higher titers of virus detected 
at 24 and 48 hours post-infection (p < 0.05, indicated by asterisks on the figure).  
Pathogenic isolate KY/180E was able to replicate better in mouse macrophages compared 




Figure 2.S1 Principal components cnalysis (PCA) of mouse lung cytokine and chemokine 
expression after challenge with clinical influenza A (H1N1) virus isolates from 
Kentucky, 2009.   
Standardized mean values for each cytokine/chemokine are plotted from Day 3 and Day 
6 post-infection (n=3, each) against the first two principal components, accounting for 





Figure 2.S2 Cytokine and chemokine profiles from mouse lung homogenate.  
DBA/2 mice were infected with KY/180E, KY/136E (105 pfu), or mock-infected with 
PBS. The mice were sacrificed 1, 3, and 5 days post-infection (n=5 mice per group-day). 
Samples from moribund mice taken after Day 5 post-infection were also analyzed when 





Figure 2.S3 Dose response of chemokines in the lungs of mice infected with KY/136 or 
KY/180 influenza A (H1N1) virus isolates.   
Mice were infected with 100, 102, or 105 pfu of virus and samples were collected upon 
euthanasia on days 1, 3, or 5 post-challenge (D1, D3, and D5, respectively).  n = 5 mice 
per dose-day for all groups except for mice infected with 105 pfu of KY/180 where only 




Figure 2.S4 Dose response of chemokines in the lungs of mice infected with KY/136 or 
KY/180 influenza A (H1N1) virus isolates.   
Mice were infected with 100, 102, or 105 pfu of virus and samples were collected upon 
euthanasia on days 1, 3, or 5 post-challenge (D1, D3, and D5, respectively).  n = 5 mice 
per dose-day for all groups except for mice infected with 105 pfu of KY/180 where only 





Figure 2.S5 Dose response of cytokines in the lungs of mice infected with KY/136 or 
KY/180 influenza A (H1N1) virus isolates.   
Mice were infected with 100, 102, or 105 pfu of virus and samples were collected upon 
euthanasia on days 1, 3, or 5 post-challenge (D1, D3, and D5, respectively).  n = 5 mice 
per dose-day for all groups except for mice infected with 105 pfu of KY/180 where only 




Figure 2.S6 Dose response of cytokines in the lungs of mice infected with KY/136 or 
KY/180 influenza A (H1N1) virus isolates.   
Mice were infected with 100, 102, or 105 pfu of virus and samples were collected upon 
euthanasia on days 1, 3, or 5 post-challenge (D1, D3, and D5, respectively).  n = 5 mice 
per dose-day for all groups except for mice infected with 105 pfu of KY/180 where only 





Figure 2.S7  Replication kinetics of KY/180E and KY/180E isolates in C57BL/6 mouse 
macrophages.  
The macrophage cell line, BEIR #NR-9465, was infected at 1.0 MOI (two independent 
experiments at n=3 per experiment) and clarified supernatants were taken at 4, 24, 48, 






















96/2 51/M 10/24/2009 10/26/2009 4 ND Survived 
99/3 35/F 10/28/2009 10/29/2009 3 ND Survived 
104/2 58/M 10/30/2009 11/4/2009 2 ND Died 






110/6 54/F 11/3/2009 11/4/2009 3 Diabetes Survived 
136/3 46/M 12/10/2009 12/11/2009 8 Diabetes, 
MRSA 
Survived 




190/2 55/F 4/10/2010 4/15/2010 12 ND Died 
*locality, 2=western Kentucky (KY); 3=eastern KY; 6=Louisville metro; LOS, Length 
of stay in hospital; MRSA, methicillin-resistant Staphylococcus aureus; COPD, chronic 










Mock 3 <1.5 * 0.0 
 6 <1.5 * 0.0 
KY/80M 3 7.2 ± 0.5 0.0 
 6 6.4 ± 0.9 33.3 
KY/80E 3 7.6 ± 0.1 0.0 
 6 7.0 ± 0.3 33.3 
KY/96M 3 7.0 ± 0.5 0.0 
 6 7.2 ± 0.5 0.0 
KY/96E 3 7.3 ± 0.4 0.0 
 6 7.4 ± 0.4 100.0 
KY/99M 3 6.4 ± 0.2 0.0 
 6 5.8 ± 0.7 0.0 
KY/99E 3 7.4 ± 0.9 0.0 
 6 7.3 ± 0.3 33.3 
KY/104M 3 6.6 ± 0.9 0.0 
 6 6.9 ± 0.5 33.3 
KY/108M 3 7.5 ± 0.6 0.0 
 6 6.6 ± 0.4 0.0 
KY/108E 3 6.5 ± 0.5 0.0 
 6 6.4 ± 0.8 33.3 
KY/110M 3 5.9 ± 0.4 0.0 
 6 6.2 ± 0.9 0.0 
KY/110E 3 5.9 ± 0.2 0.0 
 6 6.8 ± 0.7 0.0 
KY/136M 3 5.3 ± 0.3 0.0 
 6 5.8 ± 0.9 0.0 
KY/136E 3 5.8 ± 0.4 0.0 
 6 5.2 ± 0.5 0.0 
KY/180M 3 6.8 ± 0.3 0.0 
 6 5.7 ± 0.7 100.0 
KY/180E 3 6.9 ± 0.4 33.3 
 6 6.4 ± 0.1 66.7 
KY/190M 3 6.8 ± 0.5 0.0 
 6 6.3 ± 0.3 100.0 
NY/18E 3 6.9 ± 0.6 0.0 
 6 6.8 ± 1.0 33.3 
CA/07E 3 7.2 ± 0.6 0.0 
 6 6.9 ± 0.8 0.0 
BN/59E 3 6.7 ± 0.0 0.0 
 6 5.9 ± 0.1 0.0 
Legend: Virus titer (log10 TCID50/mL at a limit of detection = 10
1.5 TCID50 / mL)  
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Table 2.S1 Comorbidities associated with severe, hospitalized influenza pneumonia 
patients. 









80 Female 123.6 Tamiflu 
75 mg 
Q12H x 7 
days 
61 II yes no no MRSA yes 
96 Male 21.9 No 91 IV no no no None yes 
99 Female 76.90 No-Flu 
vaccine 
only 
54 II no no no None 0 
104 Male 26.63 Tamiflu 
75mg x2 
doses 
123 IV no yes no Proteu
sspp. 
yes 
108 Female 79.71 Tamiflu 
75 mg 
daily x 5 
days 
106 IV yes yes no None no 
110 Female 21.40 Tamiflu 
75 mg 
daily x 5 
days 
73 III no yes no None no 
136 Male 24.4 Tamiflu 
150mg 
daily x 5 
days 
76 III no yes yes MRSA yes 
180 Male 49.4 Tamiflu 93 IV yes no no None yes 
190 Female 56.4 Tamiflu 75 III yes yes no none no 
Legend: BMI, body mass index; PSI, pneumonia severity index; COPD, Chronic obstructive pulmonary 





Table 2.S2 Variants noted in amino acid sequence alignments of H1N1pdm clinical 
isolates. 
 M1 HA1 
A.A. 
Residue 













































T   
   
S 
CA/07 A G C C G G A A C A T G T T T 
NY/18 A G T C G G A A C A T G T T A 
NL/602 A G T C G G A A C A T G T T T 
KY/80 A G T C G G A G C A T G T T A 
KY/96 A G T C G G A A C A T G T T T 
KY/99 A G T C G G G A C A T G C T A 
KY/104 A G T C G A A A C A T G T T A 
KY/110 A A T C G G A A A A T G T T A 
KY/136/E A G T T G G A A C A T G T T A 
KY/180/E G G C C A G A A C A C A T T A 
KY/180/M NA G C C A G A A C G C A T T A 

















































   
L 
E   
   
D 
CA/07 A A G G A G C G G G T A G C A 
NY/18 A R G G G G C G G G T A G A A 
NL/602 A A G G G G C G G G T A G C A 
KY/80 A A G G A G C G G G T A G A A 
KY/96 A A G T G G C A G A T A G A A 
KY/99 A A G G G G C G G G T G G A A 
KY/104 A A G G G A C G G G T A A A A 
KY/110 A A G G G G C G NA NA NA NA NA A NA 
KY/136/E A A A G G G C G G G C A G A A 
KY/180/E G A G G G A C G A G T A G A T 
KY/180/M G A G G G A C G NA NA NA NA NA NA NA 





















































CA/07 A C A G G C C G C A A T C A G 
NY/18 A C A G A C C G C A A T C A G 
NL/602 A C A G A C C G C A A T C A G 
KY/80 A C A G A C C G C A A T C A G 
KY/96 A C A G A A C G C A G T A A G 
KY/99 G S A G A C C G C A A T C A G 
KY/104 A C A G A C C A C A A T C A G 
KY/110 NA NA NA G A C C G A A A C C A G 
KY/136/E A C A G A C G G C A A T C T G 
KY/180/E A C C A A C C G C G A T C A A 
                
                
                
                
                
                




 NA NP NS1 
A.A. 
Residue 
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CA/07 T G A A G A T G G C C A G G 
NY/18 T A A A G G T G A C C A G G 
NL/602 T A G A G A T A G C T A G G 
KY/80 T A A A G G T G A C C A G G 
KY/96 C A A A G G A G A C C A A G 
KY/99 T A A A G G T G A C C A G G 
KY/104 T A A A G G T G A C C A G G 
KY/110 T A A A G G T G A C C A G A 
KY/136/E T A A G G G T G A A C G G G 
KY/180/E T A A A A G T G A C C A G G 









































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2.S4 Virus titers (TCID50/ml*) on 1, 3, and 5 days post-infection in lungs and nasal 
turbinates of DBA/2 mice infected with KY/180E and KY/136E.   
  Lung NT 
 Dose  1 DPI 3 DPI 5 DPI 1 DPI 3 DPI 5 DPI 
KY/136E 100 < 1.5* 2.86 ± 2.15 0.68 ± 1.52 < 1.5 < 1.5 < 1.5 
 102 1.42 ± 1.95 3.78 ± 2.23 2.50 ± 0.00 < 1.5 < 1.5 1.94 ± 1.89 
 105 5.04 ± 0.86 3.64 ± 2.17 < 1.5 < 1.5 3.64 ± 0.76 2.92 ± 0.29 
KY/180E 100 0.50 ± 1.12 2.76 ± 2.61 4.40 ± 2.47 < 1.5 < 1.5 < 1.5 
 102 4.86 ±1.77 6.54 ± 0.36 6.42 ± 0.44 0.50 ± 1.12 5.22± 0.54 5.32 ± 0.75 
 105 7.54 ± 0.34 6.18 ± 0.46 6.38 ± 0.30 5.40 ± 0.26 4.80 ± 0.45 4.96 ± 0.36 
Legend: Dose = pfu/mouse. Values in mean log10 TCID50/mL ± S.D. (n = 5 mice per 




Table 2.S5 Relative magnitude of immune responses of H1N1pdm isolates in mice in 
groups revealed by principal component analysis clustering.   
Cytokine/ 
Chemokine 
Function DPI Group 1 Group 2 Group 3 Group 4 
IL-6 Inflammation 3 + +++ + + 
  6 + ++++ +++ + 
TNFα Inflammation 3 + +++ +++ ++ 
  6 + +++ ++++ + 
KC PMN attraction 3 + +++ ++ ++ 
  6 + +++ ++ + 
G-CSF PMN proliferation 3 + +++ ++ +++ 





3 +++ ++++ ++ +++ 





3 + +++ ++++ ++ 
  6 ++ +++ ++++ ++ 
IL-1β Inflammation 3 + ++ ++ + 
  6 ++ ++ +++ + 
CXCL3 
(MIP1α) 
PMN attraction 3 + ++ +++ + 
  6 ++ +++ ++++ + 
CXCL10 
(IP10) 
Chemoattractant 3 ++ - ++++ ++ 




3 - - + - 




3 - - + - 
  6 + ++ +++ - 
Legend:  Group 1, BN/59, CA/07, KY/80, KY/136; Group 2, KY/96, KY/99, KY/104, KY/108; Group 3, 




Table 2.S6 Summary of references to mutations in influenza A (H1N1) isolates with 
observed virulence. 
 
Gene product Mutation Source Citation 
HA1 S83P mouse, in vitro 3, 12 
HA1 S183P mouse 21, 22, 93, 94 
HA1 T203S mouse 44 
HA1 D222G human, mouse, 
macaque 
10, 30, 31, 32, 
34, 36, 38, 37, 
43, 89 
HA1 Q293H mouse 44 
HA1 V321I mouse 3, 24, 44 
HA2 E374K human 95 
NA I106A mouse 44 
NS1 V123I mouse 44 
PA V14I mouse 44 






MOLECULAR IMAGING REVEALS A PROGRESSIVE PULMONARY 
INFLAMMATION IN LOWER AIRWAYS IN FERRETS INFECTED WITH 2009 
H1N1 PANDEMIC INFLUENZA VIRUS 
 
Overview 
Molecular imaging has gained attention as a possible approach for the study of the 
progression of inflammation and disease dynamics.  Herein we used [18F]-2-deoxy-2-
fluoro-D-glucose ([18F]-FDG) as a radiotracer for PET imaging coupled with CT (FDG-
PET/CT) to gain insight into the spatiotemporal progression of the inflammatory 
response of ferrets infected with a clinical isolate of a pandemic influenza virus, H1N1 
(H1N1pdm).  The thoracic regions of mock- and H1N1pdm-infected ferrets were imaged 
prior to infection and at 1, 2, 3 and 6 days post-infection (DPI).  On 1 DPI, FDG-PET/CT 
imaging revealed areas of consolidation in the right caudal lobe which corresponded with 
elevated [18F]-FDG uptake (maximum standardized uptake values (SUVMax), 4.7-7.0).  
By days 2 and 3, consolidation (CT) and inflammation ([18F]-FDG) appeared in the left 
caudal lobe.  By 6 DPI, CT images showed extensive areas of patchy ground-glass 
opacities (GGO) and consolidations with the largest lesions having high SUVMax (6.0-
7.6). Viral shedding and replication were detected in most nasal, throat and rectal swabs 
and nasal turbinates and lungs on 1, 2 and 3 DPI, but not on day 7, respectively.  
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In conclusion, molecular imaging of infected ferrets revealed a progressive consolidation 
on CT with corresponding [18F]-FDG uptake. Strong positive correlations were measured 
between SUVMax and bronchiolitis-related pathologic scoring (Spearman’s ρ = 0.75).   
Importantly, the extensive areas of patchy GGO and consolidation seen on CT in the 
ferret model at 6 DPI are similar to that reported for human H1N1pdm infections.  In 
summary, these first molecular imaging studies of lower respiratory infection with 
H1N1pdm show that FDG-PET can give insight into the spatiotemporal progression of 
the inflammation in real-time.  
 
Introduction 
In March of 2009, an outbreak of a novel variant of H1N1 influenza A virus was reported 
in cases of influenza illness in Mexico (35).  By June 11, the World Health Organization 
raised the pandemic alert level to its highest level, declaring the first influenza pandemic 
in over 40 years (35).  Unlike seasonal influenza viruses, this novel H1N1 pandemic 
strain (H1N1pdm) tended to affect younger healthier populations and had an increased 
risk of morbidity and mortality (37, 39, 40) with 12-30% of the population developing 
clinical influenza, 4% of those requiring hospital admission, and 1 in 5 requiring critical 
care (599).   In general, however, infection of the H1N1pdm was relatively mild in most 
persons, although a fatal viral pneumonia with acute respiratory distress syndrome 
occurred in approximately 18,000 cases. 
 
In contrast to seasonal influenza in human cases, H1N1pdm infections showed a tropism 
for the lung similar to H5N1 (30). The ability of H1N1pdm viruses to infect the lower 
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respiratory track has been attributed to a broader specificity in the binding of the viral 
-3- -6-linked sialic acid (SA) receptors (284, 
336). It is reasonable that the lung tropism of the H1N1pdm contributed to the severity of 
disease in those individuals with preexisting complications such as asthma and chronic 
obstructive pulmonary disease (COPD) (6, 30, 544-546).  Data from limited human 
autopsies and animal studies of various pandemic strains also suggest contribution of the 
host innate immune response and the virus in the progression of disease (46, 394, 600, 
601). 
 
Molecular imaging can potentially play a strong role in basic infectious disease research 
and clinical response by providing a noninvasive, spatiotemporal measurement of viral 
infection and host inflammation (602, 603).  To explore the potential utility of molecular 
imaging in influenza infection, we chose the ferret (Mustela putorius furo) model. Ferrets 
have been used as an animal model of influenza infection and pathogenesis since 1934, 
when they were reported to develop an acute respiratory tract illness when exposed to 
influenza viruses from humans and swine (149). In contrast to mice, the ferret can be 
infected by human isolates without adaptation and display signs and symptoms of 
infection such as sneezing and nasal secretions that are similar to what is seen in humans 
(43, 47, 49, 256). The ferret is an attractive model for imaging influenza pulmonary 
infections given the ferret’s long trachea, large lung capacity, and bronchiolar branching. 
These anatomical features can potentially bridge imaging with histopathologic 
evaluation. Finally, the ferret more closely mimics humans in distribution of sialic acid 
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(SA) receptors in the respiratory tract with higher-2-6 SA in the upper respiratory tract 
and 2-3 SAs- in the lower (228).    
 
Historically, plain film (x-ray) radiography and computed tomography (CT) have been 
useful for clinical assessments of influenza disease severity in clinical cases (41, 604). 
These imaging modalities are limited by characterizing only anatomic changes in the lung 
parenchyma, such as ground-glass opacity (GGO) and consolidations, which represent 
different degrees of interstitial and alveolar filling by cells, edema, and inflammatory 
exudate (605).  In contrast, positron emission tomography (PET) imaging with the 
radiotracer [18F]-2-fluoro-2-deoxy-D-glucose ([18F]-FDG) can provide data on metabolic 
activity of cells by measuring sites of increased glycolysis from leukocyte chemotaxis 
and accumulation, and provide increased sensitivity in detection of cells during 
inflammation. [18F]-FDG, an analog of glucose that is moved into cells via facilitated 
transport, is commonly used in PET imaging as a radiotracer in clinical and basic science 
research.  Recent studies have demonstrated the utility of [18F]-FDG in assessment of 
infectious disease burden in animal models of schistosomiasis and tuberculosis (606-
608). PET/CT has been used in the assessment of one hospitalized H1N1pdm patient and 
revealed an intense inflammatory response (609). The uptake of [18F]-FDG in humans 
and animals suggests the predominant presence of activated neutrophils (610-613). In 
studies of mice infected with influenza A virus, neutrophils play a critical role in 
protection and recovery from infection, and participate in the process of adaptive 
immunity to the virus (78). Coupled with molecular virology and pathology, molecular 
imaging with important probes of disease has enormous potential to reveal early critical 
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factors that contribute to the clinical progression of illness as well as accelerate screening, 
the efficacy and mechanistic studies of vaccines and antiviral therapies (602, 603).   
 
To test the hypothesis that FDG-PET/CT imaging could reveal the spatiotemporal nature 
of H1N1pdm inflammation and disease progression, we chose the ferret model of 
H1N1pdm influenza infection. Further, for these studies we chose a low passage clinical 
isolate, A/Kentucky/180/2010 or KY/180, herein, which has a change in the HA1 gene, 
D222G, which correlates with increased severity of disease in patient cases from several 
countries (558, 559, 562, 563). In mice, infection with H1N1pdm engineered to include 
this change show increased viral titers and pathology, however, in ferrets there do not 
seem to be any major differences in clinical signs, transmissibility or pathogenicity (125, 
614).  Our results show for the first time, the spatiotemporal progression of inflammation 
with CT and PET using [18F]-FDG in ferrets infected with H1N1pdm in conjunction with 
histopathology and viral titers over a seven day period.  Importantly, the extensive areas 
of patchy GGO and consolidation seen in the ferret model at 6 days post-infection (DPI) 
are similar to that reported for human H1N1pdm infections (609).  In vivo imaging with 
these modalities for anatomic (CT) and molecular (PET) data suggests increased 
pulmonary inflammation as the amount of circulating virus becomes undetectable.  These 
results suggest that molecular imaging will be a great asset in gaining insight into the 






Characterization of KY/180 in female ferrets 
Due to the size of the Siemens Trimodal gantry for PET/CT imaging we chose four 
month old females rather than male ferrets. The pandemic H1N1 isolate KY/180 
employed in these studies was isolated from nasal swab sample provided by the Severe 
Influenza Pneumonia Surveillance project, a clinical study of hospitalized patients with 
influenza pneumonia in Kentucky. The patient had a severe course of influenza disease 
and died after 19 days. Sequencing of the HA1 gene from this isolate revealed the D222G 
mutation, which has been associated with severe disease in human cases (558, 559, 562, 
563). The second passage of the KY/180 seed was employed in the characterization of 
infection in the female ferrets. The 50% infectious dose in female ferrets was determined 
to be 100.07 TCID50 (data not shown).  In group 1, six ferrets were mock infected with 
PBS. In group 2, six ferrets were infected intranasally (i.n.) with KY/180 with a 0.5 ml 
dose of 0.5 x 105.7 TCID50 per naris. Ferrets were monitored for temperature for 10 DPI, 
and for body weight and clinical symptoms for 28 DPI. Two animals in each group were 
euthanized on days 2, 14 and 18 to determine virus and HI titers in blood, lung and 
several additional organs at 2 DPI. 
 
In figure 3.1A, the body weight changes are shown for mock- and KY/180-infected 
ferrets. Body weight showed a drop on day 2 where the weight remained for the 
remainder of the study. Figure 3.1B shows the average temperatures of the mock- and 
KY/180-infected ferrets for the first 10 DPI. Temperature peaked on days 1 and 5 for 
KY/180 infected animals with a mean temperature of 103.4oF (SD=1.71oF) and 103.2oF 
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(SD=0.52 oF), respectively. The average hemagglutination-inhibiting (HI) serum antibody 
titer in the blood on day 14 was 540 reciprocal dilution and the average total serum 
influenza-specific IgG by ELISA was 7610 reciprocal dilution (Fig. 3.1C). In studies to 
determine the infectious dose, additional tissues were taken from animals infected at with 
KY/180 with a 0.5 ml dose of 0.5 x 104.7 TCID50 per naris. On day 2, viral titers were the 
highest in the nasal turbinates (106.25 TCID50/g) followed by the caudal lung (10
6.0 
TCID50/g) and trachea (10
3.75 TCID50/g). The lowest levels of virus were observed in the 
cranial lobe of the lung (103.2 TCID50/g). Viral titers were measured by TCID50 in nasal 
turbinates, trachea, right cranial lobe of the lung, right caudal lobe, brain, liver, spleen, 
kidney, duodenum, jejunoilieum, colon and rectum. KY/180 was detected in jejunum in 
one animal (102.0 TCID50/g), but was not detected in any other tissues (data not shown). 
 
FDG-PET/CT imaging of the H1N1pdm-infected ferrets show progressive 
inflammation 
Female Fitch ferrets were divided into five groups, with two per group of animals that 
were mock-infected with PBS (group 1) or intranasally infected with KY/180 (groups 2-
5), in a 0.5 ml dose of 0.5 x 106.0 TCID50 per naris, on day 0 (Table 1).  Group 5 was the 
only group that was imaged each day; while groups 2-4 were imaged and sacrificed on 
days 1, 2 and 3 post-infection. This study design permitted evaluation of the progression 
of imaging with infection and pathology in two animals each day as well as continuous 




FDG-PET and CT images of the H1N1pdm-infected and mock-infected ferrets were 
successfully obtained and fused for two ferrets on days 1, 2, 3 and 6 (Fig. 3.2 and 3.3).  
Volumes of interest (VOI) and corresponding maximum standardized uptake values 
(SUVMax) were generated for any metabolically active lesions in the lung as well as 
background activity in the lungs, liver, heart, thymus, and thoracic lymph nodes.  
Baseline imaging prior to infection showed no focal areas of lung consolidation on CT 
and background standard uptake values (SUVMax) of the [18F]-FDG levels ranged from 
0.7-1.0 for PET (Fig. 3.2A and Fig. 3.3A). Each figure shows the one two-dimensional 
coronal plane that were standardized across days to provide a similar orientation and do 
not necessarily represent the SUVMax as that plane may be out of view. 
 
By 1 DPI, an area of consolidation was identified on CT in the right caudal lobe with 
corresponding radiotracer uptake on PET (Fig. 3.2B, SUVMax of 4.7).  Consolidative 
areas in the right caudal lobe increased by day 2, with a persistently elevated SUVMax of 
3.1(data not shown). By day 3, the consolidation increased in the right caudal lobe (Fig. 
3.2C and Fig. 3.3C, SUVMax of 3.7 and 4.4, respectively) and also appeared in the left 
caudal lobe (SUVMax of 3.2) of ferret 2214 (Fig. 3.3C).  By 6 DPI, there were 
widespread areas of patchy consolidation on CT with multiple areas of increased 
radiotracer uptake in both ferrets in caudal and cranial lobes (Fig. 3.2D and Fig. 3.3D, 
SUVMax of 6.0 and 7.6 on the right, 4.2 and 4.6 on the left, respectively).  These results 
suggest that inflammation progresses into the lower respiratory airways after infection 
into the upper part of the lower respiratory system. A ferret from the uninfected cohort 
was also imaged on day 6, with no focal appearance of consolidation on CT and no 
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evidence of increased [18F]-FDG uptake on PET (image not shown, background SUV of 
0.6). 
 
Viral shedding and replication of the nasal turbinates and lung tissues  
To measure viral shedding, each day each ferret was swabbed in the nasal, throat and 
fecal passages and the viral titer was measured by TCID50 (Table 2). The highest levels of 
viral shedding were measured in the throat swabs. Nasal swabs also showed viral 
shedding for most animals, while the presence of virus in rectal swabs was low although 
detectable in a few animals.  
 
Replication of H1N1pdm in nasal turbinates and lungs were determined post-mortem 
from the right caudal lobe of the lung taken on euthanasia (Table 3.3).  Four sections 
were taken per lobe to provide greater insight into the spread of the virus in the tissue 
(Fig. 3.4). High levels of virus were detected in all nasal turbinate samples at 1, 2, and 3 
DPI (95% C.I. = 5.43 +/- 1.00 TCID50/mL).  Virus was also detected in a majority of lung 
sections from 1, 2, and 3 DPI.  It was absent in the lung sections from one animal on 2 
DPI, although it was present in the ferret’s nasal turbinates, suggesting that the timing of 
infection in this animal was slower than the others. Of note, this same animal had a focus 
of consolidation on CT and radiotracer uptake on PET. This observation also suggests 
that, while the virus may have been undetectable by TCID50, low levels of virus had 
entered the lower respiratory system. No animals on day 7 post-infection had detectable 
virus in the nasal turbinates or the sampled lung tissue.  Virus was not detected in nasal, 




Histopathology of H1N1pdm-infected and mock-infected ferrets 
Upon necropsy, all but the right caudal lobe of the ferret lung was fixed with 
paraformaldehyde. Following fixation, sections were taken for histopathology from the 
right and left cranial lobes, left caudal lobe and the middle accessory lobe. Representative 
photographs from slides of the left caudal lobe are shown in figure 3.5.  The ferrets in the 
control group had intact bronchiolar walls with very minimal infiltration by neutrophils 
with the exception of the left caudal lobe from control animal 2206 sacrificed on Day 1. 
Possible causes of this pattern of change may be an underlying systemic vasculopathy 
which is typically confirmed by evaluation of other organs that were not collected (e.g., 
kidney, spleen, liver). 
 
In general pulmonary lesions associated with influenza infection were roughly 
comparable at Days 1 and 2 and consisted of variable suppurative or necrosuppurative 
bronchiolitis and mixed cell alveolitis at minimal to moderate severity levels. By 1 DPI, 
there were some small foci of inflammation without much infiltration of the bronchi or 
bronchioles. There was an increased severity of inflammatory findings in lung lobes from 
infected ferrets on day 3. Specifically, more extensive infiltration of neutrophils can be 
seen within the bronchiolar lumen, along with necrosupprative bronchiolitis and mixed 
cell alveolitis.  At Day 7, lesions observed in the lung lobes continued to exhibit an 
increased severity compared to the majority of lung lesions seen at 1 and 2 DPI. 





FDG-PET/CT and histopathology show positive correlation during infection 
To evaluate potential correlations between PET/CT with histopathology, the SUVMax of 
lesions in the right and left lung of each ferret were compared with the cumulative 
histopathology scores assigned by the veterinary pathologist (Fig. 3.6). On average, the 
SUVMax was higher in the right lung than the left lung but the slopes and Spearman’s 
correlation coefficients (ρ) were similar between the two sides.  The highest correlation 
was seen between the cumulative bronchiolitis score and SUVMax (ρ of 0.71 and 0.75 on 
the right and left, respectively).  The next highest was between the cumulative bronchitis 
score and SUVMax (ρ of 0.69 on the right and 0.67 on the left).  A weaker positive 
correlation was seen between the cumulative alveolitis score and SUVMax (ρ of 0.47 on 
the right and 0.57 on the left).  
 
Discussion 
Herein, we show for the first time the feasibility of utilizing [18F]-FDG PET coupled with 
CT imaging of H1N1pdm in ferret to track the progression of pulmonary disease in real-
time. We chose a low passage clinical isolate, KY/180, which has a change in the HA1 
gene, D222G. The D222G change in H1N1pdm correlates with increased severity of 
disease in patient cases from several countries (558, 559, 562, 563). The patient from 
which we obtained the KY/180 isolate also had a severe course of influenza illness over a 
period of 19 days that resulted in death. Recently, studies in mice and ferrets infected 
with pandemic influenza viruses A/California/04/2009 and A/Netherlands/602/2009 
engineered with the D222G mutation have shown that the D222G mutation are lethal in 
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mice, but not ferret (125, 614). The lethality in mice, but not ferrets, has been attributed 
to the greater abundance of 2-3-SA in the mouse model (125, 230).  All of these viruses 
have an affinity for 2,6-SAs associated with attachment to and replication in cells of the 
upper respiratory tract as shown by the high levels of viral replication in the nasal 
turbinates.  Thus, infection of ferrets with these H1N1pdm isolates engineered with 
D222G and our clinical isolate have not correlated with clinical findings in patients. 
These results in ferrets are not surprising given that 80% of the fatal cases of H1N1pdm 
had underlying medical conditions and bacterial infections (30).  Discovery of the 
molecular components of the host response that may promote pathogenesis will be 
critical for defining new treatments. 
 
Noninvasive imaging can provide real-time in vivo monitoring of the progression of 
infection, inflammation and disease that may give insight into the mechanisms that 
modulate disease progression. Recently, Veldhuis Kroeze et al., presented data on the 
monitoring of pulmonary lesions of H1N1pdm influenza virus-infected ferrets with CT 
scanning which correlated with disease progression and severity (615).  As those studies 
demonstrate, CT is a powerful tool, but it will not give the molecular details that can be 
provided by PET or SPECT imaging of probes that target critical host responses such as 
neutrophil invasion. In our study we coupled CT scanning with the [18F]-FDG radiotracer 
and show infection and inflammation of influenza infection in the lower respiratory 
system with foci of increased [18F]-FDG uptake corresponding to areas of lung opacity on 
CT, with underlying inflammation on necropsy. In comparison to human CT imaging 
studies of influenza, the molecular images in the ferret show strong similarity.  CT 
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findings in patients with confirmed influenza infection show patchy ground-glass 
opacities in segmental multifocal distributions, mixed with areas of consolidation in the 
lung (6, 41, 616). Moreover, the few case reports of human influenza in which lungs were 
imaged by [18F]-FDG PET demonstrate areas of high uptake in these ground-glass 
opacities and consolidation (609).   Our study similarly demonstrates this pattern in the 
ferret model, also showing patchy opacities on CT with high uptake of radiotracer on 
PET, with necroscopy-based confirmation of inflammation in the left caudal lobe.  
Specifically, we show the ferret lung demonstrated progressive consolidation on CT and 
FDG uptake on PET predominantly in the right caudal lobe, which progressed to the left 
caudal lobe by day 3 p.i.. By day 6, the diffuse metabolically active lesions seen on 
PET/CT were similar to what has been reported in the human literature during the 2009 
H1N1 pandemic (609).  
 
Histopathologic evaluation of the lungs confirmed the progressive nature of the 
pulmonary lesions and corroborated the radiologic data. Suppurative and 
necrosuppurative bronchiolitis seen on days 1 and 2 became progressively worse by days 
3 and 7 post-infection. The inflammation tended to be patchy or multifocal and an entire 
lung lobe was never uniformly affected, corresponding to the multiple patchy lesions 
seen on PET/CT by the end of the study. This also agreed with the analyses of the viral 
titers in various sections of the right caudal lobe and the PET/CT imaging. Our analyses 
of viral titers in the four representative sections suggest different levels of infiltration of 
the lobe. The histopathologic scoring for bronchiolitis correlated the best with the 
SUVMax of the lesions seen in the right and left lungs on PET. In general, the severity of 
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infection and inflammation on imaging can be represented by (1) the volume of affected 
lung (i.e. the percentage of diseased lung relative to total lung capacity), and (2) the 
extent of parenchymal destruction (disruption of pulmonary architecture) and 
inflammatory cell migration.  Our study first aims to correlate FDG uptake measurements 
with histology, thereby analyzing the extent of parenchymal destruction and cellular 
infiltrates. 
 
It should be considered that there can be variation in matching FDG uptake with 
histologic severity because more severe architectural distortion can lead to necrosis with 
more dead cells, therefore showing less uptake of radiotracer among metabolically 
inactive dead cells and nonviable tissue. Our study, however, shows that progressing 
inflammatory infiltrates on histology in the studied time period after acute influenza 
infection corresponds to radiologic trends.  Additionally, our study demonstrates spatial 
progression with increased size and number of abnormal foci in the lung parenchyma 
during acute infection. 
 
Ultimately, utilizing these new imaging tools, we envision a number of future 
experiments to delineate potential differences in the course of H1N1pdm and H5N1 
isolates infection in ferrets. We also plan to explore additional radiotracers that might 
reveal potential differences in host responses in the immune system and the process of 
acute injury in the lung. Future studies will assess differences in presentation of those 
who recover from infection versus those who eventually succumb to infection such as 
with more lethal isolates such as H5N1. This model should be valuable in rapid 
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assessment of the effect of various treatments on pulmonary inflammation and damage. 
Finally, these first PET/CT imaging approaches could be extended to a number of other 
important pulmonary infections caused by pathogens such as hantaviruses, respiratory 
syncytial virus, and SARS CoV, to gain further insight into the spatiotemporal in vivo 
dynamics of disease progression (603). 
 
Materials and Methods 
Virus and cells 
The influenza H1N1pdm virus, A/Kentucky/180/2010, (KY/180; GenBank CY99332 and 
CY99333) was isolated from the nasal swab of a severe hospitalized case (hospitalized in 
March 2010) provided by the Severe Influenza Pneumonia Surveillance project, an 
ongoing clinical study of hospitalized patients with influenza pneumonia in Kentucky 
(courtesy of Dr. Julio Ramirez).  The virus was isolated and passaged in the allantoic 
cavity of ten-day-old embryonated hens’ eggs at 37oC.  The allantoic fluid was harvested 
72 h after inoculation, pooled and stored in stored in aliquots at -80C until use. The 
infectious virus titer of the resulting seed stock was determined by TCID50 (50% tissue 
culture infectious dose) and the titer calculated by Reed and Muench (597) and confirmed 
by plaque assay on MDCK cells.  Passage E2 was used for the studies reported herein. 
 
Ferrets 
Ferret studies were approved by the University of Louisville Institutional Animal Care 
and Use Committee. University of Louisville has Veterinary Medicine tasked to monitor 
and support all animal experiments.  Research was conducted in compliance with the 
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Animal Welfare Act and other federal statutes and regulations relating to animals and 
experiments involving animals and adheres to principles stated in the Guide for the Care 
and Use of Laboratory Animals, National Research Council, 1996.  The facility where 
this research will be conducted is fully accredited by the Association for Assessment and 
Accreditation of Laboratory Animal Care International. 
 
All female Fitch ferrets were obtained from Triple F Farms (Sayre, PA). Ferrets were 
selected after screening blood samples for the presence of influenza antibodies using a 
hemagglutination inhibition assay (HI). Ferrets that were seronegative for seasonal and 
pandemic viruses were shipped directly to the University of Louisville Regional 
Biocontainment Laboratory and acclimated for seven days prior to initiation of the 
studies. Animals were fed Teklad Laboratory Diet #2072 (Harlan/Teklad, Madison, WI) 
and water ad libitum. 
 
For the characterization of the progression of infection of the KY/180 clinical isolate we 
utilized four month old, female ferrets. Prior to infection with virus, ferrets were 
anesthetized with 0.05 mg/kg atropine, 5.0 mg/kg ketamine, and 0.08 mg/kg 
dexmedetomidine intramuscularly.  Subsequently, six animals were inoculated intransally 
(i.n.) with 0.5 mL of infectious virus per naris as a bolus, which was diluted to 105.7 
TCID50/mL in phosphate buffered saline (PBS). Six additional animals were inoculated 
by i.n. with 0.5 mL of infectious virus per naris as a bolus with PBS (mock). Anesthesia 
was reversed with 0.4 mg/kg atipamezole. Ferrets were monitored daily for temperature 
and clinical symptoms. On day 2 post-infection, two ferrets were taken to measure viral 
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titers in blood, lung, brain, trachea, nasal turbinates, spleen, kidney, thymus, liver, 
duodenum, jejuno-ileum, large intestine, and rectum. Gross pathology was defined during 
necropsy for the lung. At 14 and 28 days post-infection two additional ferrets from each 
group were analyzed for viral titers and pathology in the lung. 
 
For molecular imaging studies, twelve, four-month-old female Fitch ferrets were utilized. 
Animals were fed food and water ad libitum except 4 h prior to and during CT/PET 
imaging. On day 0, ferrets were anesthetized prior to inoculation with virus or PBS with 
ketamine, dexmedetomidine and atropine.  Eight animals were inoculated i.n. with 0.5 
mL of infectious virus per naris as a bolus, which was diluted to 106.0 TCID50/mL in 
phosphate buffered saline (PBS).  Four ferrets were inoculated i.n. with 0.5 mL PBS per 
naris as a mock-infected control.  For imaging, on days 0, 1, 2, 3 and 6, anesthetic 
induction and maintenance were achieved with 1-3% isoflurane.  Blood glucose levels 
were checked prior to administration of the radiolabeled tracer to ensure that they were 
within normal limits, which typically range from 62-134 mg/dL in ferrets (617).  Glucose 
was provided to animals to compensate for body fluids lost during imaging. Typically 30 
mls of Lactated Ringer's solution (Hospira) was administered subcutaneously (s.q.) 
following completion of the imaging.  Animals were monitored for body temperature and 
vital signs during imaging.   
 
CT and PET imaging 
Imaging was performed on 0, 1, 2, 3, and 6 days post-infection (DPI).  Each day, four 
ferrets were imaged with CT and PET on hardware designed for preclinical animal 
137 
 
studies, including microCT and microPET, respectively. Two ferrets were euthanized the 
each day and necropsied to obtain tissue samples for virologic and histopathologic 
analyses (please see study design Table 1).  Image acquisition was conducted with a 
Siemens Inveon Trimodal Scanner (Siemens Preclinical, Knoxville, TN), which is a small 
animal imaging platform that combines microPET, microCT, and microSPECT 
modalities within one unit.  This combination facilitated co-registration of PET and CT 
images as the study subject was kept in a uniform position on the scanner bed, 
minimizing potentially large motion artifacts as a result of repositioning the animal 
between each scan.  The Inveon microCT scanner features a variable-focus tungsten X-
ray source with an achievable resolution of 20 µm and a detector with a maximum field 
of view (FOV) of 8.4 cm x 5.5 cm.  The source-to-object distance was 263.24 mm and 
the source-to-detector distance was 335.67 mm.  The Inveon PET detector provided an 
axial field of view (FOV) of 12.7 cm with a spatial resolution of 1.44 mm.  PET images 
were reconstructed using a 2D-filtered backprojection algorithm with attenuation 
correction provided by microCT imaging.  For the microCT scan, the following imaging 
settings were used: two bed positions, 80 kVp, 500 µA, 500 ms exposure time, and 4 x 4 
binning.  After each ferret underwent microCT imaging, the bed position was reset and 
microPET imaging with 18F-FDG (PETNET, Louisville, KY) began immediately. For 
each ferret, 2 mCi of 18F-FDG was administered (i.p.) with a 60-90 min uptake period.  
Radioactive dose was confirmed with an Atomlab 500 Dose Calibrator (Biodex Medical 




Image processing and analyses 
All imaging data were processed with PMOD software (v3.1; PMOD Technologies Ltd., 
Zurich, Switzerland).  MicroCT data were received from the Inveon platform as DICOM 
files and PET data as microPET files.  Scans were imported into the program’s local SQL 
database with the units for the PET radiotracer in kBq/cc. PET images were co-registered 
with the CT images with re-slicing done as necessary to facilitate later calculations. For 
analysis of 18F-FDG levels, the standardized uptake value (SUV) was used. SUV is a 
widely used semi-quantitative measure that normalizes radiotracer uptake in a given 






𝐷𝑜𝑠𝑒 (𝑘𝐵𝑞) ∗ 𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡 (𝑔)           𝐸𝑞. 1 
For all calculations, animal weights were expressed in kilograms and FDG activity in 
megabecquerels. For each image series, SUVs for each voxel were calculated using an 
external filter in PMOD, with the radionuclide half-life set at 6586.2 sec for 18F-FDG. 
For each pulmonary lesion, an ellipsoid volume of interest (VOI) was generated that 
encompassed the structure.  Then, automatic isocontour detection was used to refit the 
VOI by setting a threshold of 50-60% of the difference between the maximum and 
minimum intensity SUVs in the ellipsoid VOI such that 0.5*(SUVmax-SUVmin). In cases 
where the automated threshold included contiguous structures in the VOI, manual 
refitting in conjunction with the co-registered CT scan was used to exclude those 
surrounding structures.  For all VOIs, maximum SUV (SUVMax) and average and 
standard deviation of all pixels in the volume (SUVMean ± SD) were calculated.  
For CT analysis, image interpretation was performed by a radiologist (in consultation 
with the scientific team) having more than ten years of diagnostic experience along with 
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formal certifications by the American Board of Radiology (ABR) and the American 
Board of Nuclear Medicine (ABNM). Lesions on CT were identified using conventional 
criteria and terminology; Ground-glass opacity (GGO) is defined in this study as hazy 
increased lung opacity, with discernible underlying lung architecture such as visible 
bronchial and vascular structures, representing partial displacement of air in interstitial 
and alveolar airspaces; Consolidation is defined in this study as high density lung lesions 
(more dense than GGO) in which vascular and bronchial margins are obscured, 
representing complete displacement of alveolar air (605).  
 
Viral titers in swabs and tissues  
On days 1, 2, 3 and 6 and prior to euthanasia, swabs were taken from each ferret from 
nasal, throat and rectal regions.  Following scheduled euthanasia, the nasal turbinates and 
the right caudal lobe of the lung from each ferret, which was divided laterally into four 
segments, were isolated.  All swab and tissue samples were snap-frozen in liquid nitrogen 
and stored at -80oC until analyzed for virus titer by TCID50.  Frozen tissues were weighed 
and diluted 10% weight per volume into cold DMEM with 1% penicillin/streptomycin 
and 0.2% BSA before being homogenized and centrifuged to remove debris.  Tissue 
homogenate and swabs were serially diluted 10-fold in DMEM with 2 μg/mL TPCK-
Trypsin, 0.2% BSA, 4.5 g/L glucose, 1% penicillin/streptomycin, 2 mM L-glutamine, and 
25 mM HEPES.  Each sample was analyzed in quadruplicate following incubation in 96-
well plates with Madin-Darby canine kidney (MDCK) cell monolayers at 37oC in 5% 
CO2 for three days.  Supernates were collected from each well were assayed for 
hemagglutination activity using 0.5% turkey red blood cells as an indicator of infection.  
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Viral titers were expressed as log10 TCID50 / mL and were calculated using the Reed-
Muench method (618).  
 
Hemagglutination inhibition assay (HI) 
The HI test quantitates serum antibody to influenza virus which can prevent agglutination 
of turkey RBCs (Fitzgerald Industries International Inc., MA). Heat-inactivated serum 
samples were treated with receptor-destroying enzyme (Sigma-Aldrich) for removing 
nonspecific inhibitors (followed by RBC adsorption) and were diluted 2- fold serially 
from initial dilution of 1:10. HA antigen (8 HA units in 25 µL) were added onto each 
well and incubated for 1 h at RT. Following antigen-antibody reaction, 50 µL of 0.5% 
turkey RBC were added to each well and incubated for 1 h at RT. HI negative wells were 
scored based upon a diffuse sheet of agglutinated RBCs covering the bottom. HI positive 
wells were scored if they showed a well circumscribed button of nonagglutinated RBCs. 
 
Histopathology 
Lungs were inflated and stored in 10% neutral-buffered formalin.  Three lung sections 
were placed into cassettes per lung section (right cranial, left cranial, left caudal, and 
right middle lobe) until they were trimmed, paraffin-embedded, and sectioned. Sections 
were mounted on glass slides and stained with hematoxylin and eosin for microscopic 
evaluation at Experimental Pathology Laboratories, Inc. by a veterinary pathologist.  
Sections were examined for the presence of abnormal findings including supprative and 
necrosupprative inflammation; epithelial hyperplasia and cytokaryomegaly; and fibrinous 
and exudative changes. Changes were graded with a standardized scale of 0-5, with 0 
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classified as “not present”, 1 as “minimal”, 2 as “slight / mild”, 3 as “moderate”, 4 as 
“moderately severe”, and 5 as “severe / high.” For each ferret, a composite score for 
pathological changes was generated based on the locations in the respiratory tract 
(alveoli, bronchioli, bronchi) for statistical evaluation. 
 
Statistical analyses 
All statistics were performed using R version 2.13.0 and GraphPad Prism 5.  For each 
image, mean SUVMax and standard deviations were obtained.  For each ferret, SUVMax 




Figure 3.1 Characterization of KY/180 in female ferrets.  
A cohort of six control and six KY/180-infected ferrets were examined for A) body 
weight and B) temperature over a period of 10 days.  C)  Blood was examined for the 





Figure 3.2 18F-FDG PET, CT, and PET/CT fusion images of the thorax in H1N1pdm-
infected ferret 2213.  
A) Day 0 shows background activity in the lung with minimal uptake in the mediastinal 
and subcarinal lymph nodes. B) Day 1 post-infection demonstrates an area of developing 
consolidation in the right caudal lobe corresponding to increased radiotracer uptake. C) 
By day 3, the consolidation appears in the right caudal lobe and into the left caudal lobe. 
D) By day 6, there are multiple lesions in the lung parenchyma bilaterally with intense 




Figure 3.3 18F-FDG PET, CT, and PET/CT fusion images of the thorax in H1N1pdm-
infected ferret 2214.  
A) Day 0 shows background activity in the lung with minimal uptake in the mediastinal 
and subcarinal lymph nodes. B) Day 1 post-infection demonstrates an area of developing 
consolidation in the right caudal lobe corresponding to increased radiotracer uptake. C) 
By day 3, the consolidation has spread in the right caudal lobe and into the left caudal 
lobe. D) By day 6, there are multiple lesions in the lung parenchyma bilaterally with 




Figure 3.4 Right caudal lobe of ferret.  
The right caudal lobe of each ferret was divided into 4 sections, A (top), B (middle), C 
(middle-lower) and D (bottom) for measurement of viral replication. Please refer to table 





Figure 3.5 Histopathologic evaluation of the lung caudal lobe in H1N1 infected ferrets.  
A) On day 1, there are small foci of inflammation (10X) in animal 2208. A higher 40X 
magnification of the bronchiole (shown in the 10X magnification with a box) exhibits 
neutrophils within the lumen with loss of part of the epithelial layer. Mixed cell alveolitis 
surrounds the bronchiole. B) On day 3, a bronchiole with necrosupprative exudate is 
highlighted at 10X for animal 2212. In the 40X magnification (from the region in the 10X 
magnification with a box), muscle (M) defines the bronchiole from which the epithelium 
has been sloughed and the lumen is filled with neutrophils (necrosuppurative 
bronchiolitis). C) On day 7, a bronchiole with necrosuppurative exudate is surrounded by 
an extensive area of mixed cell alveolitis. Cytokaryomegaly is depicted by the variable 
large size and shape of the epithelial cells with piling up of the bronchiolar epithelium 
(hyperplasia) as shown in 10X image, and also visible in this bronchiole from another 




Figure 3.6 Correlations between SUVMax of lung lesions on FDG-PET versus 
histopathologic severity scores.  
A) SUVMax versus cumulative alveolitis severity shows minimal positive correlations in 
the right (red) and left (blue) lung. B) SUVMax versus cumulative bronchiolitis severity 
shows high positive correlation in both lungs. C) SUVMax versus cumulative bronchitis 
severity demonstrates moderate correlation.  
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Table 3.1 Study design for ferret imaging and sample collection* 
Group Animal ID Day 0 Day 1 Day 2 Day 3 Day 6 Day 7 
1 2206/2207 £ † †    
2203/2210    †  † 
2 2208  £†     
2209  £†     
3 2202   £†    
2204   £†    
4 2211    £†   
2212    £†   
5 2213 £ £ £ £ £ † 
2214 £ £ £ £ £ † 
†Date for necropsy; £ Date for imaging; *Swab samples were collected for viral 
shedding daily and upon necropsy  
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Table 3.2 Viral shedding. 
Group Animal 
ID 
Area Day 1 Day 2 Day 3 Day 7 
1 2206 Nasal 0*    
Throat 0    
Rectal 0    
2207 Nasal  0   
Throat  0   
Rectal  0   
2210 Nasal   0  
Throat   0  
Rectal   0  
2203 Nasal    0 
Throat    0 
Rectal    0 
2 2208 Nasal 0    
Throat 4.7    
Rectal 2.2    
2209 Nasal 4.7    
Throat 5.3    
Rectal 0    
3 2202 Nasal 3.0 3.5    
Throat 3.5 3.5    
Rectal 1.2 0    
2204 Nasal 0 3.0    
Throat 3.5 3.5    
Fecal 0 0    
4 2211 Nasal 0  0  0   
Throat 3.8  4.7  4.3   
Rectal 1.0  0  0   
2212 Nasal 0  3.5  0   
Throat 4.5  4.3  3.5   
Rectal 1.0  0  0   
5 2213 Nasal 3.8  4.3  3.5  1.5  
Throat 5.5  2.7  5.0  2.0  
Rectal 0  0  0  0  
2214 Nasal 4.0  3.7  3.3  0  
Throat 6.7  3.7  5.3  0  
Rectal 2.7  0  2.3  0  
*Numerical values are log base 10 TCID50/g  
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Table 3.3 Distribution of H1N1pdm in right caudal lung and nasal turbinates 
Day  Animal 
ID 
RC A RC B RC C RC D NT 
1  2208 6.7* 6.5 5.0 5.7 5.7 
 2209 0 6.5 0 1 6.8 
2  2202 0 4.4 3.3 4.5 5.0 
 2204 0 0 0 0 4.5 
3  2211 4.2 0 0 2.8 6.0 
 2212 5.8 6.5 3.5 6.3 4.7 
7  2213 0 0 0 0 0 
 2214 0 0 0 0 0 
*Numerical values represent log base 10 TCID50/g; Abbreviation: right caudal (RC) lung 





LOWER RESPIRATORY TRACT INFECTION OF THE FERRET BY PANDEMIC 
INFLUENZA A(H1N1)2009 VIRUS TRIGGERS BIPHASIC, SYSTEMIC AND 
LOCAL NEUTROPHIL RECRUITMENT 
Overview  
Infection of the lower respiratory tract by influenza A viruses results in an increase in 
inflammation and immune cell infiltration in the lung.  The dynamic relationships among 
the lung microenvironments, the lung and systemic host responses during infection 
remain poorly understood. Herein, we used an extensive systematic histologic analysis 
coupled with live imaging to gain access to these relationships in ferrets infected with the 
pandemic A(H1N1)2009 virus [H1N1pdm].  Neutrophil levels rose in lungs of 
H1N1pdm-infected ferrets 6 hours post-infection and became concentrated at areas of 
H1N1pdm-infected bronchiolar epithelium by 1 dpi (days post-infection).  In addition, 
neutrophils were increased throughout the alveolar spaces during the first 3 dpi, and 
returned to baseline density by 6 dpi.  Histochemical staining revealed neutrophil 
infiltration in the lungs occurred in two waves, at 1 and 3 dpi, and gene expression within 
microenvironments suggested two types of neutrophils.  Specifically, CCL3, but not 
CXCL8/IL-8, levels were greater within discrete lung microenvironments, and coincided 
with increased infiltration of neutrophils in the lung.  We used live imaging of ferrets to 
monitor host responses within the lung over time with 18fluorodeoxyglucose (FDG).
152 
 
Sites within the H1N1pdm-infected ferret lung with high FDG had high levels of 
proliferative epithelium.  In summary, neutrophils invaded the H1N1pdm-infected ferret 
lung, globally, and focally, at sites of infection. The microenvironments with increased 
neutrophils, did not correlate with FDG, and hence, FDG-uptake may reflect prior 
infection and inflammation that has experienced damage as reflected by bronchial 
regeneration of tissues in the lungs at sites of high FDG.  
 
Importance  
Severe influenza disease is characterized by an acute infection of the lower airways that 
may rapidly progress to organ failure and death.  Well-developed animal models that 
mimic human disease are essential to understanding the complex relationships of the 
microenvironment, organ and system in controlling virus replication, inflammation, and 
disease progression. Employing the ferret model of H1N1pdm infection, we used live 
imaging and comprehensive histological analyses to address specific hypothesis 
regarding spatial and temporal relationships that occur over the progression of infection 
and inflammation. We show the general invasion of neutrophils at the organ level (lung), 
but a distinct pattern of localized accumulation within the local microenvironment at the 
site of infection. Moreover, we show that these responses were biphasic within the lung. 
Finally, live imaging revealed an early and sustained host metabolic response at sites of 





The annual impact of seasonal influenza A viruses (IAV) on public health is fairly 
predictable and is mostly preventable in normal, healthy populations with currently 
available vaccine strategies (619-621).  However, novel IAV variants arising from 
antigenic shift in zoonotic reservoirs are not predictable and may not be immediately 
preventable with contemporary vaccines (622-624).  In the last 100 years, IAV have 
emerged with high transmissibility and virulence (1918 H1N1), high transmissibility and 
moderate virulence (2009 H1N1 pandemic), and low transmissibility and high virulence 
(H5N1, H7N9) (122, 625, 626). Virulence factors of IAV have been attributed to specific 
mutations in the hemagglutinin (HA) and polymerase (PB2) viral proteins (627, 628).  
Moreover, the specific sialic acid-binding affinity of the HA determines the cell types 
infected in the respiratory tract and hence the location of infection (i.e., upper versus 
lower) (116, 281).   In general, IAV strains that are able to infect the lower respiratory 
tract cause more inflammation and have greater lethality (52, 281, 294, 629).   
 
Controlled inflammation is required for resolution of IAV infection, yet increased 
inflammation is correlated with more severe influenza disease, and a dysregulated 
immune response to infection with highly pathogenic avian IAV (HPAI, e.g., H5N1) may 
be fatal (9, 253).  Seasonal H3N2 and H1N1 IAV typically infect only the upper 
respiratory tract and result in mild inflammation of the nasopharynx and trachea.  
Infection and increased inflammation in the lung was observed in cases of the 2009 
pandemic H1N1 IAV (H1N1pdm), which caused increased mortality compared to 
seasonal strains (6, 30, 42, 127, 132, 630).  Studies in humans and ferrets show that 
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highly pathogenic avian influenza (HPAI) viruses (e.g., H5N1) and the H1N1pdm viruses 
infect and replicate well in the lower respiratory tract (95, 629), yet cases of H1Npdm 
virus had much lower lethality compared to H5N1 and did not cause severe immune 
dysregulation. Thus, the precise relationship between location of infection and location of 
inflammation is complex, and pathogenesis may depend on other specific immune 
responses to certain IAV isolates.   
 
We know very little about how most respiratory viral infections, and the resulting 
immune responses, progress in real-time within the local microenvironments of the upper 
and/or lower respiratory tract in humans or in animal models. Live, whole body imaging 
of pathogens or host responses may offer a bridge to gain insight into these dynamics 
(603). During the 2009 H1N1pdm outbreak, molecular imaging of patients revealed that 
FDG (fluorodeoxyglucose) increases and becomes concentrated in sites of consolidation 
and ground-glass opacities within the lung (6, 42, 602, 609). This motivated our 
exploration of live, FDG-imaging in the ferret model of IAV infection (631). The ferret 
serves as a critical animal model to ask questions regarding IAV disease progression 
given the similarity in its clinical signs and disease with those in humans (266, 272, 631, 
632).  Similar to those observations in human cases of H1N1pdm disease, H1N1pdm-
infected ferrets have a focal pattern of FDG uptake in the lungs that correlated with 
bronchiolitis and bronchitis histopathology scores (631).  
 
We and others have shown that IAV infection initiates in discrete foci of the respiratory 
tract (285, 631, 633). Viral replication triggers inflammation in the form of cytokines, 
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chemokines, and the infiltration of innate immune cells in the lungs (30, 135, 360).  
Cellular uptake of FDG in acute lung injury correlates with inflammatory cell infiltration 
(612, 634).  We and others have hypothesized that cellular uptake of FDG in the lung 
following infection may be due to inflammatory cell infiltration, e.g., neutrophils and 
monocytes (631, 635, 636).  Neutrophils are among the first to respond to many types of 
inflammation, particularly bacterial infection (16, 18, 60). Neutrophils perform many 
functions during bacterial infection (e.g., phagocytosis, release of anti-bacterial proteases, 
reactive oxygen species) yet very little is known about their contributions to viral 
infections (472).  In mild and severe human cases of influenza, neutrophils and neutrophil 
chemoattractant signals are elevated in blood and nasal lavage and are independent of 
bacterial co-infection (6-8, 30, 99, 105).  In mouse models of influenza, depletion of 
neutrophils results in increased virus replication and increased disease severity (84, 577, 
637, 638). However, it is known that neutrophils are increased in the lungs of mice during 
severe IAV infection (85, 253, 294, 363, 639).   
 
Currently, we know very little about the timing and spatial distribution of neutrophils as 
they infiltration the lungs following viral infection, and importantly, how they function in 
disease resolution or exacerbation. Herein, we used an extensive systematic histologic 
analysis coupled with live imaging to probe the temporal dynamics of virus distribution 
and inflammation within microenvironments of lungs of ferrets infected with a clinical 
H1N1pdm isolate. Given their importance early in infection, we focused on neutrophils 
and hypothesized that neutrophils would migrate to sites of IAV infection preferentially, 
creating an inflammatory microenvironment (16, 80, 472, 636). IAV distribution, 
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neutrophil accumulation and selected immune gene expression profiles were measured 
within discrete sections of a lung lobe.  We show that recruitment of neutrophils to the 
lung following infection occurs in two waves, coincides with chemokine gene expression, 
and may reflect two different states of neutrophil activation.  Using extensive histological 
sampling, we show that neutrophilic inflammation correlates with the temporal and 
spatial distribution of IAV in the lungs of infected ferrets. Importantly, the neutrophil 
recruitment and accumulation occurs at the tissue level (i.e., the whole lung) and at sites 
of IAV infection. Finally, we show that FDG uptake in the infected lungs is not due to 
neutrophilic infiltrates, but correlates with epithelial cell proliferation and regeneration 
following infection. 
 
Materials and Methods 
Virus and viral titers.  
Ferrets were infected with a clinical isolate of IAV H1N1pdm (A/Kentucky/180/2010) 
taken from a fatal case of H1N1pdm (130) that has been previously described in ferret 
(631), DBA/2 mouse (130) and human primary cell culture (331) models.  Virus was 
grown in 10-day old embryonated hen eggs and diluted in phosphate buffered saline 
(PBS).  The concentration of virus stock was determined using 50% tissue culture 
infectious dose assay (TCID50) in Madin-Darby canine kidney cells as described 




Ferrets, ferret virus challenge, and ethics statement. 
Four month old (16-20 weeks) female Fitch ferrets were obtained from Triple F Farms 
(Sayre, PA, USA).  Ferrets were determined to be seronegative for A/Uruguay/716/2007 
(H3N2), seasonal A/Brisbane/59/2007 (H1N1), and A/Kentucky/180/2010 (H1N1pdm) 
subtypes of IAV by hemagglutination inhibition assay (631).  Animals were housed for 
an acclimation period of at least one week at the University of Louisville Regional 
Biocontainment Laboratory prior to virus challenge (this research facility is fully 
accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care International).  Animals were maintained on a 12-hour light/dark cycle and provided 
Teklad Laboratory Diet #2072 (Harlan/Teklad, Madison, WI) and water ad libitum. The 
research described herein complied with federal statutes and regulations relating to 
animal experimentation, including the Animal Welfare Act, and adhered to principles 
stated in the Guide for the Care and Use of Laboratory Animals, published by the 
National Research Council, 1996.  Experiments involving ferrets were approved by the 
University of Louisville Institutional Animal Care and Use Committee. 
 
Ferrets were inoculated with 106 TCID50 influenza A/Kentucky/180/2010 (H1N1pdm) as 
a 1 mL bolus. To prepare animals for infection with virus, ferrets were sedated with 
intramuscular 0.05 mg/kg atropine, 5.0 mg/kg ketamine, and 0.08 mg/kg 
dexmedetomidine.  Sedated ferrets were scruffed and held with their nose pointing 
upwards and neck extended while 0.5 mL of virus or PBS was given per naris.  Following 
intranasal (i.n.) inoculation, animals were held in place for 1 min before anesthesia was 
reversed with 0.4 mg/kg atipamezole.  Following infection, ferrets were measured daily 
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for temperature and weight and monitored twice daily for clinical signs (dyspnea, nasal 
and ocular discharge, loss of appetite, neurological signs, sneezing, lethargy, anorexia, 
diarrhea, and other abnormalities) through study completion. Body temperatures were 
measured via subcutaneous implanted microchip IPTT transponder (BioMedic Data 
Systems, Inc.).  Right caudal lung tissues were snap frozen on liquid nitrogen and stored -
80°C until homogenized and stored in TRIzol® reagent (Invitrogen).  Blood was taken in 
sodium-ethylenediaminetetraacetic acid tubes and stored in TRIzol®. Other lung tissues 
were taken for immunohistochemistry (IHC) as described below.    
 
Analysis of gene expression levels by RT-PCR. 
Previously, the right caudal lung lobe of each ferret was divided into four sections and 
each section was homogenized for quantification of virus by determining the TCID50 
(631).  Following homogenization, a portion of the lung tissue was placed in TRIzol® 
reagent and stored at -80°C.  Herein, total RNA was extracted from these samples and 1 
g RNA was used to make cDNA using Superscriptase III.  Ferret mRNA gene-specific 
primers were generated using published ferret sequences (Table 1).  Primers were 
designed to span exons when possible by comparing to known human and canine splice 
sites.  Primers were chosen to identify cell type-specific targets (e.g., granulocyte colony 
stimulating factor receptor [G-CSFR, Csf3r gene], myeloperoxidase [MPO, Mpo gene], 
and neutrophil elastase [ELANE, Ela2 gene] transcripts which are specific to neutrophils; 
monocyte colony stimulating factor receptor [M-CSFR, Csf1r gene] which is used as a 
macrophage/monocyte marker; NCR1 [Ncr1 gene] which is a natural killer cell receptor; 
and CD11b [Itgam gene] which is an integrin expressed on inflammatory leukocytes), as 
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well as soluble inflammatory signals (interleukin-6 [IL-6, Il6 gene], CXCL8 [also known 
as interleukin-8, Il8 gene], interferon-beta [IFN-, Ifnb gene], CCL2 [also known as 
monocyte chemotactic protein 1, Ccl2 gene], CCL3 [also known as monocyte inducible 
protein 1 alpha, Ccl3 gene], and tissue necrosis factor-alpha [Tnf]).  Real time-
polymerase chain reaction was performed using SYBR Green dye on a ViiATM 7 real 
time PCR machine (Applied Biosystems).  Primers were validated using mitogen-
stimulated whole blood from donor ferrets (Marshall Farms; data not shown).  Transcript 
fold-increase measurements were compared to housekeeping genes (glyceraldehyde 3-
phosphate dehydrogenase [Gapdh]) and average mock-infected animals using the delta-
delta-cycle threshold method (ΔΔCt); the fold change is expressed here as the 2-Ct value. 
 
Histology.  
Lungs were inflated with 10% neutral-buffered formalin and fixed for 48 h.  Lungs were 
trimmed, placed into cassettes, dehydrated through ethanol to Limonene-D, paraffin-
embedded, and sectioned at 5 m. For systematic sampling of the lungs, the right and left 
caudal lung lobes (RCa and LCa, respectively) were trimmed into four consecutive 
transverse slices approximately 0.5-cm thick moving from the lung hilum to the posterior 
of the lobe, as illustrated in Fig. 1.  Sections (1, 2, 3) followed the main bronchus to 
approximately the lower-middle of the lung, as shown on Fig. 1 (left panels).  The 
sections were paraffin-embedded and two serial 5 m sections were mounted onto each 
glass slide (Fig. 1, middle panel).  Slides were dewaxed in 3 xylene washes, and 
rehydrated in decreasing ethanol gradients to water for IHC, and regions of the slides 




IHC and tissue staining.  
For detection of IAV nucleoprotein (NP), antigen was retrieved with 1% Pronase in 
CaCl2 solution and was detected with a primary monoclonal antibody (HB65 clone 
EVS238 from East Coast Bio, Inc.)(640) and avidin-biotin complex amplification (Vector 
Labs) was used to visualize the antibody with diaminobenzidine (DAB) peroxidase 
substrate.  The slides were dehydrated through increasing ethanol gradients, cleared in 
xylenes, and mounted under coverglass with toluene solution.  Neutrophils were stained 
pink with a 30 min incubation in naphthol AS-D chloroacetate esterase (NACE) at 37°C 
according to manufacturer’s instructions (Sigma-Aldrich) and one serial section was 
counterstained with hematoxylin to identify anatomical features.  Slides were mounted 
with coverglass under an aqueous mounting medium (Vectamount AQ, Vector Labs).  
For each NACE-stained slide, the next consecutive slide was similarly stained for IAV 
antigen.  Rehydrated tissue slides were incubated in 3% hydrogen peroxide and 
avidin/biotin blocking buffer (Vector Labs) for 15 min each at room temperature before 
blocking in 5% fetal calf serum for 1 h at room temperature.  For both NACE and NP 
staining, one section per slide was counterstained with hematoxylin for anatomical 
reference, and a second unstained section was used for image processing as described 
below. Antigen retrieval for Ki-67 and histone-3 was performed by heating rehydrated 
slides in a 72°C water bath overnight in target retrieval buffer (Dako).  A monoclonal 
antibody cross-reactive to ferret Ki-67 (Dako, clone MIB-1) was used as above to stain 
with DAB peroxidase substrate, and rabbit polyclonal anti-human histone-3 antibody 
(Abcam) was stained red with alkaline phosphatase substrate Vector Red (Vector Labs).  
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Sirius red staining was performed by incubating rehydrated tissue slides for 30 min in 
saturated picric acid containing 0.1% Sirius Red and 0.1% Fast Green, then dehydrating 
and mounting under Permount (Fisher Scientific). 
 
IHC analyses.  
Images from IHC slides were analyzed with the “Threshold Colour” plug-in of the FIJI 
package of ImageJ software (641).  Briefly, pixels of a certain hue and saturation (bright 
pink for NACE-stained neutrophils, red for Sirius Red, and brown for DAB-stained NP-
positive or Ki-67-positive cells) were selected and the percentage of total pixels was 
calculated for each image.  The percent consolidation was calculated for each image by 
converting each image to high contrast 8-bit (black-and-white) and calculating the 
percentage of black pixels (i.e., the number of pixels containing tissue, eliminating 
airspace).  A Java computer language script (available upon request) was generated to 
analyze all images in the same way using validated settings.  Neutrophil density is 
reported here as the percent NACE-positive pixels divided by percent consolidation in a 
single image. To validate this measurement, two independent observers counted the 
number of NACE-positive neutrophils in 50 images and there was a 95% correlation 
between the automated method and visual inspection (data not shown).   
 
Comprehensive, systematic sampling of the caudal lung lobes was performed by a 
blinded observer choosing four regions per NACE-stained tissue section and 
photographing three images per region at 20X magnification (squares in right panels of 
Fig 1).  To correlate the amount of neutrophils with foci of IAV infection, NP antigen-
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positive areas were photographed and their anatomical locations were recorded (i.e., 
bronchial epithelium, bronchiolar epithelium, submucosal epithelium, alveolar region). 
The same site was located on the NACE-stained slides and photographed (i.e., a serial 
section of tissue no greater than 15 m away from the NP-positive site).  IAV NP 
antigen-negative regions were anatomically site-matched to NP-positive focus and 
located in the same general regions (e.g., a region of bronchiolar epithelium that was 
antigen-negative was selected on a slide where bronchiolar epithelium was antigen-
positive, and therefore was always < 0.5 cm from the original antigen-positive focus).  
NACE-positive neutrophils, IAV NP-positive cells, and Sirius Red-stained collagen were 
measured using automated image analysis as described above.  The number of Ki-67-
positive cells per slice was estimated by two observers using a scoring index (642, 643). 
 
Ferret molecular imaging.  
Ferrets were anesthetized by isoflurane induction and 2 mCi of FDG was administered 
intraperitoneally as previously described (631, 644).  The dose was confirmed before and 
after injection with an Atomlab 500 Dose Calibrator; Biodex Medical Systems Inc., NY.  
Ferrets were kept warm under sedation with isoflurane for 1 h prior to intubation and 
during imaging using the Siemens Trimodal as described previously (631, 644). 
Following imaging, ferrets were removed from isoflurane, given intramuscular ketamine 





PET-CT Image Analysis.   
After PET and CT images were acquired from the Trimodal scanner, PET images are 
aligned to CT anatomical reference space in order to provide one-to-one voxel 
correspondence between anatomical and functional images. Since pathology on CT (e.g., 
consolidation) can confound true lung volume and boundary estimation, the lungs were 
segmented from CT images using a robust algorithm (i.e., interactive region growing) 
proposed in (645) by which users had chance to correct any mis-segmented lung portion 
interactively if necessary. Then, significant uptake regions were segmented using affinity 
propagation PET delineation algorithm (646). Once all the metabolically active lesions 
were identified and delineated, maximum standard uptake values (SUVmax) and 
maximum intensity values were calculated as an evaluation metric for the FDG uptake. 
These measurements were taken from regions coinciding with histopathology slices, 
locating the slices on the registered and segmented PET-CT scans manually. The 
alignment between histology and PET-CT was ensured by processing 9-parameter affine 
registration and using prior knowledge about the anatomy, particularly the airway 
structures and the lung lobes. For airway structure extraction, we used the hybrid 
algorithm for delineation of the airway tree as proposed in (647). Due to the 2D nature of 
the histopathology slices, registration operations were all done in 2D. After alignment of 
the histopathology slices into PET-CT scans were satisfied, in vivo imaging correlation 




Statistical analyses.  
All statistics were performed using R version 2.13.0 and GraphPad Prism 5.  In general, 
nonparametric statistical tests were used as stated in the results, even when sample size 
was large non-independent measurements within the same ferret made parametric 
analyses undesirable.  Pairwise post hoc tests were adjusted for multiple comparisons 
using Bonferroni’s method.  For generalized linear modeling of neutrophil density, 
variables such as time post-infection, individual ferret, lung lobe within ferret, and 
sample region within lung lobe approximated a nested block design with repeated 
measures within ferrets, and within lobes within ferrets.  The fully factorial model was 
reduced using stepwise regression to find the best fitting model as determined by 
significant reduction in Akaike information criterion.  For all statistical tests, the Type-I 
error rate was set to  = 0.05; although values p < 0.1 are given consideration here due to 
sample size limitation and pseudoreplication as discussed below. 
 
Results 
Previously we have shown that infection of ferrets with H1N1pdm 
(A/Kentucky/180/2009) causes moderate disease, evidenced by the brief febrile period, 
low weight loss, and clinical signs recorded during infection (i.e., lethargy, rhinorrhea) 
(631).  Virus was detected from nasal swabs, throat swabs, nasal turbinates, and right 
caudal lung lobes on 1, 2, and 3 dpi, but was undetectable by 7 dpi (one animal had low 
amounts of virus in nasal and throat swabs on 7 dpi) (631).  Histopathology revealed a 
focal bronchitis and bronchiolitis characterized by infiltration of leukocytes (neutrophils 
and exudate macrophages) during H1N1pdm infection (631).  Cellular uptake of FDG 
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correlates with leukocytic infiltration in certain model systems (612, 635, 636).  In this 
ferret model, we have observed progressive increase of FDG uptake in distinct foci of the 
H1N1pdm-infected ferret lung (631).  Therefore, herein, we tested the overarching 
hypothesis that FDG uptake during ferret IAV infection was due to infiltrating 
neutrophils and macrophages.  We first determined which leukocytes were likely to be 
increased in these regions by measurement of immune gene expression profiles within 
discrete lung microenvironments. 
 
Lung microenvironments of IAV infection have increased CCL2 and CCL3 gene 
expression 
First, the expression of signature immune genes was analyzed in the right caudal lobe of 
one mock and two H1N1pdm-infected ferrets on 1, 2, 3, and 7 dpi.  As stated above, the 
right caudal lobe had the greatest levels of FDG uptake following infection (631).  
Primers for IAV HA and inflammatory cytokines and chemokines were used to confirm 
the presence of virus and the host immune response to infection.  Genes were chosen to 
detect cytokines and chemokines that are known to be increased during the acute phase of 
influenza infection and are important for leukocyte activation and chemoattraction (e.g., 
IFN, TNF, IL-6, CCL2, CCL3, and CXCL8).  First, IAV HA mRNA was detected at 
1, 2 and 3 dpi, but not 7 dpi, and was not uniformly distributed within the right caudal 
lobe (data not shown). This matched the pattern of IAV infection as measured by TCID50, 
previously reported from the same ferret lung sections (631).  The fold-change in gene 
expression of inflammatory cytokines (IFN, TNF, IL-6) and chemokines (CCL2, 
CCL3, CXCL8) in sections were compared to mock-infected controls.  No significant 
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change in inflammatory expression levels was detected in the blood (data not shown). In 
some lung sections, the cytokines IL-6 and TNF (not shown) were elevated at 2 dpi, but 
not in all sections from infected ferrets.  Other inflammatory signals (e.g., IFN-, 
CXCL8) were not elevated above mock-infected animals (data not shown).  Gene 
expression levels of CCL2 and CCL3 were both slightly increased at 1 dpi and 
significantly increased on 3 dpi (p < 0.05, Fig. 2).  Both CCL2 (p = 0.01) and CCL3 (p = 
0.04) were significantly increased in all lung sections expressing viral HA gene mRNA 
(compared to all HA-negative sections, including those within the same ferret; Mann-
Whitney U = 105 & 73, respectively for CCL2 and CCL3). 
 
Neutrophil-specific gene expression is detected in lung microenvironments 
Primers for leukocyte-specific genes which encode cell surface receptors and other cell-
specific proteins were used to determine the presence of neutrophils (G-CSFR, MPO, 
ELANE, CD11b), macrophages (M-CSFR, CD11b), and natural killer cells (NCR1, 
Granzyme A, CD11b) in the lung.  The monocyte/macrophage specific gene, Csf1r (M-
CSFR), was increased slightly at 2 and 3 dpi, and increased expression of the natural 
killer cell receptor, Ncr1 (NCR1), was detected in some sections at 2 and 3 dpi (data not 
shown).  Some lung sections had increased expression of the leukocyte cell surface 
integrin, CD11b, and the median expression value of CD11b in HA-positive sections was 
significantly increased above mock (median = 2.6, p = 0.01, Wilcoxon test, data not 
shown).  Expression of the neutrophil growth factor receptor gene, Csf3r (G-CSFR), was 
increased in lung sections at 3 dpi (p < 0.05) (Fig. 3A).  Expression of Csf3r was not 
significantly increased in tissue sections that were positive for HA gene expression 
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compared to HA-negative sections (Mann-Whitney U test).  Neutrophil specific granule 
genes (e.g., Mpo, Elane) were not significantly upregulated compared to the mock-
infected animals (data not shown).   
 
Neutrophils have biphasic infiltration into the lungs of IAV-infected ferrets 
The major inflammatory signals in the right caudal lung sections were the neutrophil-
specific gene Csf3r and the leukocyte chemoattractants CCL2 and CCL3.  To confirm the 
temporal pattern of neutrophils detected by gene expression in the lungs of these ferrets, 
NACE staining was used to label neutrophil specific granules.  One histological 
preparation per lung lobe (except right caudal lobe which was used for gene expression, 
above) from H1N1pdm-infected and mock-ferrets were stained and inspected for 
neutrophils.  To estimate the number of neutrophils within the stained histological 
sections, image analysis software was used to determine the amount of NACE-positive 
pixels per unit of tissue in an image (20X objective) of the NACE stained lung, as 
described in the methods (expressed as the estimated “neutrophil density”).  Image 
analysis of sites chosen haphazardly within each tissue slice revealed that the overall 
density of neutrophils in the lung was biphasic, showing a maximum at 1 dpi (p < 0.05) 
with another peak at 3 dpi (n.s.) following a decrease at 2 dpi (Fig. 3B).  Thus, the major 
peak of neutrophils did not correspond to the major peak of neutrophil-specific gene 
expression in the lung.  The other lung lobes showed a wide range of neutrophil density, 
similar to the gene expression data, suggesting there were foci of neutrophil infiltration 




Neutrophils may hone to specific sites of IAV infection in the lungs 
To determine the precise distribution of IAV within the lungs, IHC was used to detect NP 
antigen in paraffin-embedded sections of the remaining lung lobes (except of right caudal 
lobe).  Infection was detected in bronchial, submucosal, and bronchiolar epithelial cells 
(Fig. 4A-D), but not alveolar epithelium (not shown).  IAV NP was detected from all 
infected ferrets at 1 and 3 dpi, and from one animal at 2 dpi; but was not detected from 
infected animals 7 dpi.  H1N1pdm infection was highly focal in the lung, and was 
primarily restricted to sites in bronchioles and bronchi (Fig. 4A-D).  Similarly, the pattern 
of antigen positivity matched the IAV mRNA expression, the pattern of chemokine and 
neutrophil-specific gene expression and the pattern of NACE staining.  Counterstaining 
NP-labeled sections with hematoxalin allowed the identification of increased numbers of 
inflammatory macrophages and neutrophils, some of which were antigen-positive (Fig. 
4D), at foci of infection in the bronchioles.  Therefore, neutrophils appeared to hone to 
the sites of infection in specific anatomic regions.  
 
Comprehensive sampling of the lung lobes for neutrophil infiltration 
he preliminary data suggested that neutrophils infiltrate the lungs and hone to sites of 
IAV infection, driven by chemokine gradients (e.g., CCL3).  However, the data were 
correlative because the sampling was not comprehensive and data were obtained from 
different lobes (i.e., gene expression from the right caudal lobe, neutrophil and NP 
staining from the four remaining lung lobes).  Therefore, we performed a second ferret 
study to confirm these observations using a systematic histological sampling of the lung.  
Six female ferrets were infected with 106 TCID50 of H1N1pdm (plus 2 mock-infected) 
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and 2 animals were euthanized per time-point at times that were established to have peak 
neutrophil infiltration (1 dpi and 3 dpi) as well as an early time post-infection (0.25 dpi).  
Left and right caudal lung lobes were formalin-fixed, then sectioned into four 0.5 cm 
cross-sections from the hilum moving posteriorly, embedded in paraffin, and prepared for 
histology (three cross-sections shown in Fig. 1).  Tissue slices were NACE-stained and 
photographed to quantify neutrophils.  To establish factors important neutrophil 
distribution in the lung, a methodical sampling was performed to provide data for a 
generalized linear model.  Four regions from each slice were chosen blindly, and three 
non-overlapping images were taken from each region to quantify the number of NACE-
positive pixels as a function of total tissue (excluding airways) per image using ImageJ 
(Fig. 1).  This established a 3-D grid of sampling locations within the caudal lung lobes, 
wherein three images are taken from locations within each caudal lung lobe (n = 48 
images per lung lobe).   
 
Neutrophils infiltrate the right caudal lobe at early times after infection 
Step-wise model testing of the generalized linear model revealed that the best-fitting 
model included time post-infection, lung lobe (left versus right), and the distance from 
the lung hilum.  Post hoc analyses confirmed that neutrophils were significantly 
increased at 1 dpi and at 3 dpi as in the previous study (Fig. 5A, p < 0.001 in the left and 
right caudal lobes), however increased neutrophil density was measured in the lungs of 
infected animals above mock as early as 0.25 dpi (Fig. 5A, p < 0.05 in the left caudal 
lobe, n.s. in the right caudal lobe).  The distribution of neutrophils was highest in the right 
caudal lobes at 0.25 and 1 dpi (Fig. 5A, p < 0.001) compared to the left, but not at other 
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time points.  Additionally, it is important to note that a range of neutrophil density was 
observed, yet, in general, infected animals had higher baseline levels of neutrophils in 
either lobe at 0.25 dpi, 1 dpi, and 3 dpi. Thus, neutrophils appeared to be focally 
distributed throughout the lung, and these observations (e.g., increased right caudal lung) 
suggest that they are driven by IAV infection. 
 
Neutrophils are increased at sites of IAV infection. 
To test the hypothesis that neutrophils were increased at foci of IAV-infected epithelial 
cells, IHC staining for IAV NP was performed in serial sections of the NACE-stained 
tissues taken from right and left caudal lobes as described above and Fig. 4.  Using NP-
stained serial sections as a reference, images were taken from three areas of NACE-
stained tissue slices defined by their distance from NP-positive.  First, three non-
overlapping images were taken from each antigen-positive site.  For each antigen-positive 
site, two other sites were chosen and three non-overlapping images were analyzed: sites < 
1cm from antigen-positive sites (within the same histology slice), and sites > 1 cm from 
antigen-positive sites (other histology slices within the same lobe).  These three groups of 
images were also compared to images taken of NACE-stained mock-infected controls, 
and image analysis software was used to calculate the estimated neutrophil density as 
described above. There was no linear relationship between distance from focus of 
infected cells and density of neutrophils, i.e., neutrophils were increased in all sites 
relative to mock-infected control animals (Fig. 5B, p < 0.01).  However, a pattern was 
revealed by resolving the spatial distribution over time: neutrophil density was 
significantly greater at NP-positive sites and at sites <1 cm from known NP-positive sites 
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at 1 dpi (Fig. 4, 5B, p < 0.01).  There was no difference in spatial distribution at 3 dpi, 
and neutrophil density remained increased relative to mock-infected controls (Fig. 5B, p 
< 0.01).   
 
Neutrophils are increased at specific locations of IAV infection. 
To test the hypothesis that anatomical location explained the distribution of neutrophils 
after infection, sites of IAV-positive bronchi (e.g., Fig. 4A), seromucinous glands (e.g., 
Fig. 4B), and bronchioles (e.g., Fig. 4C, 4D) were identified (no antigen-positive alveolar 
epithelial cells were detected).  These sites and antigen-negative sites within the same 
ferret (matched to a similar anatomic region) were located on NACE-stained serial 
sections, imaged (Fig. 4E-G), and analyzed using image analysis software to calculate the 
estimated neutrophil density as described above. There was a significantly higher density 
of neutrophils in IAV-positive bronchioles compared to controls (Figs. 4C, 4D, 4G, 4H, 
and 5C, p < 0.01).  Neutrophils were not increased in bronchi or seromucinous glands 
above antigen-negative regions (Figs. 4E, 4F, and 5C).  Furthermore, neutrophils were 
increased in bronchioles and alveoli where there was no IAV-positive antigen present by 
IHC (Fig. 5C).  Interestingly, certain areas containing neutrophils in the lumen of 
bronchioles near IAV-positive epithelial cells had extracellular Histone H3 staining (data 
not shown), an indicator of neutrophil extracellular trap formation (NETosis).  However, 
there were insufficient sites of NETosis and a lack of available reagents for the ferret 




Approach to analyze PET- FDG images to achieve direct spatial correspondence 
with histology 
We have previously reported that molecular imaging of ferrets using FDG-PET showed 
progressive increase in inflammation following infection with H1N1pdm (correlated with 
bronchiolitis and bronchitis pathology scores) that was greatest in the right caudal lobe 
but also focally distributed throughout the other lung lobes (631).  We hypothesized that 
this may be due to increased inflammatory cell infiltration at sites after infection (612, 
631, 635, 636).  Therefore, we injected infected ferrets with FDG and imaged them with 
PET-CT prior to euthanasia on 0.25, 1, and 3 dpi (Fig. 6).  Using the same ferrets in the 
second study, we analyzed PET-CT data similar to histological data (i.e., a 3D grid) and 
achieve direct spatial correspondence between the histology and imaging.  Automated 
airway segmentation of CT images was first performed to extract the lungs and airways 
from the images (Fig. 6).  Then, stacked 3D image constructions were used to locate the 
exact positions of tissues taken for IHC using anatomical features as references (such as 
branching of bronchi, location of the heart, and bone structure) as well as gross 
anatomical photographs taken during necropsy to ensure accurate correspondence 
between CT and IHC.  Next automated registration of PET-CT images was performed to 
ensure PET-CT were aligned, which then allowed us to measure the uptake of FDG at 
sites taken for histology (Fig. 6).  
 
FDG uptake did not match the pattern of neutrophil infiltration 
We tested whether FDG uptake was associated with sites of increased neutrophil 
infiltration.  The stacked CT images were used to locate the regions from which NACE 
173 
 
image analysis had been performed, and FDG uptake (SUVmax) was determined on PET 
images from these same regions.  There was an early increase in FDG SUVmax at 0.25 
dpi, which immediately decreased below mock levels before gradually increasing to 3 dpi 
(Fig. 6). For both left and right caudal lobes, uptake in mock-infected animals was 
significantly greater than uptake at 1 dpi (p < 0.05, Fig. 7A).  Temporally, this did not 
align with the pattern of neutrophil infiltration (Fig. 5A).  Due to differences in resolution 
between the two modalities (PET-CT and IHC) we averaged the three non-overlapping 
images from each region measured by IHC and this compared to a single SUVmax from 
that region.  Over all time-points, there was no association between FDG uptake and the 
neutrophil density (data not shown).  However there was a significant linear association 
between SUVmax and neutrophil density at 1 dpi, although the association was 
comparatively weak (R2 = 0.26) and was likely due to outliers (non-zero slope, p < 0.001, 
data not shown).  This finding was very surprising, therefore we attempted to identify 
what was responsible for the FDG uptake using this data set for which we had confidence 
in our correspondence between PET-CT and histology. 
 
FDG uptake did not match sites of IAV infection 
We tested the hypothesis that FDG uptake occurs in sites of H1N1pdm infection in ferret 
lungs.  Using a similar approach to the one above for NACE-stained sections, we 
measured FDG-PET uptake (SUVmax) at sites of IAV-positive cells determined by IHC.  
We also measured SUVmax at two other sites based on distance from IAV-positive cells: 
< 1 cm from any known IAV-positive area, and < 1 cm from any known IAV-positive 
area, both were measured from regions within the same ferret lobe.  There was 
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significantly less FDG uptake at sites of IAV-positive cells compared to mock-infected 
animals (p < 0.01 for all regions compared to mock, Fig. 7B).  Because this approach was 
also potentially confounded by the disparity in resolution between PET-CT and 
microscopic imaging modalities, we tested whether IAV infection may increase the 
uptake of glucose in vitro by infecting immortalized cell lines with several IAV isolates. 
We experimentally infected several human cells and cell lines (e.g., A549 and well-
differentiated human bronchial epithelial cells line, 16HBEo-), and we observed slightly 
increased uptake of FDG in some but not all treatments (data not shown).  Thus, we may 
infer that increased FDG uptake in infected ferrets was not associated with IAV infection 
directly. 
 
FDG uptake measured proliferation in the lungs following IAV infection 
We then tested the hypothesis that proliferating cells were responsible for the increased 
FDG uptake in lung tissues by detecting Ki-67 protein with IHC.  Ki-67 is a nuclear 
protein that is present in high amounts during cellular proliferation.  In order to estimate 
the amount of proliferating cells, we used a Ki-67 proliferation index (Fig. 8, images 
show examples of each score, 0-3) which is an established method for grading tumors 
clinically (642).  No significant regions of proliferating epithelium were detected in the 
ferrets imaged at 0.25 dpi, 1 dpi, and 3 dpi; therefore we included histological samples 
from the previous study described above (i.e., two infected ferrets and one mock ferret 
were taken at each of 1, 2, 3, and 7 dpi, the right caudal lobe is excluded from these 
sections) (631).  Three non-overlapping images were taken haphazardly from each of 
three anatomical regions per tissue slice and were scored by two independent observers in 
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a blinded fashion.  Both alveolar and bronchiolar regions had baseline levels of 
proliferating cells and there was no difference between lung tissues taken from mock and 
infected animals in these anatomical regions (not shown).  However, there was an 
increase over time in the amount of proliferating cells in the bronchi, which peaked at 7 
dpi (p < 0.01; Fig. 8). 
 
Discussion 
The pathology of human infection with IAV is often only known from lethal endpoints, 
taken at autopsy (6-9).  In humans, severe IAV infection affects the LRT, and results in 
the massive infiltration of neutrophils (6, 42).  Similarly, severe IAV disease in ferrets is 
characterized by early infiltration of neutrophils (123, 253).  With respect to neutrophils 
in the lungs during IAV infection, pathology reports from lethal, human influenza 
pneumonia typically state the presence of suppurative necrosis, mixed cellular infiltrates, 
or neutrophilic infiltration (6-8, 30, 272, 630).  However, few studies have directly 
addressed simple questions about the relationship between neutrophils and IAV infection.  
For example: when do neutrophils arrive in the lungs following IAV infection? What is 
the pattern of neutrophil infiltration, i.e., is it specific to anatomical locations? Is it 
specific to sites of IAV? Or is it specific to sites of damage and necrosis? How important 
are the various inflammatory signals released in viral microenvironments to the activation 
and chemoattraction of neutrophils during IAV infection?  Answers to these questions 
will provide a basis for answering more important questions, such as how does the 
severity of disease affect neutrophil infiltration (or vice versa)?  Severe IAV infection 
often results in a form of acute lung injury and the formation of ARDS, and neutrophils 
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are implicated as both contributing to and recovering from this syndrome (16, 18, 60).  
Based on mouse studies, the role of neutrophils during IAV infection show importance in 
protection from lethal disease, however much remains unknown about their relationship 
in the ferret model (84, 85, 577, 637, 639). 
 
Despite the importance of the ferret model in the study of IAV pathogenesis, and despite 
it being used for nearly 80 years for this, the ferret model is challenging.  For example, 
there are no ferret-specific commercially available reagents, and the cross-reactive 
antibodies are unverified (279, 280).  To overcome the limitations in availability of 
immunological reagents, we have explored the use of molecular imaging as a tool to 
study the pathogenesis of IAV in the ferret lung (631).  Molecular imaging modalities, 
such as PET, rely on the in vivo accumulation of injectable non-species-specific 
radioisotope-labeled probes that can be imaged in 3-dimensions, and images can be fused 
with CT images to provide anatomical references (645, 648).  Their use in infectious 
disease imaging is quickly developing (635, 645), and preliminary data provides the 
foundation for the use of FDG-PET imaging in diagnosis or prognosis of clinical cases of 
IAV (42, 609, 631). To further develop this tool, and to expand the tools available for the 
use of ferret model, we established a model of FDG-PET during ferret infection with 
H1N1pdm (631, 644).  To complement the comprehensive 3-D nature of the images 
provided by PET-CT fusion, we chose a systematic sampling of the lung to measure 
infiltrating neutrophils in ferrets.  Our sampling approach differed from methods 
previously used to determine the spatial and temporal dynamics of IAV infection in the 
ferret (123, 132, 270), which typically focus measurements to the site of infection and/or 
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lung lesions.  Additionally we relied on gene expression in discrete sections of tissue to 
test changes in the viral microenvironment because antibody-based staining of tissues 
(e.g., IHC) or cells (e.g., flow cytometry) is currently unavailable. In doing so, we were 
able to test many hypotheses about neutrophil infiltration following H1N1pdm infection.  
 
Neutrophils migrate into the lungs early and accumulate in sites of infected bronchioles.  
The increase of neutrophil density in the lungs until 1 dpi may be due to the increase in 
chemokine transcription within specific lung microenvironments (649, 650).  Leukocyte 
chemoattractant chemokines such as CXCL8, CCL2, and TNF are known to be present 
at sites of infection following experimental human IAV infection (99), and levels are 
increased in patients with H1N1pdm compared to seasonal IAV (105, 112).  Previously 
we and others have shown increased secretion of leukocyte chemoattractant chemokines 
(TNF, CCL2, CCL3, and CXCL8) following in vitro infection of well-differentiated 
normal human bronchial epithelial cell culture with H1N1pdm compared to seasonal IAV 
infection (331, 334). In IAV-infected ferrets, we and others have shown increased gene 
expression of other leukocyte chemoattractants (CCL2, CCL3, and CXCL10) as well as 
leukocyte-specific genes (G-CSFR, M-CSFR, CD11b, and CTSB) in the blood (126, 516, 
600).  Therefore, it is likely that neutrophils infiltrate the lungs following H1N1pdm 
infection following chemokine gradients to the site of infection.  Moreover, we observed 
that the distribution of neutrophils was higher in the right caudal lobes at 1 dpi, which 
matched our observations and others’ that i.n. and aerosol challenge of ferrets with IAV 




It remains unknown what specific signal drives neutrophil chemoattraction in ferrets 
during IAV infection.  Herein, we demonstrate that CCL3 was upregulated in discrete 
locations within the lung that were correlated with the presence IAV HA mRNA, 
neutrophils and a neutrophil-specific gene (G-CSFR) (Figs. 2 and 3).  The significant 
increase in gene expression for CCL3 occurred at 3 dpi, which indicates another 
chemoattractant may be more important for early recruitment at 1 dpi (Fig. 2).  Similarly, 
depletion of neutrophils from a mouse model of influenza infection decreased the amount 
of CCL3, suggesting that neutrophils may also be a source of this chemokine (577).  In 
this study, we found that ferrets did not upregulate CXCL8 following infection with 
H1N1pdm.  CXCL8 is the major chemoattractant chemokine for neutrophils during many 
human infections (651). It is known that neutrophil chemoattraction is somewhat species 
specific, and some mammals do not possess CXCL8.  For example, in mice the chief 
neutrophil chemoattractant chemokines are CXCL1 and CXCL2 (652).  In humans, 
neutrophils display the chemokine receptors CCR1 and CCR5, which are important for 
their chemotaxis and oxidative burst in response to CCL3.  The ferret genome contains 
orthologs for these gene sequences (NCBI Gene ID: 101693329 and 101692743, 
respectively) (649, 653), however it is not known if these are similarly expressed on 
ferret neutrophils.  Additionally, neutrophil chemoattractants not commonly associated 
with viral infection, such as eicosanoid molecules (leukotriene) and complement, were 
not measured (472).  In general, sectioning the lung lobe revealed the highly focal nature 
of inflammatory gene expression in the lungs, which matched the focal nature of viral 
distribution in this ferret model.  Although not shown, the increased expression of IL6 
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and TNF in certain sections but not others indicates a complex relationship between 
infection and immune response. 
 
We measured the focal nature of infection in two ways: sampling discrete sections of a 
single lung lobe for gene expression and virus titration, as well as an unbiased semi-
comprehensive histological analysis of two lung lobes.  Using NACE-stained tissues, the 
latter showed a range of neutrophil densities that was greater in infected animals 
compared to mock-infected.  By resolving the distance from NP-positive cells over time, 
we show that neutrophils become greatly enhanced at specific viral foci by 1 dpi (Fig. 
5B).  We observed occasional neutrophil NETosis at sites of IAV-infected cells, but we 
were unable to make any further statistical correlation to spatial or temporal aspects of 
disease without further sampling.  Together, these observations indicate that neutrophils 
migrate to sites of IAV infection, and perform functions there.  Thus, we conclude that 
inflammation caused by IAV was focal and driven by the presence of IAV-infected cells, 
yet the entire lung experiences increased infiltration as a result of infection.  This may be 
due to the specific migratory patterns of neutrophils through the lung to sites of 
inflammation (654).  The increased “background” neutrophil infiltration in infected 
animals (i.e., before and after 1 dpi and at 1 dpi away from foci) was not obvious by 
standard hematoxalin and eosin IHC - neutrophils were uniformly distributed throughout 
the lung at a density that was quantifiably greater than mock-infected controls. 
 
We detected two waves of neutrophils following H1N1pdm infection using the 
histochemical stain, NACE.  As discussed above the peak of the first wave occurred at 1 
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dpi, and was concentrated at sites of influenza infection.  A second wave of neutrophils 
was detected a 3 dpi, by both NACE staining and gene expression signatures.  This 
biphasic pattern of neutrophils following H1N1pdm infection has been reported 
elsewhere (123). Neutrophil-specific transcriptional markers were only detected in lung 
microenvironments at 3 dpi (e.g., G-CSF receptor [Csf3r], and Itgam, the alpha-m 
subunit of the Mac-1 integrin leukocyte activation marker, CD11b) (Fig. 3).  Thus, there 
appears to be two different pools of neutrophils invading the lung following infection 
which differ in their gene expression status, and the second may be responding to or 
producing CCL3.  Currently, it is thought that steady-state neutrophils are mature, 
terminally differentiated cells with limited cell-specific gene regulation, e.g., mature 
neutrophils have pre-formed granules, but neutrophils themselves are capable of gene 
transciption in response to certain stimuli (655, 656).  This may explain why gene 
expression of neutrophil granule contents were not detected (MPO, ELANE, CTSB). We 
hypothesize that the first wave at 1 dpi consists of mature neutrophils, and the second at 3 
dpi represents a more immature population, perhaps as a result of emergency 
granulopoiesis, that have been recruited to the lung from the bone marrow as a direct 
result of IAV infection and systemic inflammation, and thus contain mRNA for the 
neutrophil growth factor receptor, G-CSFR (472, 657).  Additionally, these gene 
signatures provide support for the biphasic infiltration of neutrophils observed in other 
lung lobes, showing a relationship between systemic activation and recruitment of 
neutrophils and their subsequent concentration at specific viral microenvironments.  
These observations should be studied further, as this may indicate distinct functions of 




The lung is a known reservoir of steady-state neutrophils, perhaps due to the large blood 
volume of the lung capillaries (62, 472, 658).  An early increase in airway and circulating 
blood neutrophils is a feature of IAV infection in humans (7, 8), and is common in 
experimental IAV infection in mice (130, 253, 363) and ferrets (123, 266, 659).  We 
show this happens as early as 6 hours post-infection (Fig. 5A,B).  However, increased 
numbers of neutrophils in the lower airways has been correlated with increased influenza 
disease severity (85, 123, 132, 253, 600), and fewer neutrophils are found in the lungs of 
ferrets infected with virus isolates causing less severe influenza disease (123, 659).  
Excessive neutrophil infiltration may contribute to acute lung injury by causing alveolar-
capillary damage (577, 578, 639).  Conversely, neutrophils are essential to the recovery 
from IAV infection as part of the innate immune response as well as the adaptive immune 
response (84, 319, 637, 638).  For example, depleting mice of neutrophils prior to IAV 
infection leads to increased viral replication and increased clinical disease (85).  This 
suggests that the balance between damage from excessive neutrophil infiltration and the 
generation of controlled immune responses during IAV-infection is a critical determinant 
of disease outcome.  This study shows a unique pattern of neutrophils and suggests they 
are honing to specific sites of infection and inflammation during H1N1pdm-infection.  It 
is not known how these patterns of infiltration will change in response to a more severe 
IAV infection or to infection with a HPAI which causes immune dysregulation. 
 
As it pertains to our findings, a majority of neutrophil research has been centered on their 
relationship to acute injury (particularly acute lung injury) and bacterial infection 
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(reviewed in (16),(18), and (60)).  Indeed, pulmonary bacterial co-infections are clinically 
common during and following IAV infection and are thought to represent the major risk 
factor for mortality from an IAV infection. Bacterial co-infection was not evident in any 
of the ferrets examined by histopathology.  No further effort was made to detect bacteria 
(e.g., PCR, IHC, or direct culture) since commensal bacteria are known to exist 
throughout the respiratory tract, and any pathogenic bacterial infection would be 
distinctive on histopathology.  Further, our methodology for ferret husbandry and i.n. 
infection is in line with contemporary standards, and we would not expect bacterial co-
infection to occur in this controlled laboratory model.  Previous studies have shown that 
neutrophils are capable of recognizing IAV and IAV-infected cells (660-663), although 
disagreements in data suggest that neutrophil responses to IAV are dependent on the viral 
strain (661-664).  The role of neutrophils in viral disease remains a topic that is quickly 
growing (80, 456, 471, 665) and deserves further research. 
 
We have hypothesized that increases in FDG uptake following infection is due to 
increases in inflammatory cell infiltration in the lungs (612, 631, 635, 636).  Large FDG 
lesions (SUVmax > 3) begin to be detected in the lungs of IAV-infected ferrets at 3 dpi 
and increase (SUVmax ≥ 5) until 7 dpi (631).  However, the density of neutrophils in the 
lung did not match the temporal or spatial pattern of FDG uptake in the lung.  We 
previously reported greater uptake of FDG in the right caudal lung where we and others 
have measured increased viral replication and neutrophilic infiltration (272, 285, 631).  
Another hypothesis to explain increased FDG uptake is that IAV increases cellular 
glucose metabolism (666).  We found that infection with IAV isolates caused an increase 
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in FDG uptake by immortalized human epithelial cell lines (A549) in vitro, but not by 
differentiated human bronchial epithelial cells (16HBEo-) (data not shown) (331, 631).   
Increased glucose promotes the acidification of cellular endosomal compartments, a step 
required for IAV infection of cells (666, 667).  In hospital clinics, FDG is used to detect 
metabolically active tumors throughout the body, including the lungs, as it is taken into 
cells through glucose transporters and accumulates (648, 668, 669).  In this study, we did 
not detect an increase in gene expression of GLUT1 (Slc2a1) or GLUT4 (Slc2a4) in lung 
tissues (data not shown).  Thus, we could not detect IAV-dependent increased glycolysis 
in vivo via uptake of FDG at the times tested in this study (Fig. 7). We have reported 
gradually increasing FDG uptake until 7 dpi (SUVmax scores >5) (631) which is after 
IAV is cleared from the lungs.  Therefore we cannot support the hypotheses that FDG 
uptake is related to neutrophil infiltration nor inflammation directly within the IAV-
infected microenvironment. 
 
We tested the hypothesis that FDG uptake was related to lung regeneration and repair 
after IAV-induced injury and inflammation.  IHC staining for the nuclear antigen, Ki-67, 
detects cells undergoing proliferation (i.e., cells in S, G2, and M phase of the cell cycle) 
(670) and is used on biopsy tissue as a diagnostic tool to confirm tumor diagnosis or the 
presence of neoplastic tissue (671). In lung cancer, Ki-67 staining is known to be 
correlated with FDG uptake measured by PET imaging (672, 673).  We found a low 
background of cell proliferation in the lungs, especially in bronchioles, but higher in 
alveolar spaces.  There was marked increase in the proliferation of cells within the 
bronchial epithelium up to seven dpi with IAV (Fig. 8).  This matches the timing of FDG 
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uptake in ferrets seen previously (631), and corresponds to the increase in bronchiolitis 
and the presence of bronchiolar cytonecrosis, which was replaced by metaplastic 
bronchiolar epithelium beginning as early as 3 dpi and detected fully at 7 dpi.  It is still 
unknown if proliferating cells contribute to the early FDG uptake (< 3 dpi) in infected 
ferrets.  Small foci of FDG are often seen in locations within the thorax soon after 
infection.  This may indicate the initiation of an adaptive immune response (e.g., within 
lymph nodules by migratory dendritic cells, stimulated with IFN signaling from NK 
cells). 
  
The often extensive cytonecrosis of the airway epithelium, followed by metaplasia of 
pneumocytes and large airway epithelium (depending on the severity of disease), is a 
common feature of infection by many IAV subtypes, including H1N1pdm (6, 8).  
Normally, lung cells are quiescent and only enter the cell cycle after infection and injury 
as part of the regeneration process (reviewed in (674)).  We have reported a significant 
enrichment of genes associated with cellular proliferation in primary human bronchial 
epithelial cell culture after IAV infection and found reduced virus replication in 
undifferentiated versus well-differentiated bronchial epithelial cells (331).  Others have 
shown that ferrets infected with mild seasonal viruses, but not HPAI, also show 
significant enrichment of genes involved in cellular growth and proliferation (675).  
Recently, IAV has been used to elucidate the method by which the distal airways rebuild 
from basal-like stem cells, a process which may continue for up to one month post-
infection (676).  Our studies suggest FDG could be used to probe the recovery of the 
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lungs after infection.  Such data could be valuable for screening compounds that assist 
repair and regeneration of the lungs during this sensitive time. 
 
Conclusions 
The microenvironmental dynamics of IAV infection are important for controlling virus 
replication, inflammation and disease progression (52, 95, 126, 281, 660), however 
processes of inflammation extend beyond the site of infection (9, 85, 253, 360).  Whereas 
in vitro experimental approaches are important for defining cellular and subcellular 
effects of virus infection, well-defined relevant animal models are essential for 
understanding how these cellular interactions define organ and organismal responses to 
infection (52, 600, 629, 632).  These data support the importance of the whole organ 
response to infection, as well as immunological changes that occur at viral foci.  
Neutrophils migrate into the lungs early and accumulate in sites of infected bronchioles, 
potentially responding to chemokines released by IAV-infected cells.  A second wave of 
neutrophils is detected a 3 dpi, which have altered gene expression profiles suggesting 
differences in maturation/phenotype.  Live imaging of infected ferrets suggested 
increased uptake of FDG at sites of cellular proliferation, and not necessarily at sites of 
leukocytic infiltration. Future studies should address several questions raised by the data 
herein, such as the site-specific actions of neutrophils; the mechanism behind the biphasic 
temporal distributions; and the phenomenon of epithelial regeneration in the context of 




Figure 4.1. Sampling scheme for experiments on the temporal and spatial distribution of 
inflammation and infection in ferrets after H1N1pdm challenge.   
A comprehensive histological sampling of ferret lungs was performed at time points 
following intranasal infection of ferrets with 106 TCID50/ferret H1N1pdm virus 
(A/Kentucky/180/10).  Samples were taken at 0.25, 1, and 3 dpi from 2 infected ferrets 
per time point, and 2 mock-infected ferrets at 3 dpi, immediately following PET-CT 
imaging.  The diagram of a ferret lung (left) shows the method by which the left caudal 
lobe was divided (dashed lines on expanded lobe) for histology.  The right caudal lobe 
(cuts not shown) similarly was divided into at least 4 cross-sections along the main 
branching bronchus.  The resulting cross-sections of tissues are shown in the center 
column as black-and-white photos of histological slides, numbered according to locations 
on the lung diagram.  To the right, outlines of the tissues were given to a blinded observer 
to select four regions for IHC analysis (black squares on the right).  This sampling 
scheme for IHC was used to analyze the pattern of neutrophil infiltration, as well as 
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computed tomography and positron emission tomography images. Ferret lung lobes are 
labeled as follows: RCr, right cranial lobe; LCr, left cranial lobe; RCa, right caudal lobe; 





Figure 4.2. Inflammatory cytokine and chemokine gene expression in the ferret lung after 
infection with influenza A virus (H1N1pdm).   
Female ferrets were infected with 106 TCID50 per ferret of H1N1pdm virus, 
A/Kentucky/180/2010 (n = 2 ferret per timepoint). The right caudal lung lobe from each 
H1N1pdm-infected and mock-infected ferrets (n = 1 ferret per timepoint) was taken upon 
euthanasia on days 1, 2, 3, and 7 post-infection and divided into four sections. Each 
section was homogenized separately and cDNA synthesis was prepared for gene 
expression analysis.  Ferret gene-specific primers were developed to cross exons and RT-
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PCR was performed to identify gene expression of leukocyte chemoattractant 
chemokines (A) CCL2 and (B) CCL3.  Fold expression is compared to expression of 
housekeeping controls (GAPDH) and mock-infected animals using the delta-delta Ct 
method.  Asterisks indicate significant differences between days by nonparametric 




Figure 4.3. Neutrophils were detected in ferret lung sections after infection with influenza 
A virus (H1N1pdm).   
Female ferrets were infected with 106 TCID50 per ferret of H1N1pdm virus, 
A/Kentucky/180/2010 (n = 2 ferret per timepoint). (A) The right caudal lung lobe from 
H1N1pdm-infected and mock-infected ferrets (n = 1 ferret per timepoint) was taken upon 
euthanasia on days 1, 2, 3, and 7 post-infection and divided into four sections. Each 
section was homogenized separately and cDNA synthesis was prepared for gene 
expression analysis.  Ferret gene-specific primers were developed to cross exons and RT-
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PCR was performed to identify gene expression of a neutrophil-expressed gene (Csf3r/G-
CSFR) relative to housekeeping controls and mock-infected animals.  Asterisks indicate 
significant differences between days by nonparametric statistical tests, corrected for 
multiple comparisons.  (B) Other lung lobes (left cranial, right cranial, left caudal, and 
middle) taken from each ferret were prepared for IHC, and one slice from each was 
stained for neutrophils (NACE).  Neutrophils were quantified in 20X images taken from 
3 regions on each of the NACE-stained slides using ImageJ image analysis software.  The 
number of NACE-pixels divided by the number of total tissue-containing pixels are 
presented as the “neutrophil density”. Asterisk indicates significant difference in 




Figure 4.4. Immunohistochemical staining of influenza nucleoprotein and neutrophils in 
ferret lungs.   
Histological preparations from the right caudal lobe of a female ferret 1 day post-
infection with 106 TCID50 of an H1N1pdm virus isolate (A/KY/180/2010).  On the left 
panels (A-D), influenza antigen (nucleoprotein, NP) is stained brown with hematoxalin 
(blue) counterstain. On the right panels (E-H) neutrophils are stained pink with naphthol 
AS,D chloroacetate esterase (NACE) in a serial section of the same region of lung as the 
IHC NP stain (A-D) (without counterstain in E-F to show bright pink NACE stain, blue 
hematoxalin counterstain in F). (A) Influenza-infected cells (stars) in the pseudostratified 
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columnar epithelium of the bronchus of a ferret 2 days post-infection.  (B) Infected 
seromucinous glands (three are marked with stars but more are visible).  (C) Infection of 
the bronchiolar epithelium (lumen marked “b”) was more common than other sites, and 
antigen can be seen within luminal cells. (D) Magnification of the indicated region in (C) 
shows that many NP-positive cells (star) are macrophages, and the lumen of the 
bronchiole is filled with polymorphonuclear neutrophils (arrows show two but many 
more are visible).  (E) Few neutrophils are present within the epithelial layer of the 
bronchus at sites of influenza-infected epithelial cells (arrowhead), but more are present 
within the alveolar spaces adjacent to this site (arrows). (F) Inflammatory cells within the 
infected submucosal glands are neutrophils (three areas are indicated with arrows but 
more are present in each gland). (G) Extensive neutrophil infiltration in the bronchiolar 
lumen (“b”). (H) Magnification of a serial section of (G) that is stained for NACE and 
counterstained with hematoxalin to show the morphological features defining neutrophils 
(arrows show three but many more are visible).  Panels A-C and E-G were taken with 
10X objective, D and H were taken with 40X objective. Horizontal black bars in all 




Figure 4.5. Neutrophils in the lungs of ferrets after infection with influenza A virus 
(H1N1pdm).  
Ferrets were infected with 106 TCID50 of an H1N1pdm virus isolate (A/KY/180/2010), 
and lung tissues were taken upon euthanasia and processed for histology.  Caudal lung 
lobes, taken from two infected ferrets per day (0.25, 1, and 3 days post-infection, dpi), 
were systemically divided and prepared for histology.  Neutrophils were quantified from 
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histochemical staining with napthol AS,D choroacetate esterase (NACE) using image 
analysis software, and data are presented as neutrophil density - the number neutrophil-
positive pixels per total tissue pixels on each image.  (A) Neutrophil density is quantified 
over time, dividing data by lobe.  Asterisks indicate significant differences from mock-
infected animals, and significant comparisons between lobes are shown as bars with 
asterisks above (nonparametric statistical tests, p < 0.05). (B) Influenza nucleoprotein 
(NP) was identified on histological sections with IHC. The neutrophil density was 
calculated from the serial NACE-stained section, grouped according to distance from 
known NP-positive cells and matching sites of IAV-positive cells to distant sites within 
the same ferret (red, pink, and white dots to indicate NP-positive, < 1 cm from NP-
positive, and > 1 cm from NP-positive sites, respectively) to mock-infected animals 
(black dots).  Data are plotted over time, and means within a given timepoint are shown 
colored according to distance (red, pink, and grey lines for NP-positive, <1 cm rom NP-
positive, and > 1 cm from NP-positive sites, respectively). Asterisk indicates significant 
difference between sites within a given timepoint. (C) Neutrophil density was calculated 
from pictures taken at sites of known influenza infection (NP-positive) and grouped by 
anatomic region (alveoli, bronchioles, and bronchi with submucosal [SM] glands).  These 
images were site-matched within the same ferret (< 1 cm from known IAV-positive sites) 
to anatomic regions that had no IAV-positive cells (NP-negative). N.B., NP-positive cells 
at alveolar sites were leukocytes; and mock-infected animals are not shown on this panel, 
but are shown above.  Asterisks indicate significant difference between NP-positive and 




Figure 4.6. Rendering of PET-CT images of ferret lungs at different time points post-
infection with H1N1pdm.   
Stacked whole lung images give a 3-dimensional view of ferrets at three timepoints 
following infection with 106 TCID50 H1N1pdm virus (A/KY/180/2010); only one ferret 
shown per time point, including a mock-infected shown at 3 days post-infection (DPI). 
Ferrets were injected with an intraperitoneal dose of radio-labeled [18F]-
fluorodeoxyglucose (FDG) and imaged using PET-CT one hour later. For each image, the 
light pink surface corresponds to the border of the lung which was segmented from CT 
images by an automated CT analysis.  PET-CT fusion images were used to define the 
uptake of FDG within the segmented lung space, and the intensity of FDG uptake is 
illustrated as small colored volumes within the lung borders.  Regions of FDG uptake are 
colored according to voxel intensity within the FDG-PET image as shown on the color 




Figure 4.7.  Distribution of cellular uptake of radiolabeled FDG during influenza 
infection in ferrets.   
Female ferrets were infected with 106 TCID50 of H1N1pdm virus (A/KY/180/2010).  A 
radiolabeled glucose analog ([18F]-fluorodeoxyglucose, FDG) was injected at 0.25, 1, and 
3 days post-infection and ferrets were imaged 1 h later (n = 2 per time point).  Ferrets 
were euthanized immediately after imaging and lung tissues were prepared for histology. 
(A) The temporal distribution of FDG uptake (maximum standard uptake value, 
SUVmax, within a defined volume) was measured in images taken by positron emission 
tomography after locating histology slices using anatomical references in registered 
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computed tomography images. These areas matched areas analyzed for neutrophil 
infiltration, and approximate a 3-D grid of each ferret caudal lung lobe.  (B) The spatial 
distribution of FDG uptake at sites in the ferret lung grouped by distance from IAV 
nucleoprotein (NP)-positive cells within the lungs.  The presence of H1N1pdm was 
measured with immunohistochemistry staining for viral nucleoprotein. Asterisks indicate 




Figure 4.8. Proliferation of lung epithelial cells measured by Ki-67 labeling index.   
The top four images are representative of the scoring system used to grade (labeling 
index values of 0-3) the extent of lung cellular proliferation (Ki-67 antigen positivity) in 
immunohistochemical sections taken from ferrets infected with 106 TCID50 H1N1pdm 
virus (A/KY/180/2010). The left and right cranial, left caudal, and middle lobes were 
taken at necropsy (at 8, 24, 48, 72, and 168 hours post-infection, HPI) and prepared for 
histology.  Various anatomical locations were analyzed in one lobe of each ferret per 
timepoint, including bronchi, bronchioles, and alveolar spaces.  The images were grouped 
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anatomically and scored by two independent observers for the amount of Ki-67 positive 
cells using the guides above.  The bottom figure shows the mean proliferation index per 
anatomic region over time. For reference of scale, the height of the numbers is 50 m in 
the images. Asterisks indicate significant difference from mock within each anatomical 
region (***, p < 0.01) using nonparametric statistical tests.  
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Table 4.1. Primers used to identify ferret leukocyte-specific and inflammatory genes. 
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) 
ELANE GCTGCTGAATGACATCGTG CACGTTCCTGTTGATGGTG 
CCL2 CAGAAGTGGGTCCGGGATTC TTCATGGCTTTGCAGTTTGGG 
CSF3R AGAGCTGGAAGATGGAGCAT TAGAGCTGAAAGGGCCTGAT 
CCL3 GGTCTTCTCTGCACCATTTG CTTGCGTGTAATCTGCTTGG 
MMP9 AGCGAGAGACTCTTCACCCA CAGTGGTGCAGGTGGAGTAA 
CSF1R ATGGAGACACCAAGCTCACA CATCTTGGAAGCCTACGTGA 
CD11B CTGGAGCTGCCTGTGAAATA ATAATGCGGCTGGTCTTCTC 
TNFA CCAGATGGCCTCCAACTAAT CAGCTTCAGGGTTTGCTACA 
IL6 ACCGGTCTTCAGGAGTTTCA AAGAACTGGAGCAGGTGTTTG 
IFNB TCCCAGAAGTTCCAGAAGGA TCGACAATGCTCTCATTCCA 
IL8 GTGAAGCTGCAGTTCTGACG GGGCCACTGTCAATCACTCT 
SLC2A1 CTGCTGAGCGTCATCTTCAT TTCTTCAGCACACTCTTGGC 
NCR1 GCACCGAGAAGCAGAATCTT GCTGGTACTTCACAGCCTCA 
GZMA AGCTCACTGTGTCCTGAACAA TCAAAGCACGGATAAGGAAA 
MPO TCCCTGAGGAGGAAGAGATG GCTGGTGTCAGCATGTCAGT 
GAPDH AGCTGAATGGGAAGCTCACT CTGCTTCACCACCTTCTTGA 








Influenza A viruses (IAV) may cause severe respiratory disease, and emergent strains 
with increased virulence have the potential to infect the world’s population within a short 
time frame.  These points have been illustrated in just in the last fifteen years with the 
emergence of H5N1 in 2003, the re-emergence of a swine-origin H1N1 resembling the 
1918 Spanish influenza in 2009, and the emergence of avian-origin H7N9 in 2013.  
Fortunately, in the aftermath of each virus outbreak, none had both the virulence and 
transmissibility that is feared of the next IAV pandemic.  Importantly, these events have 
resulted directly or indirectly in increased surveillance and increased funding into IAV 
research, and valuable data has been collected.  To date, few infectious diseases have 
received more attention than the 2009 H1N1 “pandemic” IAV (Figure 5.1).  This 
dissertation uses H1N1pdm infection of mouse and ferret animal models to investigate 
the timing and magnitude of general and specific host immune responses to IAV viruses.  
In conclusion, the findings from the experiments presented herein are summarized in the 
context of very recent publications in the field of IAV research, highlighting the benefits 
and limitations of animal models for understanding IAV pathogenesis in humans. 
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The timing of an IAV infection 
The earliest responses to IAV.  The studies presented here help establish a temporal-
spatial course of disease for H1N1pdm and provide a model to test determinants of 
lethality (Figure 5.2).  Shortly following H1N1pdm infection, the virus enters cells and 
begins to replicate its genome.  The ferret model provided information that neutrophils 
arrive in the lungs as early as 6 hpi (Figure 5.2). This coincides with the gene expression 
of type I IFN and release of ISG products, such as CXCL10, from in vitro infection of 
human primary epithelial cell culture with H1N1pdm at 6 hpi (331, 332, 334, 335).  
Others have shown that virus detection and inflammatory response genes, such as IL-6, 
CXCL8, and CCL5, are upregulated as early as 3 hpi following in vitro infection of 
human primary bronchial epithelial cells with both seasonal H1N1 and H1N1pdm (330, 
333).  Detectable secretion of these products into cell culture media is detected by 24 hpi 
(330-332, 334, 335).   
 
The expanding inflammation.  Host responses within the viral microenvironment are 
important determinants of influenza pathogenesis; however these effects are transmitted 
systemically (360, 363).  The systemic amplification of these signals, which influence the 
recruitment of inflammatory cells during IAV infection, is determinants in the outcome 
of IAV disease (9, 14, 94).  This amplification occurs through endothelial cells, which are 
also important for leukocyte recruitment to the site of infection (20, 60, 64, 360, 472, 
538).  In mouse models, it has been suggested that increased inflammation and increased 
inflammatory leukocytic infiltration in the lungs contributes to the increased 
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pathogenicity of IAV (85, 86, 130, 136, 139, 247, 253, 323, 363, 375, 379, 430, 539).  
What remains unclear is the connection between inflammation at the site of infection and 
how this amplification of inflammation systemically affects disease outcome, specifically 
with regard to innate leukocyte recruitment and activation. 
 
The severity of disease is related to the quality of the “signal.”  The fidelity of this 
immune signal – the timing and the context – is critical to the responses of recruited 
white blood cells to a localized virus infection in order to contain the infection.  We have 
established the recruitment of neutrophils to sites of inflammation and infection is very 
specific in space and time during a non-lethal H1N1pdm infection of ferrets (Chapter IV).  
Infiltrating leukocytes respond to the IAV-infected lung viral microenvironment by 
releasing effectors, such as ROS or additional chemoattractants, to additionally shape the 
microenvironment (441, 442).  An abundance of activating signals for infiltrating 
leukocytes may contribute to the creation of an unrestricted “macroenvironment,” one 
that results in unmanageable inflammation for the host (86, 253, 380, 381, 396).  
Increased inflammation (due to viral determinants or chronic inflammatory disease in the 
host) may alter critical timing of the recruitment of immune cells, which may not be able 
to respond appropriately (e.g., recruited immature neutrophils do not have type I IFN 
receptors (530)).  Moreover, IAV strains which alter specific signals, such as suppression 
of type I IFN production from infected cells (69, 199) or disabling neutrophil responses 
(421, 422, 431, 440), increase disease severity in ferrets and mice, respectively.  In these 
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scenarios, the absence of a typical “viral” lung microenvironment restricts valuable 
information to needed to elicit an appropriate response. 
 
The importance of macrophages in the immune response to IAV infection 
Airway macrophages are also capable of responding quickly to IAV infection, as shown 
by experiments which infected primary human macrophages in cell culture (74, 341, 342, 
374, 377, 595, 677).  Macrophages infected with H1N1pdm are able to secrete CXCL10, 
TNFa, IL6 as early as 8 hpi (74), and increased secretion by 24 hpi (75, 342, 359, 377, 
678) (Figure 5.2).  More importantly, experiments using co-culture systems have shown 
that these interactions may regulate epithelial apoptosis within a viral microenvironment 
during IAV infection via TRAIL-DR5, and CD40-CD40L, and therefore may be 
important mediators of mucosal barrier integrity during severe infection (61, 65, 312, 
341, 343, 344, 347, 352, 353, 373).  These experiments have shown that type I IFNs are 
extremely important signals regulating these responses and therefore establish the viral 
microenvironment.  Thus, multiple in vitro systems have indicated that the response of 
specific cell types to IAV infection is immediate, gene expression can be detected as 
early as 3 hpi, and secretion of immune mediators can be detected within the first 24 
hours following infection.  However, more research should focus on the use of coculture 
systems to reveal the importance of cellular interactions at the site of infection since these 




While co-culture models of infection and immune response are essential to establish a 
role for macrophages in IAV pathogenesis, it remains to be demonstrated whether IAV 
modulates the in vivo macrophage response to infection.  Thus far, demonstrating viral 
replication within airway or exudate macrophages provides valuable background to 
support mechanistic studies of the affect infection has on the functions of macrophages 
during IAV infection (73, 74, 359, 375). Apart from their role as pathogen sensors and 
inflammatory signalers, resolution of infection (and inflammation) relies in part on the 
phagocytic functions of macrophages to clear debris and necrotic cells within these 
microenvironments (61, 79, 459, 679).  This causes the release of anti-inflammatory 
cytokines which, in the case of increased inflammation, may not be sufficient to tip the 
balance towards recovery (61, 79, 459, 679).  Indeed, the most severe form of IAV in 
humans causes a hypercytokinemia, which is characterized by both pro- and anti-
inflammatory signals simultaneously expressed (9, 10, 14, 94).  Much remains to be 
discovered about these critical fine-scale interactions at IAV viral foci.  As we 
demonstrate, the ferret is an excellent model in which to pursue these questions. 
 
Animal models for the study of influenza A virus pathogenicity in humans  
Clinically, severe respiratory disease, including IAV, progresses in one of four ways: 
early or late recovery, and early or late death (680).  Children and young adults (<65 
years of age) were at increased risk for hospitalization from H1N1pdm infection during 
the first two waves of the outbreak in 2009-2010 (133, 681, 682).  Additionally, patients 
with certain comorbidities experienced a more severe disease (e.g., obesity, chronic lung 
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disease)(133, 682).  It was important to establish whether the variability in human 
response to H1N1pdm virus was solely host comorbidity or if viral variants contributed 
to differential pathogenicity.  The laboratory mouse is genetically homogeneous, and 
therefore variability in disease outcome following H1N1pdm infection is driven by virus-
specific factors.  Using the mouse model, we and others have shown that the variability in 
human responses to H1N1pdm infection may have been due, in part, to circulating 
genetic variants of H1N1pdm (130, 136, 247, 683-686).  Importantly, key differences in 
disease between mice infected with closely related IAV strains was the timing and 
quantity of chemokines in the lungs and the resulting recruitment of inflammatory cells 
such as neutrophils (130, 136, 685, 687).  Moreover, genetically similar H1N1pdm 
viruses produced variable host responses in outbred animal models as well including 
ferrets and macaques (127, 130, 132, 247, 683, 686).  Animal models were essential to 
understanding these very basic features of the 2009 H1N1 global pandemic, when only 
genetic information and patient reports were available (127, 132).  Therefore, it is 
important to understand the benefits and limitations in animal models, which currently 
offer the best information for inferring human IAV disease severity. 
  
Testing the limits of the mouse model: host determinants of pathogenicity 
In nature, there is no such thing as “mouse influenza” (as far as we know, and there is 
limited interest in understanding IAV pathogenesis in mice for the benefit of mice).  It is 
known that IAV virulence determinants are mouse strain-specific, further illustrating the 
need for caution in using mouse models (136, 250, 683, 684).  Thus, our discovery of 
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three-to-four distinct mouse immune responses to H1N1pdm infection, although a useful 
tool to understand differences between H1N1pdm isolates (viral determinants), may not 
offer great insight into pathogenicity in humans (host determinants). One group has 
recently demonstrated that the variability among genetically similar H1N1pdm isolates is 
only observable in certain mouse strains, indicating that our discovery may not even 
extend to mice other than DBA/2J mice (130, 136).  However, certain aspects of IAV 
infection of the respiratory tract seem to be similar for many mammalian species.  In 
humans, increased cytokines and chemokines in the blood and respiratory samples (e.g., 
nasal lavage) during H1N1pdm infection were correlated with increased disease severity 
(105, 112).  Cytokines and chemokines such as IL-6, TNFa, CCL2, CXCL8, and 
CXCL10 were also higher during infection with a more lethal H1N1pdm virus isolate in 
macaques (e.g., (686)), ferrets (e.g., (71)), and mice (e.g., (130, 683)).  It has been 
demonstrated that release of these chemokines are related to the increased recruitment of 
inflammatory leukocytes to the site of IAV infection in mice (85, 86, 130, 247, 294, 323, 
363, 539, 683). However, the precise relationship between increased cytokines and 
chemokines and disease severity remains unclear, and this may be where the limit of a 
mouse model is drawn.   
 
Testing the limits of the mouse model: viral determinants of pathogenicity 
While interpretation of host determinants of increased IAV pathogenicity must require 
strict prudence, is the same true for the interpretation of data showing viral determinants 
of increased pathogenicity in the mouse?  Does pathogenicity of emergent IAV hold true 
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for all mammals?  Are there species-specific determinants of pathogenicity and how are 
they linked to host response?  This is an interesting problem in the field. 
 
Preliminary data linking viral traits and immune response 
Using the advances in reverse genetics, it possible to test hypotheses regarding the 
contribution of specific amino acid constellations in viral proteins that affect the timing 
and magnitude of specific immune responses.  For example, in we (chapter III) and others 
have observed that H1N1pdm viruses possessing an HA with an alpha 2,3-linked SA 
binding affinity are lethal in DBA/2 mice (e.g., a D222G mutation in HA (125, 129, 131, 
685)), which supports the hypothesis that receptor binding drives pathogenicity in mice 
(50, 125, 230, 247).  In preliminary studies currently underway, we have used reverse 
genetics to create a virus with this HA molecule on the background of another H1N1pdm 
virus that is lethal in mice but does not have alpha 2,3-linked SA affinity 
(A/Netherlands/602/2009 [= “NL602”] differs from KY180 HA at 6 amino acid 
positions).  Materials and methods for these experiments were similar to those in chapter 
II (e.g., 6-8 week old female DBA/2 mice were infected intranasally with 30 µL virus).  
There were no differences in lethality or morbidity (weight loss) between KY180- and 
NL602-infected mice (102 TCID50/mouse), indicating that NL602 has increased virulence 
independent of alpha 2,3-linked SA binding (Figure 5.3).  Moreover, we did not observe 
differences in virus in the bronchoalveolar lavage (BAL) at 3 dpi, nor in cytokine and 
chemokine secretion in the BAL at 3 dpi between mice infected with either wildtype 
viruses or the reassortant virus (105 TCID50/mouse) (Figure 5.4).  However, at this 
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dosage, mice infected with viruses possessing an alpha 2,3-linked SA binding HA had 
reduced lung cellularity and an altered balance between airway macrophages and 
neutrophils following infection (Figure 5.5).  Thus, for H1N1 viruses in mice, specific 
mutations in HA may be traced to surprising effects beyond receptor tropism, and these 
effects are related to the interaction between systemic and local inflammatory responses 
(254, 688, 689).   
 
Host adaptation approach to identify virulence determinants 
As mentioned previously, this specific polymorphism in HA (D222G/N/S) was also 
associated with increased virulence in humans (125, 547, 558, 559, 561-563, 690, 691).  
Thus, perhaps we can infer that increased affinity to avian-type SA linkages is a common 
virulence determinant for mice and humans.  To attempt to identify additional viral 
variants that have increased virulence in humans for which mice can be used to study 
pathogenicity, we may try a reverse approach.  Adaptation of IAV (and many other 
viruses) within a host species typically leads to attenuation of the virus upon coevolution 
over many cycles of continued transmission (682).  Perhaps we can identify viral variants 
that have disappeared from the H1N1pdm gene pool following for prolonged 
transmission between humans and ask: were these were associated with increased 
pathogenicity in humans, and were these associated with increased pathogenicity in 
mice?  Researchers in the United Kingdom divided sequenced human H1N1pdm isolates 
into first/second/third wave to show human adaptation (692).  Elderfield, et al. showed 
that third wave H1N1pdm isolates induced less type I IFN in human cells in vitro, had 
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distinct mutations in HA which increased tropism for alpha 2,6-linked SA, and increased 
polymerase activity within mammalian cell culture (692). More to the point, these 
mutations were less lethal in mice (136). 
 
A similar analysis is presented in Table 5.1, comparing the circulating polymorphisms of 
H1N1pdm in humans taken three years after the 2009 emergence of H1N1pdm in the 
United States to those circulating during 2009 (i.e., during the first two waves of the 
H1N1pdm).  The HA, PA, and PB2 genes are compared, since these are established 
virulence factors for many IAVs and mutations within these genes are known to 
contribute to virulence differences (177, 251, 275, 294).  For simplicity, polymorphisms 
are compared to two Kentucky H1N1pdm sequences of known lethality in mice (130).  In 
general, the results suggest that increased pathogenicity was associated with rare variants 
that were likely not adapted to mammals.   
 
Polymerase proteins: For example, 3 of the 4 polymorphic sites in PA have mutations in 
2009 that disappear from the circulating human viruses by 2012 (Table 5.1).  Therefore, 
PA I14, PA D610, and PA Q716 are likely avian-adapted mutations, and they may 
contribute to altered fitness and/or virulence in mammals. This is not surprising since it is 
known that the PA and PB2 both came from avian-adapted ancestors (1).  Therefore, 
reverse genetics approaches that focus on the contribution of these mutations to virulence 




Hemagglutinin: Interestingly, only one of the selected sites in the HA protein shows 
potential adaptation to mammals (HA2 E47K).  The lysine at position 47 of HA2 went 
from 20% of the circulating viruses to 100%.  This polymorphism was shown to be 
involved in stability of the virion, and specifically the pH stability of the HA (287).  This 
type of change is a known avian-to-mammalian host-adaptation, and it is important for 
fusion and entry of the virus into the host cell (693, 694).  Using syncytium formation 
assays and erythrocyte lysis assays (common assays to determine pH of fusion for viral 
hemagglutinin proteins), we determined that there was no difference in pH of fusion for 
this viral polymorphism alone (HA2 E374K, unpublished data).  This is further supported 
by the finding by others that an additional mutation is needed to alter pH of fusion for 
H1N1pdm viruses (287).  The other polymorphisms in HA show limited evidence of 
human adaptation.  Therefore, the isolate with decreased mouse lethality had the 
dominant variants (>90% of 998 isolates analyzed) in human cases of H1N1pdm isolated 
in the U.S. in 2012.  HA is under many selective pressures, including herd immunity as 
well as host adaptations, and thus variants identified here may not necessarily indicate 
attenuation (or increased virulence).  However, one of these variants was extremely well-
studied (D222G/N/S/Y), and illustrates the type of evidence needed to connect viral 
genotype with phenotype in humans using animal models. 
 
HA1 D222G, a case in point  
Mice typically are not susceptible to infection with human isolates of IAV, and therefore 
it is common practice to adapt H1N1 and H3N2 IAV to mice by serial passage (249).  
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The immediate result is an IAV that replicates well in the respiratory tract of mice and 
causes increased lethality in mice (255, 695).  Some of the variants isolated from 
Kentucky patients during the first and second waves of H1N1pdm had mutations in HA 
that have arisen from mouse adaptation and these mutations, alone, are known to increase 
the lethality in mice: D222G and S183P (255, 685).  The mutation D222G, near the SA 
binding site in the head of the HA molecule, was also discovered from reconstructed 
samples of the 1918 Spanish flu, and was responsible for increased transmission of the 
virus between ferrets (276).  This specific mutation, a glycine at position 222, is a 
virulence determinant in macaques (689) and in ferrets (125), and results in altered 
receptor tropism in human cell culture (563) and on glycan array (125).  The G222 
substitution is thought to allow the HA increased binding to alpha 2,3-linked SA while 
maintaining alpha 2,6-linked SA tropism, whereas the D222 virus has affinity to only 
alpha 2,6-linked SA (125, 276, 563, 689).  Therefore, again, increased binding to avian-
type receptors is an important virulence determinant considering the distribution of 
receptors in the host, particularly when there is an increase in avian-type receptors in the 
lower respiratory tract. 
 
A fascinating study showed that the HA D222 mutation may function as a site for 
diversifying viral population (696).  Memoli, et al. found this pattern of adaptation within 
a single patient with H1N1pdm over time, where the dominant D222 variant switched to 
a G222 dominant population.  They turned to the ferret model to test the virulence of 
these populations, since the ferret is more similar to humans with respect to the 
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relationship of virus tropism and virulence.  Ferrets were infected with a population of 
100% D222 variants HA, a population where G222 was the major variant (8% D222), or 
a plaque-purified 100% G222 IAV population.  They found that only the plaque-purified 
isolate (100% G222) had increased pathogenicity, but also led to the greatest diversity of 
the quasispecies group after infection (127, 132).  This illustrates the implications of how 
viral quasispecies can affect the course of IAV disease, and how quasispecies can 
complicate testing hypotheses for a specific viral variant.  Ultimately, it is important to 
frame these types of questions in the context of understanding human disease.  Two 
additional studies (n = 7 and 357) showed that the D222 mutant was significantly 
associated with mild human cases of H1N1pdm, and the G222 mutant (or more 
specifically the D/G222 quasispecies) was associated with more severe cases of 
H1N1pdm (690, 691).  In all, this well-studied mutation from H1N1pdm shows the level 
of evidence required to make a convincing argument for HA position 222 as a viral 
determinant of pathogenicity, and the utility of animal models for establishing this. 
Interestingly, both D222G and S183P emerged from a single passage within a BALB/c 
mouse model, perhaps eluding to the fact that more than one variant contributes to 
differential pathogenicity of quasispecies (138).   
 
Future directions 
We showed that increased H1N1pdm replication in mouse macrophage cell culture was 
associated with the isolate that caused increased lethality.  This increased replication was 
not seen in human monocyte-derived macrophages (Gerlach, et al. unpublished).  
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However, viruses with increased lethality in mice may show differences in human 
monocyte-derived macrophage immune signaling (Gerlach, et al. unpublished).  It is not 
known if this is true for mouse macrophages, or what the implications are of this in 
humans.  Additionally, we observed increased neutrophils in the bronchoalveolar lavage 
(BAL) of mice infected with a lethal isolate compared to a non-lethal isolate of 
H1N1pdm (130).  Because very little is known about neutrophils and IAV infection, we 
turned to the ferret model to validate this finding (Chapter IV).  The ferret model showed 
that neutrophils are, indeed, recruited to the lungs and may become concentrated at sites 
of H1N1pdm infected epithelium.  This establishes a foundation for further research into 
their role in IAV pathogenicity.  Much more is known about neutrophils in mice, in 
general, and therefore cautious research on IAV and neutrophils may move back into the 
mouse model.   
 
For both ferrets and mice, an important part of the neutrophil story is missing: the role of 
viral determinants of increased pathogenicity.  What drives the increased lethality in 
mice? And is the increase in neutrophils related to the increased lethality in mice?  
Perhaps a proof-in-principle would be to make a virus that increases neutrophils in the 
lungs of mice without causing increased pathogenicity. These approaches to these 
questions in mouse models of H1N1pdm rely on the use of reverse genetics.  For IAV, 
plasmid-based reverse genetics systems allow genetic manipulations of the viral genome 
– site directed mutagenesis, (limited) insertion of genes, or knock-out of certain gene 
functions – to study IAV pathogenicity (150, 697, 698).  Currently, the best technique 
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involves simultaneously co-transfecting 8 plasmids into 293T cells (an easily 
transfectable cell line) and Madin-Darby canine kidney (MDCK) cells (for IAV, an easily 
“infect-able” cell line).  The plasmids, one for each virus gene segment, contain bi-
directional mammalian promoters to make both viral mRNA (for viral protein production 
necessary to make infectious virions) as well as minus-sense viral nucleic acid.  Viruses 
are rescued and passaged in hen eggs or in MDCK cells to make virus stocks. 
 
The Kentucky clinical isolates of H1N1pdm published in Camp, et al. (2013) provide 
unique tool to study IAV pathogenesis (130).  There are 50 known polymorphisms 
among all 8 isolates, 22 between the lethal and non-lethal isolates which were focused on 
for publication (130).  With the exception of D222G, none have been convincingly 
studied for their role in increased lethality.  However, Camp, et al. (2013) show that 
lethality is not necessarily the only endpoint available; it may be possible to identify 
mutant viruses that increase lung neutrophilia, for example.  (This may not be probable, 
as the host response is similarly complicated and inter-related.)  It is fairly well 
established that mutations that affect receptor binding determine the pathogenicity in 
humans, mice, ferrets, and macaques; however, it has been shown that this is not always 
the case.  Recently, experimental manipulation of H1N1pdm viruses to purposefully alter 
their receptor binding preference (i.e., their affinity for only alpha 2,3-linked or only 
alpha 2,6-linked specificity) did not show altered replication or virulence in the ferret 
(688).  Perhaps this binary paradigm for receptor specificity and virulence (i.e., high 
versus low virulence is due to avian versus mammalian SA distribution in the LRT versus 
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URT, respectively) is more complicated, and perhaps differences in the frequency and 
distribution of complex sialic acid linkages within a specific host’s respiratory tract is 
most important for understanding virulence (688), or perhaps it is just the remnants of a 
viral quasispecies in this specific experiment masking effects of specific viral variants 
(690, 691, 696).  Again, this illustrates the fascinating complexities of understanding viral 
determinants of pathogenicity, and the importance of animal models to test hypotheses 
about IAV pathogenesis. 
 
Influenza A viruses are looming and carry a potential to infect every human on the planet.  
The study of influenza A viruses is fascinating and complex, owing to their impressive 
variability.  As a tool, they will continue to provide important insights into immune 





Figure 5.1 Research interest in viruses affecting humans. 
The relative amount of scientific research devoted to each of 5 selected viruses is 
measured by the number of publications per year over the last 50 years (inset shows 3 
additional viruses on a different scale over the same time frame).  Source: NCBI PubMed 
searches for given terms; RSV = Respiratory syncytial virus; HIV-1, human 





Figure 5.2 A course of disease following influenza A virus infection. 
This figure is a prototype course of disease following infection with influenza A virus.  
Shown are major events in the viral replication cycle (red), the host immune response 
(blue), and the effects on the host tissue environment (green).  A critical points for the 
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formation of severe disease is established following 48 hours.
 
Figure 5.3 Weight loss and survival of mice infected with wild type and reassortant 
influenza A(H1N1)pdm09 viruses. 
Mice were infected with human clinical isolates of influenza A(H1N1)pdm09 
(H1N1pdm) viruses to test the hypothesis that the alpha 2,3-linked sialic acid (SA) 
binding is a major virulence determinant for mouse infection.  It is known that 
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A/Kentucky/180/2010 (KY180) is lethal in DBA/2 mice, and the hemagglutinin (HA) 
binds alpha 2,3-linked SA. The A/Netherlands/602/2009 (NL602) isolate is also lethal in 
DBA/2 mice, however it does not possess an alpha 2,3-linked SA affinity.  We used 
reverse genetics to create a reassortant virus that had the hemagglutinin (HA) of KY180 
with the remaining gene segments from NL602 and infected mice intranasally with 102 
TCID50 of each virus.  (A) All viruses caused weight loss following infection and (B) the 





Figure 5.4 Virus replication and immune response in the lungs of mice infected with wild 
type and reassortant influenza A(H1N1)pdm09 viruses. 
DBA/2 mice were infected with human clinical isolates of influenza A(H1N1)pdm09 
(H1N1pdm) viruses: A/Kentucky/180/2010 (KY180) or A/Netherlands/602/2009 
(NL602).  Both isolates are lethal in DBA/2 mice, however the hemagglutinin (HA) from 
KY180 possesses alpha 2,3-linked SA binding affinity.  We used reverse genetics to 
create a reassortant virus that had the HA of KY180 with the remaining gene segments 
from NL602 (KY180HA+NL602) and infected mice intranasally with 105 TCID50 of 
each virus.  (A) All viruses were detected at similar titers in the bronchoalveolar lavage 
(BAL) and (B) the interferon alpha (IFNa), interleukin-6 (IL6), and CCL2 were present 




Figure 5.5 Cellular infiltration into the lungs of mice infected with wild type and 
reassortant influenza A(H1N1)pdm09 viruses. 
DBA/2 mice were infected with human clinical isolates of influenza A(H1N1)pdm09 
viruses: A/Kentucky/180/2010 (KY180) or A/Netherlands/602/2009 (NL602).  Both 
isolates are lethal in DBA/2 mice, however the hemagglutinin (HA) from KY180 
possesses alpha 2,3-linked SA binding affinity.  We used reverse genetics to create a 
reassortant virus that had the HA of KY180 with the rest of the seven gene segments 
from NL602 (KY180HA+NL602) and infected mice intranasally with 105 TCID50 of 
each virus.  (A) Flow cytometry was used to measure the population of cells within the 
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bronchoalveolar lavage (BAL) at 3 dpi.  The total number of CD11b+ cells was counted 
and the number of CD11b+Ly6G+ and CD11b+Ly6C+ cells are shown stacked within 
the total number of CD11b+ cells.  The animals infected with viruses containing 
KY180HA had reduced overall lung cellularity compared to NL602-infected mice.  (B) 
The percentage of Ly6G+ (neutrophils) cells and Ly6C+ (macrophages) cells relative to 
all CD11b+ cells in the BAL show that there are proportionately fewer neutrophils in the 









































































































































































































































































































































































































































































































































































Hemagglutinin (HA, top), and two polymerase subunit proteins (PA & PB2, bottom) of 
H1N1pdm viruses isolated from patients in the United States in 2009 and 2012.  
Frequency of specific amino acid (A.A.) mutations at each site (top row) expressed as a 
percentage of the total known polymorphisms at each site for each year.  The variants are 
divided into low virulence and high virulence (Virul.) based on the lethality of two 
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